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1
PA IN
e ‘International Association for the Study of Pain’ (IASP) de!ned pain in 1979 as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage.” [1]. Recently this de!nition has been 
debated and revised in “a distressing experience associated with actual or potential tissue 
damage with sensory, emotional, cognitive, and social components.” [2]. Worldwide, 1 
in 5 individuals is experiencing acute, intermittent or chronic pain. is is leading to 
employment issues, depression and chronic comorbidities, especially in a prolonged and 
inadequately controlled setting [3]. e experience of pain is very subjective and multidi-
mensional, displaying substantial variability between individuals even when exposed to an 
identical pain-evoking stimulus. Di$erences in gender, age, ethnicity and anxiety level [4, 
5] are among the known factors that contribute to this interindividual variability in the 
experience of pain.
In the present setting, with the exception of age, neither the choice of analgesics nor 
the doses selected are based on these factors. In  recent years, genetic variation in genes 
involved in the disposition of analgesics as well as genes responsible for the analgesic e$ect 
itself has been suggested to play an important role in variation in response.
A SSE SSM ENT OF PA IN
Pain experience is very subjective. Due to the lack of objective markers for pain [6], self-re-
ports remain the gold standard. is is particularly challenging for speci!c patient groups, 
such as young children (< 5–6 years) or cognitive impaired individuals, who are generally 
less able to adequately communicate their pain to health care practitioners. Critically ill 
patients admitted to an intensive care unit are frequently receiving respiratory support 
and are sedated, which also complicates pain assessment. To su/ciently manage pain in 
speci!c groups (e.g. neonates, infants, children, critically ill adults) and circumstances 
(e.g. procedures, postoperative and prolonged pain), observational pain assessment instru-
ments have been developed and validated in pediatrics (COMFORT-B, FLACC, MAPS 
and PIPP-R) [7] and critically ill adults (CPOT) [8].
Although procedural pain is decreasing in children admitted at an intensive care, still 
on average they are exposed to 11.4 (SD =  5.7) painful/stressful procedures per day [9, 
10]. Adequate analgesia is needed from an ethical perspective as well as to avoid negative 
neurodevelopmental consequences due to pain experience during life [11], in particular in 
pre-terms although still under debate [12–14]. As a consequence 33.3 % of the children is 
exposed to analgesics and sedative drugs, with up to 89.3 % in tracheal ventilated children 
[15]. In the adult population, adequate pain management is of importance because 20 % of 
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the individuals develop chronic pain after a surgical procedure. is may lead to reduced 
quality of life, a rise in unemployment and concordantly an increase in healthcare costs 
[16]. Because inadequate treatment of pain is non-ethical and may have serious mental, 
physical and economic consequences, there is a need for predictive markers in the manage-
ment of pain.
PH A R M ACOLOGIC A L TR E ATM ENT
e WHO pain scale (Pain Ladder) was initially developed to tailor the treatment of 
cancer related pain in adults, but the basic principle of this strategy is now also applied 
in other non-malignant pain conditions. Mild pain is controlled with anti-inQammatory 
drugs (e.g. acetaminophen, ibuprofen). When pain relief with these analgesic agents is 
insu/cient, or when patients present initially with mild to moderate pain, weak opioids 
are prescribed (e.g. codeine, tramadol). Further escalation in pain intensity or the oc-
currence of moderate to severe pain at presentation is treated with strong opioids such 
as morphine and fentanyl [17]. Cancer related pain or chronic pain with a neuropathic 
component are inadequately controlled with these analgesic agents and require a di$erent 
pharmacological approach (e.g. antidepressants, anticonvulsants) [18]. ese analgesics 
are, however, outside the scope of this thesis.
Opioids are generally an e$ective approach in relieving acute moderate to severe pain, 
especially by use of compounds with a short half-life or by rapid absorption due to ad-
ministration via non-oral route. As with most pharmacological interventions, the use of 
opioids is not without limitations. In the chronic pain setting, 5.8–10.3 % of the patients 
report poorly controlled pain and 12.1–22 % discontinue pain medication as a consequence 
of adverse events (AEs) [19].
Young children are more prone to develop AEs, such as respiratory depression, as a 
consequence of immature organ function and dosing challenges [20]. In addition to the 
non-life threatening AEs (e.g. constipation, vomiting, sedation, pruritus) that either re-
solve over time or are treated symptomatically, serious toxic e$ects can increase morbidity 
and mortality risk in this vulnerable group [21]. Several cases from the pediatric popula-
tion with severe toxicity and fatal outcomes while exposed to opioids have been reported 
in the literature [22–24].
Currently, the pharmacological management of pain is reQected by a trial-and-error ap-
proach in providing adequate analgesia, with periods of remaining pain or the occurrence 
of toxicity. e starting dose is similar for patients, with some adjustments based on age 
and/or weight. is can lead to delayed or inadequate pain relief in some or toxicity in 
others. Ideally, one would want to distinguish these patients pre-emptively before the !rst 
drug and dose are administered.
Chapter 1: General Introduction 13
1
GENETIC IMPACT
e variability observed in pain experience and opioid response is a complex interplay 
of several clinical and environmental factors. Twin studies assessing pain phenotypes and 
analgesia highlight genetics as one of the contributing factors [25, 26]. e use of genetic 
information in guiding pharmacological treatment (drug selection and dosing) is the focus 
of the Pharmacogenetics (PGx) science !eld. e PGx term is used interchangeably with 
pharmacogenomics, although the latter !eld covers a broader range including the e$ect of 
the genome (combination genes) on drug therapy [27]. Currently the relevance of PGx is 
mainly recognized outside the pain area, in e.g. psychiatry, cancer, cardiology and internal 
medicine [28].
e implementation of PGx in a clinical setting remains a slow process. Challenges 
encountered in the clinical translation process are unawareness of available analysis among 
health care providers, lack of harmonization in laboratory results, translating genotype 
in phenotype di/culties [29], lack of appropriate cost-e$ectiveness analysis and clear 
reimbursement policies [30]. To overcome the translational gap between genetic research 
and clinical use, the Clinical Pharmacogenomics Implementation Consortium (CPIC) has 
developed evidence-based guidelines that report gene-drug interactions and give action-
able decision tools for the physician in the prescription process [31]. In the Netherlands, it 
is the Royal Dutch Association for the Advancement of Pharmacy - PGx Working Group 
(KNMP) who performs these analyses since 2005, with recommendations for drug dosing. 
ese evidence-based dosing recommendations are taken over by the USA (www.phar-
mgkb.org), demonstrating the leading position of the Netherlands in this particular !eld.
Genetic variability within the cytochrome P450 (CYP) enzymes has been extensively 
studied, characterized and translated to genotype predicted phenotypes. For the highly 
polymorphic CYP2D6 enzyme, over 100 allelic variants have been reported in the Human 
Cytochrome P450 Allele Nomenclature Database (http://www.cypalleles.ki.se/cyp2d6.
htm). ese variant alleles can be translated to predict phenotypes, such as poor metabo-
lizer (PM), intermediate metabolizer (IM), normal/extensive metabolizer (EM) or ultra-
rapid metabolizer (UM) status [32]. e frequencies of these predicted phenotypes may 
vary between ethnic populations. Where up to 5–10 % of the individuals is CYP2D6 PM 
in the European population, CYP2D6 PM status in Asians and Africans is less frequent 
(< 2 %). In contrast, approximately 2–5 % of the Caucasian population is a CYP2D6 UM 
whereas the percentages in the African and Asian population are up to 40 % and 2 %, 
respectively [33].
Considering the management of pain, a CPIC guideline on codeine addressing the 
genetic variability in the metabolizing enzyme CYP2D6, responsible for activating co-
deine into morphine, has been published [34]. e guideline states that both codeine and 
tramadol should be avoided in individuals with CYP2D6 genotypes predicting UM or PM 
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status. ese patients are more prone to either morphine toxicity (UMs) or ine/cacy of 
treatment (PMs). A case report in Lancet in 2006 described the death of a newborn due 
to codeine intoxication in a mother with the CYP2D6 UM status [35]. Due to increased 
conversion of codeine into morphine by CYP2D6, high levels of morphine did reach the 
neonate through the breast milk, thus causing respiratory depression as a result of exposure 
to high morphine concentrations. Codeine toxicity in relation to CYP2D6 genotype was 
also the cause of three additional deaths in children aged between 4–10 years [36]. Also for 
tramadol, an alternative opiate, severe respiratory depression has been observed in a child 
with obstructive sleep apnea syndrome that had the CYP2D6 UM status [24].
For pain PGx, it is thus far only a small subset of !ndings that is translated to the 
clinic. In contrast, a large number of genetic variants has been described in the literature 
regarding the relation to pharmacokinetic (PK) pro!les and response of opioids [37, 38]. 
Examples are the genes encoding metabolizing enzymes (UGT2B7) and transporters 
(ABCB1, ABCC3, SLC22A1), but also the mu-opioid receptor (OPRM1) and its second 
messenger system (KCNJ6, ARRB2) or other enzymes involved in pain such as the 
catechol-O-methyltransferase enzyme (COMT).
us, there seems to be a large potential of DNA markers available, yet, clinical imple-
mentation is not achieved and it is di/cult to assess which of these potential markers are 
suitable for further exploration in a clinical setting.
INTER PL AY DE V ELOPM ENTA L PAT TER N A ND GENET ICS
While most PGx studies have been performed in adult patients, the evidence in the 
pediatric population is scarce. Ethical concerns, lack of data on PGx utility, lack of cost 
e$ectiveness information in combination with developmental aspects also a$ecting drug 
metabolizing capacity in this population have been mentioned as obstacles [39]. Chil-
dren are subject to physiological maturation and developmental changes a$ecting the 
absorption, distribution, metabolism and elimination (ADME) of drugs. e absorption 
of drugs is altered in children as a consequence of pH changes in the gastrointestinal 
tract, increased gastric emptying and lower intestinal surface area compared to adults. 
Renal elimination is a$ected by maturation of the glomerular !ltration rate and tubular 
secretion process. Adult rates are reached between 8 to 12 months. Also the distribution of 
drugs is di$erent in children due to changes in body (more water vs. fat tissue) and plasma 
proteins composition but also due to ontogeny of transporters such as P-glycoprotein 
(ABCB1). [40].
e metabolizing enzymes in the PK process are also highly subjective to an age-
dependent maturation. For the most important cytochrome P450 enzyme with respect to 
drug metabolism, CYP3A4, adult activity levels are not reached until the age of 1–2 years 
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[41–43]. In children drugs metabolized by this enzyme will have a lower degradation as 
compared to adults, and thus will lead to higher drug concentrations. CYP2D6 matures 
more rapidly with 90 % expressed after the !rst postnatal week [44]. A CYP2D6 genotype 
predicted phenotype can be accurately predicted by 2 weeks of postnatal age (PNA) [44, 
45]. e e$ect of a CYP2D6 genotype has already been observed in the neonatal popula-
tion, when looking at tramadol disposition [46].
e developmental pattern of these drug metabolizing enzymes and transporters leads 
to alterations in the formation and elimination of active compounds and metabolites, 
hereby a$ecting e/cacy and drug toxicity risk. Findings on genetic markers for analgesia 
in adults predicting pharmacokinetics of analgesics cannot always be simply translated to 
the pediatric population [47]. For instance, low protein expression and thus activity of an 
enzyme or transporter will disrupt any genotype-phenotype correlation in this population 
since all individuals will be a poor metabolizer, irrespective of genetic composition [48].
SU M M A RY
Numerous genetic variants have been implicated in pain and analgesia. An overview 
with the most potential candidate polymorphisms for application in clinical practice is 
needed. e role of candidate genes needs to be validated in adult postoperative and 
cancer cohorts. As opposite to adults, data on the relevance of PGx for pain treatment 
in the pediatric population is limited. Since found genotype-phenotype associations are 
not directly translatable to (the youngest) children due to the inQuence of developmental 
changes on the phenotypic activity, research addressing this topic is highly required.
A IMS A ND OUT LINE S OF THIS THE SIS
e aims of this thesis are:
Ⴜ To investigate which genetic variants are potential candidates
Ⴜ To validate whether selected genetic variants are related with the observed variability 
in opioid response in an adult postsurgical situation and in adults treated for cancer-
related pain
Ⴜ To assess in healthy children associations between experimentally induced pain and 
these candidate genes
Ⴜ To investigate the e!ect of known genetic variants in DME’s and drug transporters on 
the PK of opioids in the neonatal population
Ⴜ To explore whether the most commonly addressed candidate genes are correlated with 
opioid response in the pediatric population
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"is thesis starts in Part I with an overview of the available PGx literature for their cor-
relation with e!ectiveness of opioids and relation with side e!ects in adults and children 
(Chapter 2). Part II (Chapter 3–5) is addressing the role of PGx in the adult population: 
the role of genetics on thermal, postsurgical acute and chronic pain of patients undergo-
ing cardiac surgery is discussed in Chapter 3 whereas the clinical and genetic factors in 
oncological populations is investigated in Chapter 4 and 5. Part III (Chapter 6–10) 
focusses on the role of PGx on pain and its treatment in the pediatric population. Chapter 
6 describes the genetic contribution in an experimental pain setting in children. Chapter 
7 and 8 are addressing the e!ect of ADME gene polymorphisms in relation to morphine 
and tramadol PK. "e e!ect of OPRM1 and COMT genetic variants on morphine e#cacy 
is described in Chapter 9 and withdrawal during opioid treatment in children admitted to 
the neonatal and pediatric intensive care unit is presented in Chapter 10. Finally, in Part 
IV, a discussion on the main $ndings of this thesis in a broader perspective is included 
(Chapter 11), taking into account recent data from literature and speculating on future 
directions. "e thesis is concluded with a summary (Chapter 12).
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A BSTR ACT
Aim: To identify clinical and genetic factors associated with outcome of opioid treatment.
Patients & methods: We performed an exploratory analysis in a cohort of 353 patients 
treated with fentanyl, morphine, oxycodone and/or hydromorphone for cancer-related 
pain, exploring selected clinical and pharmacogenetic factors for a correlation with treat-
ment failure for all and per type of opioid.
Results: Use of adjuvant pain medication, intensity of pain at rest and age were associ-
ated with treatment failure in the various cohorts. Only the genetic variants rs12948783 
(RHBDF2) and rs7016778 (OPRK1) correlated statistically signi$cant in univariate, but 
not in multivariable analysis.
Conclusion: Several clinical and genetic factors were identi$ed that warrant further study 
to clarify their role and use in opioid treatment.
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INTRODUCT ION
Opioids are the cornerstone of treatment for moderate to severe cancer-related pain. 
Although treatment is successful in the majority of patients, 25–40 % does not achieve 
su#cient pain control and/or experiences serious side e!ects limiting dose escalation [1, 
2). In these cases, opioid rotation is successful in about two-thirds of patients. However, 
opioid rotation is time-consuming, which is unwanted in a population with limited life-
expectancy (3, 4). As we are currently unable to predict the clinical response to speci$c 
opioids for an individual patient, $nding the right type and dose of opioid is still a matter 
of trial and error. "e e!ects on pain and the occurrence of side e!ects are the result of a 
complex interplay between clinical / demographic, pharmacokinetic and -genetic factors 
(5, 6). So far, factors related to treatment-failure of individual opioids that can be used to 
guide treatment decisions (2, 7–10) have not been identi$ed.
Studies in twins, separating environmental from genetic in=uences, have demonstrated 
that up to 60 % of the inter-individual variation in pain perception and analgesia can be 
attributed to a person’s genetic predisposition (11, 12). In the last decade, a large number 
of studies have found associations between genetic variants of drug metabolizing enzymes 
(CYP3A4, CYP2D6), membrane drug transporters (ABCB1, ABCC3, OCT1), molecules in-
volved in opioid receptor signaling (OPRM1, OPRK1, OPRD1, KCNJ6) and pain modula-
tors (COMT) on the one hand and opioid e#cacy, required dose, and toxicity on the other 
hand (5, 13). "ese studies mostly had a small sample size, focused solely on morphine, or 
data from various types of opioids were pooled. "e European Pharmacogenetic Opioid 
Study (EPOS) included a large number of cancer patients and studied the in=uence of 
genetic variability on opioid dose, during opioid treatment. No statistically signi$cant as-
sociations were found between 112 single nucleotide polymorphisms (SNPs) in 25 candidate 
genes and opioid dose (14). Sub studies from the EPOS patient cohort focused on pharma-
cokinetics of fentanyl (15), pharmacokinetics of oxycodone (16), occurrence of nausea and 
vomiting (17) and constipation (18). "e study on pharmacokinetics of fentanyl reported 
that the CYP3A4*22 and CYP3A5*3 variants accounted for a small proportion of the 
variability in pharmacokinetics of fentanyl (15). For oxycodone, CYP2D6 genotypes were 
shown to in=uence the pharmacokinetics of oxycodone, but not the pharmacodynamics 
(16). For nausea and constipation, although a correlation was found with 8 and 5 SNPs, 
respectively, only two SNPs (rs1672717 in the 5-Hydroxytryptamine (Serotonin) Receptor 
3B (HTR3B) for nausea (17); and rs2020917 in the enzyme Catechol-O-methyltransferase 
(COMT) for constipation (18)) passed the Benjamini-Hochberg criterion for a 10 % false 
discovery rate. However, EPOS was a cross-sectional study, in which outcomes were 
studied at a random time point during opioid treatment. To our knowledge, no studies 
have assessed whether a combination of clinical and genetic factors is related to the e#cacy 
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or failure of treatment with individual opioids, whereas this information could help to 
personalize pain management in cancer patients (19).
With the aim to identify clinical and genetic factors related to treatment failure of opi-
oids, we performed an exploratory prospective study in patients treated with morphine, 
oxycodone, fentanyl, or hydromorphone for cancer-related pain.
PATIENTS A ND M ETHODS
Patients admitted to the department of Medical Oncology of Erasmus MC Cancer In-
stitute (Rotterdam, the Netherlands), who were treated with opioids for moderate-severe 
nociceptive cancer-related pain (with or without a neuropathic component) were included 
in this prospective study. Patients with an expected duration of hospitalization < 72 h and 
patients unable to give informed consent were excluded from the study. Patients were 
admitted to our specialized acute palliative care unit (PCU) or one of two general oncol-
ogy wards. Pain was treated stepwise following the World Health Organization analgesic 
ladder (20) and only patients treated with strong-acting (step III) opioids were eligible. 
Treatment was given in line with our institutional protocol for the treatment of oncologi-
cal pain, which is based on (inter-) national guidelines. Of note, because many patients 
on the PCU are admitted with complex pain problems; high doses of opioids, opioid 
rotation, parenteral administration of opioids and/or adjuvant analgesics were often neces-
sary. In general, the type of opioid used before hospital admission was continued unless 
dose escalation was not possible due to side e!ects or problems related to administration. 
In patients with severe pain, we generally used subcutaneous morphine or fentanyl for 
titration. Doses were titrated while closely monitoring the e!ect on pain (by numeric 
rating scale 0–10 twice daily) and side-e!ects (10 most common side e!ects assessed using 
a 4-point Likert scale twice daily). Opioid rotation was performed in case of insu#cient 
pain control despite adequate dose escalation and/or dose limiting side-e!ects and/or the 
occurrence of other dose limiting events, such as volume related problems with subcutane-
ous infusions. Adjuvant pain medication was started in case of an insu#cient e!ect of 
opioids in patients with mixed nociceptive-neuropathic pain. Selection of the opioid of 
$rst, second or third choice was based on clinical factors (i.e. renal function, possibility 
for use of oral route) and treatment history. In opioid naive patients, our protocol advises 
oxycodone as a $rst choice.
Clinical and demographic data were collected. All data were registered in an electronic 
database (©2004–2012 OpenClinica, LLC and collaborators). Patients were categorized 
in treatment groups according to the type of opioid(s) they received. In case of rotations 
between di!erent types of opioids, patients were included in all the speci$c treatment 
groups.
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For the analysis, we de$ned T0 as the start of the clinical titration period for the opioid 
of study. In case of pain requiring opioid titration at admission, T0 was set at the time 
of hospitalization irrespective of the use of opioids before referral. When an opioid was 
started after hospitalization, T0 was set at the moment of that start. In case of an opioid 
rotation, a new titration period started. "erefore, at T0, patients could be opioid naive, 
already using the respective opioid (before hospitalization) or starting a new opioid after 
rotation. For every patient, the treatment response per opioid was classi$ed as failure or 
non-failure. "e response was classi$ed as failure in case of: 1) a rotation to another type 
of opioid because of insu#cient pain control and/or side e!ects, 2) a treatment with 
intrathecal opioids because of persistent pain and/or side e!ects, or 3) the use of palliative 
sedation because of refractory symptoms associated with opioid treatment in the dying 
phase. In all other patients the response was classi$ed as non-failure. A rotation from 
oxycodone to another type of opioid given parenterally was considered as failure only 
if the reason for rotation included adverse events. We excluded patients rotating solely 
because of a need for (fast) parenteral titration, as oxycodone for parenteral use is not 
available in our hospital. "e study was approved by the Erasmus MC medical ethics 
review board (study ID: MEC 09.332) and conducted in accordance with the Declaration 
of Helsinki. "e trial was registered at the Dutch Trial Registry (Trial registration ID: 
NTR4369). Written informed consent was obtained from all participants, with separate 
informed consent for the DNA analysis.
Analyses of SNPs
Blood samples for pharmacogenetic analysis were collected concurrent with the $rst 
venipuncture for blood sampling for a medical indication and after obtaining informed 
consent. DNA was isolated from 1 mL EDTA blood on the MagNA Pure LC 2.0 instru-
ment (Roche Diagnostics®). Genetic variants were selected based on evidence from litera-
ture, taking into account allele frequency, clinical impact and reproducibility of e!ect. 
"e analysis was performed with the TaqMan allelic discrimination method on the 7500 
Real-Time PCR System (Life Technologies®). CYP2D6 duplication and deletion (*5 allele) 
were determined on the ProFlexTM PCR system (Life Technologies®) and visualized via 
gel electrophoresis on 1 % agarose gel.
Violation of Hardy-Weinberg (HW) equilibrium was calculated for all genetic variants 
with the chi-squared – test. Additionally, the observed minor allele frequency (MAF) was 
compared with the MAF from HapMap in dbSNP (National Centre for Biotechnology 
Information). "e COMT, CYP2D6 and OCT1 haplotypes were estimated based on the 
expectation-maximization (EM) logarithm with R (version 3.1.1) haplo.stats package, us-
ing a posterior probability > 0.98. Patients genotyped GGC (rs4680, rs4818, rs4633 resp.) 
for COMT were categorized in the low pain sensitivity (LPS) group, ACT genotype in 
average pain sensitivity (APS) group and GCC in high pain sensitivity (HPS) group, as 
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previously this haplotype has been related with experimental pain sensitivity (21) and 
opioid consumption (22{Tan, 2016 #5836, 23, 24). "e LPS group consisted of patients 
with the LPS/LPS or LPS/APS alleles, APS from APS/APS or LPS/HPS alleles and HPS 
from the alleles HPS/HPS or APS/HPS.
Statistical analysis
Data were analyzed using STATA® version 13. Descriptive statistics were used to sum-
marize patients’ characteristics. Statistical analyses were performed for the whole group of 
patients and per type of opioid. For the analysis of all patients, the $rst opioid that was 
used for titration during admission for which an observation period of at least 24 hours 
was available, was selected. Logistic regression analysis was used with treatment failure as 
the dependent variable and the SNPs described in the previous paragraph and clinical/
demographic factors as covariates. For the analysis in the whole group of patients only 
SNPs in genes related to pharmacodynamics or pain sensitivity were tested. "e follow-
ing clinical/demographic factors were explored: gender, age, radiotherapy on any tumor 
localization related to the pain for which opioid treatment was initiated (either 1–8 weeks 
before T0 or 1 week before - during hospitalization), use of adjuvant pain medication 
(pregabalin, gabapentin, or amitriptyline) or use of corticosteroids started before T0 and 
continued or started on T0 or during hospitalization, pain at rest and worst pain at T0 
(rated using Numeric Rating Scale (NRS 0–10) and divided into categories mild (NRS 
0–4), moderate (NRS 5–6) and severe pain (NRS 7–10) and opioid dose at T0. For the 
analysis of all patients, doses were recalculated to the median oral morphine equivalent 
daily dose (MEDD) according to published equi-analgesic dose tables: oral morphine 
60mg/d = parenteral morphine 20 mg/d = transdermal fentanyl 25 mcg/h = oral oxyco-
done 40 mg/d = parenteral hydromorphone 4 mg/d (25). For the whole group, as well as 
the opioid speci$c groups, doses were divided into 2, 3 or 4 equally sized dose level groups 
based on the appropriate quantiles (Q)). For the ordinal factors (pain, opioid dose) each 
category was analyzed using the $rst category as reference. Patients already using opioids 
before admission, who were rotated within 24 hours after admission were excluded for the 
analysis of time-dependent variables for the opioid used at admission. Reported p-values 
are two-sided and because of the exploratory nature of this analysis, factors with a p-value 
< 0.10 in univariate analysis were entered into the multivariable analysis. "e ‘backward 
elimination’ method was used to $nd the combination of clinical and genetic factors asso-
ciated with treatment failure. Again, we used a threshold of 0.1 for signi$cance. Resulting 
p-values were not corrected for multiple testing because of the exploratory nature of this 
analysis. "e multivariable analysis was performed twice, with and without adjustment 
for opioid dose at T0.
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R E SU LTS
Between January 2010 and April 2014, a total of 356 individual patients were included 
in this study. "ree patients were not evaluable because they used di!erent opioids si-
multaneously during the entire study period and therefore 353 patients were analyzed. 
"e median age of the patients was 61.5 years (range 24–86) and 168 (48 %) patients were 
male. "e most frequent tumor origins were the urinary tract (20 %), gastro-intestinal 
tract (18 %) and breast (16 %). Most patients had advanced stages of cancer (80 %) and the 
median WHO performance status was 2. "e median duration of hospitalization – and 
therefore follow-up – was 9 days (range 1–48). For all but 2 patients the duration of 
follow-up exceeded 72 hours.
"e majority of patients (n = 214) was treated with a single type of opioid, whereas 113 
patients were treated with 2 opioids, 22 patients with 3 and only 4 patients with 4 opioids 
(<gure 1). In the fentanyl group, most patients (66 %) already used fentanyl before hospital 
admission, while in the morphine group patients were mostly rotated from another type 
of opioid (58 %). In the oxycodone cohort most patients were either opioid naive (38 %) or 
already used oxycodone (43 %) before study entry. As expected, the hydromorphone cohort 
contained mostly patients in whom treatment with other opioids had failed (89 %). A 
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Figure 1. A Venn diagram showing the numbers of patients treated with the specied opioid consecu-
tively throughout the study. For example, 20 patients were treated with both morphine and oxycodone 
and studied in both cohorts.
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wide range of treatment doses was observed for all types of opioids. Regarding the median 
morphine equivalent daily dose (MEDD), doses were quite similar in the fentanyl (120 
mg) and morphine group (101 mg) but lower treatment doses were given in the oxycodone 
cohort (30 mg), whereas, as expected, MEDD was highest in the hydromorphone group 
(504 mg). 'e number of patients in whom treatment failed divided by the total number 
of patients per group was 81/353 (23 %) for all patients, 59/233 (25 %) for fentanyl, 56/163 
(34 %) for morphine, 27/81 (33 %) for oxycodone and 9/45 (20 %) for hydromorphone.
Genotype distributions
From the total cohort, written informed consent for DNA-analysis and a blood sample 
were available for 346 patients. 'e undetermined genotype results ranged from 0.9–2.3 % 
per assessed genetic variant. None of the SNPs violated HW equilibrium (p > 0.05), nor 
were there large di7erences observed between the study and MAFs reported in the litera-
ture (Supplementary table 1).
Association of treatment failure with clinical and genetic factors in 
univariate and multivariable analysis
All patients: In univariate analysis, factors associated with failure of treatment were 
age (Odds ratio (OR) 0.58, 95 % Condence Interval (CI) 0.39–0.97, p = 0.039), use of 
adjuvant pain medication started on T0 or later (OR 3.04, 95 % CI 1.76–5.24, p = 0.000), 
use of corticosteroids started on T0 or later (OR 1.95, 95 % CI 1.15–3.29, p = 0.012), pain 
at rest (category severe pain OR 3.13, 95 % CI 1.29–7.56, p = 0.011) and worst pain at T0 
(category severe pain OR 3.21, 95 % CI 1.19–8.69, p = 0.022), the MEDD at T0 (Q3: OR 
2.27, 95 % CI 1.04–4.92, p = 0.038 and Q4: OR 3.10, 95 % CI 1.45–6.63, p = 0.004) and the 
rs12948783 SNP in RHBDF2 (OR 0.55, 95 % CI 0.32–0.96, p = 0.035). Of these, the use of 
adjuvant pain medication (OR 3.49, p = 0.000), severe pain at rest (OR 2.67, p = 0.048) 
and the rs12948783 SNP in RHBDF2 (OR 0.37, p 0.056) were (possibly) independent as 
shown in multivariable analysis (tables 1–3). When the analysis was corrected for opioid 
dose, results were unchanged.
Fentanyl: In univariate analysis, factors associated with failure of fentanyl treatment were 
age (Odds ratio (OR) 0.98, 95 % Condence Interval (CI) 0.95–1.00, p = 0.071), use of 
adjuvant pain medication started on T0 or later (OR 2.45, 95 % CI 1.20–5.00, p = 0.013), 
use of corticosteroids started on T0 or later (OR 2.88, 95 % CI 1.42–5.87, p = 0.004), pain 
at rest (category severe pain OR 5.72, 95 % CI 1.61–20.37, p = 0.007) and worst pain at 
T0 (category severe pain OR 7.67, 95 % CI 0.98–59.84, p = 0.052), the dose of fentanyl 
at T0 (Q3: OR 3.41, 95 % CI 1.16–10.09, p = 0.026 and Q4: OR 2.90, 95 % CI 0.91–9.29, 
p = 0.072) and the rs1799971 SNP in OPRM1 (OR 0.44, 95 % CI 0.19–1.06, p = 0.066). Of 
these, age (OR 0.95, p = 0.081), the use of adjuvant pain medication (OR 1.83, p = 0.067), 
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Table 3. Results of univariate and multivariable analyses for all patients and per type of opioid
 
 
Univariate analysis Multivariable analysis
Odds 
ratio
95 % Condence 
Interval P
Odds 
ratio
95 % Condence 
Interval P
All       
- Age 0.58 0.35 – 0.96 0.035       
- Adjuvant pain medication ≥ T0 2.49 1.48 – 4.19 0.001 2.61 1.25–5.44 0.011 
- Corticosteroids ≥ T0 2.24 1.35 – 3.72 0.002       
- Pain at rest             
Ⴜ Mild pain 1     1     
Ⴜ Moderate pain 1.06 0.44 – 2.53 0.898 1.11 0.45–2.72 0.819 
Ⴜ Severe pain 3.5 1.49–8.24 0.004 3.27 1.31–8.14 0.011 
- Worst pain             
Ⴜ Mild pain 1           
Ⴜ Moderate pain 1.57 0.46 – 5.36 0.474       
Ⴜ Severe pain 4.14 1.41 – 12.19 0.010       
- Dose at T0             
Ⴜ Q1 1           
Ⴜ Q2 1.91 0.91 – 4.02 0.086       
Ⴜ Q3 2.27 1.04 – 4.92 0.038       
Ⴜ Q4 3.10 1.45 – 6.63 0.004       
- rs12948783 (RHBDF2)             
Ⴜ A carrier 0.50 0.27–0.93 0.029 0.44 0.24–0.99 0.083 
Fentanyl       
- Age 0.98 0.95–1.00 0.071 0.95 0.91–1.01 0.081 
- Adjuvant pain medication ≥ T0 2.45 1.20–5.00 0.013 2.82 0.93–8.54 0.067 
- Corticosteroids ≥ T0 2.88 1.42–5.87 0.004       
- Pain at rest             
Ⴜ Mild pain 1     1     
Ⴜ Moderate pain 0.52 0.10 – 2.55 0.42 0.53 0.10–2.74 0.448 
Ⴜ Severe pain 5.72 1.61–20.37 0.007 5.68 1.52–21.28 0.010 
- Worst pain       
Ⴜ Mild pain 1     
Ⴜ Moderate pain 3.14 0.36–27.64 0.30 
Ⴜ Severe pain 7.67 0.98–59.84 0.052 
- Dose at T0       
Ⴜ Q1 1     
Ⴜ Q2 1.87 0.59–6.02 0.289 
Ⴜ Q3 3.41 1.16–10.09 0.026 
Ⴜ Q4 2.90 0.91–9.29 0.072 
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and severe pain at rest (OR 5.68, p = 0.010) were independent as shown in multivariable 
analysis (tables 1–3). When the analysis was corrected for opioid dose the use of adjuvant 
pain medication was no longer signicant (p = 0.106).
Morphine: For morphine, age (OR 0.97, 95 % CI 0.94–1.00, p = 0.081), use of adjuvant 
pain medication started on T0 or later (OR 2.50, 95 % CI 1.23–5.13, p  =  0.012), use of 
corticosteroids started on T0 or later (OR 1.94, 95 % CI 0.98–3.86, p = 0.058) and the dose 
of morphine at T0 (Q3 OR 3.33, 95 % CI 1.36–8.13, p = 0.008) were found to be correlated 
with treatment failure in univariate analysis. None of the genetic variants correlated with 
failure of treatment (all: p > 0.10). In multivariable analysis use of adjuvant pain medica-
tion (OR 2.51, p  <  0.013) and age (OR 0.96, p  =  0.047) were found to correlate with 
treatment failure (tables 1–3). As for fentanyl, when the analysis was corrected for opioid 
dose, the use of adjuvant pain medication was no longer signicant (p = 0.10).
Oxycodone: For oxycodone, use of adjuvant pain medication started on T0 or later (OR 
6.22, 95 % CI 1.69–22.88, p = 0.006) and the SNPs rs12948783 (RHBDF2) (OR 0.23, 95 % 
Table 3. Results of univariate and multivariable analyses for all patients and per type of opioid (con-
tinued)
 
 
Univariate analysis Multivariable analysis
Odds 
ratio
95 % Condence 
Interval P
Odds 
ratio
95 % Condence 
Interval P
- rs1799971 OPRM1       
Ⴜ 118G carrier 0.44 0.19–1.06  .066
Morphine       
- Age 0.97 0.94–1.00 0.081 0.96 0.93–0.99 0.047 
- Adjuvant pain medication ≥ T0 2.50 1.23–5.13 0.012 2.51 1.22–5.19 0.013 
- Corticosteroids ≥ T0 1.94 0.98–3.86 0.058 
- Dose at T0       
Ⴜ Q1 1.00 -   
Ⴜ Q2 1.41 0.63 – 3.14 0.40 
Ⴜ Q3 3.33 1.36–8.13 0.008 
Oxycodone       
- Adjuvant pain medication ≥ T0 6.22 1.69–22.88 0.006 11.18 2.21–56.40 0.003 
- rs12948783 (RHBDF2)             
Ⴜ A carrier 0.23 0.06 - .88 0.032 0.19 0.03–1.12 0.066 
- rs7016778 (OPRK1)             
Ⴜ T carrier 0.30 0.09–1.00 0.050 0.20 0.04–1.09 0.063 
≥ T0: started on T0 or during hospitalization, Q1 #rst quantile, Q2 second quantile, Q3 third quantile, Q4 fourth 
quantile
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CI 0.06–0.88, p = 0.032) and rs7016778 (OPRK1) (OR 0.30, 95 % CI 0.09–1.00, p = 0.050) 
were identi#ed in univariate analysis. In multivariable analysis, all three variables remained 
in the model, without and with correction for opioid dose on T0. (adjuvant pain medica-
tion OR 11.18, p  =  0.003); rs12948783 in RHBDF2: OR 0.19 p  =  0.066; rs7016778 in 
OPRK1: OR 0.20, p = 0.063) (tables 1–3).
Hydromorphone: Fe number of patients in the hydromorphone group was considered 
too small for further analyses and to draw conclusions.
DISCUSSION
In this cohort of cancer patients treated with opioids, we found that in 20–34 % treatment 
with fentanyl, morphine, oxycodone or hydromorphone failed because of insuHcient pain 
control and/or dose limiting side eKects. Fis is in line with previously reported data (1, 
2, 26, 27). Clinical factors associated with treatment failure were the use of adjuvant pain 
medication started after T0 and severity of pain at rest at T0. In the morphine and fentanyl 
cohorts, younger age was also associated with a worse outcome. For the selected SNPs, we 
identi#ed rs12948783 (RHBDF2) and rs7016778 (OPRK1) as factors to be explored further 
in a future study. Previous studies assessing clinical risk factors for the need of opioid rota-
tion have yielded variable results. In a large and prospective study, 118/345 (34.2 %) patients 
underwent opioid rotation and no association between the need for rotation and pain type, 
use of adjuvant drugs or opioid doses was found (28). In another, retrospective, analysis, 
103/273 patients (37.5 %) rotated from their #rst line opioid. Although no correlation with 
age, type of pain or co-analgesics was found, the use of corticosteroids was associated with 
a signi#cantly lower rate of opioid rotation (29). In our study, the use of corticosteroids 
was correlated with higher rates of failure, but only in the univariate analyses. A possible 
explanation is that in our cohort of patients, corticosteroids were given to patients with 
severe complex pain. It is also possible that corticosteroids may alter pharmacokinetics 
(e.g. by induction of CYP3A4) and pharmacodynamics of opioids. Fe association with 
the use of adjuvant pain medication is complex. Adjuvant drugs are preferentially used 
when a neuropathic mechanism may contribute to the clinical presentation. Neuropathic 
pain is more diHcult to treat, as was shown in a validation study of the Edmonton Clas-
si#cation System for Cancer Pain. In that study, neuropathic pain and initial severity of 
pain were found to be signi#cant predictors of pain complexity and positively correlated 
with the number of days needed to achieve stable pain control, the use of more adjuvants 
and higher doses of opioids (30). In another study in cancer patients using morphine, 
neuropathic pain was associated with a higher opioid escalation index (31). In our study, all 
patients had nociceptive pain but patients with a neuropathic component, were eligible. 
Chapter 4: Opioid treatment failure cancer pain adults 83
4
Adjuvant drugs were prescribed in case of a suspected neuropathic pain component, which 
were usually more complex pain syndromes. Further studies should assess neuropathic 
pain using validated tools. Fe correlation with age has been observed before. Ericson et 
al. reported a decrease in risk of treatment failure of 3 % per 10-year increase in age. Above 
the age of 65 the risk decreased even 13 % per 10-year increase (32). In the present analysis, 
the correlation between age and failure to morphine and fentanyl remained unchanged 
when the multivariable analysis was corrected for opioid dose at T0 and therefore the asso-
ciation cannot be explained by lower treatment doses in elderly patients. We can speculate 
that diKerences in opioid metabolism play a role or even that elderly patients and/or their 
doctors are less likely to report insuHcient pain control or severe side eKects because they 
are less demanding and/or more often fear dose escalation. Finally, the association with 
pain intensity at rest was not unexpected and was reported before (30).
Fe genetic analysis was also set-up as an exploratory analysis in order to identify candi-
date SNPs associated with treatment failure of (speci#c) opioids. While the frequencies of 
the studied SNPs followed widely reported prevalence rates, none of the selected genetic 
variants were found to be signi#cantly correlated with failure of treatment in the entire 
cohort and the fentanyl, morphine and oxycodone cohorts in the multivariable analysis. 
We did however #nd an association between the variant upstream of the RHBDF2 gene 
(rs12948783) and treatment outcome (p < 0.10). In a previous genome wide association 
study (GWAS), this SNP was found to be signi#cantly associated with decreased pain 
relief from opioids (33). As this gene is coding for inactive rhomboid protease, an enzyme 
that has been associated with cancer growth (34, 35), the found hit could be due to cancer 
demographics of the analyzed cohort, which were not speci#ed in the GWAS study. In 
our cohort we observed a trend in the opposite direction, i.e. a lower rate of treatment 
failure. Fe distribution of tumor types might have been diKerent which, combined with 
low number of patients, may explain these seemingly contradictory #ndings. Although 
the genetic variation (rs1672717) in the HTR3B gene, coding for the serotonin receptor 
subtype 3B, was previously associated with opioid induced nausea and vomiting in more 
than 1,500 Caucasian cancer patients (17), we did not #nd an association with opioid 
failure. Opioid failure is a composite endpoint and although a substantial part of patients 
failing treatment had dose limiting adverse events, the proportion of patients with severe 
nausea and vomiting as the main reason for treatment failure was probably too low to 
detect an association.
Interestingly, we found no correlation between the frequently investigated OPRM1 SNP 
(rs1799971) and opioid failure. A meta-analysis has illustrated the relevance of this SNP 
for opioid requirement in postoperative patients, especially within Asians treated with 
morphine for visceral pain (36), but the results have been conXicting for opioid response 
in cancer induced pain (14, 17, 37–43). Although genetic variation in the KCNJ6 gene has 
been previously associated with increased opioid requirement in postoperative pain (44) 
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and a tendency toward less opioid eKectiveness in chronic pain (45), this variant does not 
seem to predict opioid failure in our cohort. Fe minor allele of OPRK1 rs7016778 SNP 
has been previously associated with an increased experimental pain threshold (46). Fis 
could be caused by increased expression of the kappa receptor and as a consequence a 
higher aHnity for endogenous opioids. Since oxycodone may exert (part of ) its analgesic 
eKect primarily via the kappa receptor (47), it is expected that OPRK1 genetic variants 
could alter the response and thus the need to switch to a non-kappa-binding opioid. 
While the relevance of the kappa receptor above the mu-opioid receptor for oxycodone 
has been discussed (48), in our cohort carriers of the minor allele had a (non-statistically 
signi#cant) lower risk of treatment failure with oxycodone, which is in line with the 
decreased pain sensitivity reported in the experimental pain setting. Lastly, none of the 
SNPs related to metabolism of speci#c opioids (CYP3A4, CYP2D6, OCT1, UGT2B7 and 
ABCC3) correlated with failure of treatment in our analysis. Fis might be due to our 
limited sample size. Furthermore, up till now little is known about the eKect of changes in 
pharmacokinetics on pharmacodynamics.
Although we assembled longitudinal data in a large group of cancer patients and studied 
a clinically relevant endpoint we must also acknowledge some limitations. Per treatment 
group numbers were small and the included population was heterogeneous in terms of 
treatment phase with opioids and opioid dose at T0. Furthermore we compared patients 
in whom treatment failed with patients in whom treatment did not fail. Although we 
strictly de#ned failure of treatment, we categorized all other patients as not failing treat-
ment although some may not have been successfully treated. Also, we studied failure as 
a composite endpoint although analgesia and (central) side eKects may be independent 
treatment outcomes (38). Sample size did not allow us to create subgroups according to 
the reason(s) of failure.
In conclusion, we have identi#ed that the use of adjuvant pain medication, pain in-
tensity at rest and age were associated with failure of treatment with fentanyl, morphine, 
oxycodone and hydromorphone in this exploratory study. Furthermore, a trend to a 
negative correlation with treatment failure was seen for the single nucleotide polymor-
phisms rs12948783 (RHBDF2) in all patients and the oxycodone cohort and for rs7016778 
(OPRK1) in the oxycodone cohort. As these factors are not opioid speci#c, they cannot be 
used to guide treatment and the choice for a speci#c type of opioid. Fe variant rs7016778 
(OPRK1) warrants further research with this respect. Ideally, future studies should include 
large and homogeneous patient populations and protocolized treatments strictly. How-
ever, such a trial will be diHcult – if not impossible – to perform in a palliative clinical 
care setting.
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Supplementary Table 1. Genotype frequencies and HW-equilibrium
SNP n MAF study (%) MAF Literature (%) HW (p-value)
CYP3A4 rs2242480 (*1G)  12 7 0.07
Ⴜ  *1/*1 175 
Ⴜ  *1/*1G 41 
Ⴜ  *1G/*1G 6 
CYP3A4 rs35599367 (*22)  6 5 0.37
Ⴜ  *1/*1 196 
Ⴜ  *1/*22 25 
Ⴜ  *22/*22 0 
CYP2D6 rs35742686 (*3)  4 2 0.68
Ⴜ  *1/*1 71 
Ⴜ  *1/*3 7 
Ⴜ  *3/*3 0 
CYP2D6 rs3892097 (*4)  21 28 0.34
Ⴜ  *1/*1 48 
Ⴜ  *1/*4 23 
Ⴜ  *4/*4 5 
CYP2D6 deletion (*5)  2 5 0.86
Ⴜ  Negative 76 
Ⴜ  Positive  3 
CYP2D6 rs5030655 (*6)  2 1 0.86
Ⴜ  *1/*1 76 
Ⴜ  *1/*6 3 
Ⴜ  *6/*6 0 
CYP2D6 rs28371725 (*41)  9 9 0.71
Ⴜ  *1/*1 65 
Ⴜ  *1/*41 13 
Ⴜ  *41/*41 1 
CYP2D6 XN  2 3 0.86
Ⴜ  Negative 76 
Ⴜ  Positive 3 
UGT2B7 rs7438135  45 50 0.79
Ⴜ  GG 49 
Ⴜ  GA 77 
Ⴜ  AA 33 
OCT1 rs72552763 (*2)  21 15 0.45
Ⴜ  *1/*1 247 
Ⴜ  *1/*2 86 
Ⴜ  *2/*2 10 
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Supplementary Table 1. Genotype frequencies and HW-equilibrium (continued)
SNP n MAF study (%) MAF Literature (%) HW (p-value)
OCT1 rs12208357 (*3)  8 10 0.31
Ⴜ  *1/*1 298 
Ⴜ  *1/*3 43 
Ⴜ  *3/*3 3 
OCT1 rs34130495 (*4)  4 2 0.47
Ⴜ  *1/*1 319 
Ⴜ  *1/*4 26 
Ⴜ  *4/*4 0 
OCT1 rs34059508 (*5)  1 1 0.81
Ⴜ  *1/*1 336 
Ⴜ  *1/*5 9 
Ⴜ  *5/*5 0 
ABCC3 rs4793665  52 49 0.59
Ⴜ  CC 38 
Ⴜ  CT 75 
Ⴜ  TT 44 
COMT rs4680  51 48 0.28
Ⴜ  GG 85 
Ⴜ  GA 160 
Ⴜ  AA 95 
COMT rs4818  37 42 0.07
Ⴜ  CC 141 
Ⴜ  CG 144 
Ⴜ  GG 56 
COMT rs4633  51 48 0.35
Ⴜ  CC 83 
Ⴜ  CT 161 
Ⴜ  TT 97 
OPRM1 rs1799971  11 16 0.77
Ⴜ  AA 269 
Ⴜ  AG 68 
Ⴜ  GG 5 
KCNJ6 rs2070995  79 80 0.22
Ⴜ  AA 9 
Ⴜ  AG 112 
Ⴜ  GG 217 
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Supplementary Table 1. Genotype frequencies and HW-equilibrium (continued)
SNP n MAF study (%) MAF Literature (%) HW (p-value)
RHBDF2 rs12948783  15 15 0.99
Ⴜ  CC 246 
Ⴜ  CT 89 
Ⴜ  TT 8 
HTR3B rs1672717  60 58 0.23
Ⴜ  CC 57 
Ⴜ  CT 152 
Ⴜ  TT 133 
OPRK1 rs7016778  13 12 0.38
Ⴜ  AA 255 
Ⴜ  AT 81 
Ⴜ  TT 4 
OPRK1 rs7824175  10 10 0.73
Ⴜ  CC 274 
Ⴜ  CG 64 
Ⴜ  GG 3 
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A BSTR ACT
Aims: Assess association between genetic variants and opioid requirement in cancer 
patients.
Patients & Methods: A prospective observational trial of 243 advanced cancer patients 
with inadequate analgesia treated by the palliative care team (PCT) was analyzed for 
ABCB1, ARRB2, COMT, GCH1, IL1RN, KCNJ6, OPRM1, RHBDF2, SCN9A and Stat6 
polymorphisms.
Results: For patients carrying OPRM1 118AG/GG and COMT 472GG (Val158Val) or these 
genotypes alone, a signi#cant higher median percentage dose increase was observed (95.2 % 
[32.8–345]) compared to OPRM1 118AA and COMT 472GA/AA (158Met allele carriers) 
(48.5 % [0–98.8]) (p = 0.0016). No associations were found with morphine equivalent dose 
after consultation PCT or ketamine use.
Conclusions: Patients with the combined OPRM1 118AG/GG and COMT 472GG geno-
type required 50 % higher dose increase for suHcient analgesia.
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INTRODUCT ION
Pain is one of the most frequent and uncomfortable symptoms in cancer patients. It has 
an incidence ranging from 33 % after curative treatment to up to 64 % in the advanced 
stage of cancer [1]. Pain is also one of the most common indications in cancer patients 
arriving at the emergency department [2]. A European cancer survey illustrated that pain 
treatment is insuHcient in this population, where moderate to severe pain was reported by 
56 % and breakthrough pain by 63 %. Fe ‘quality of life’ aspect was insuHciently covered 
according to 50 % of patients [3]. Daily opioid requirement among cancer patients ranges 
from 25 mg to 2000 mg, which makes pain treatment even more complicated [4]. Due to 
the complex etiology, a personalized treatment algorithm would have a great advantage in 
clinical practice.
Cancer pain is primarily caused by the tumor itself, and less frequent by cancer treat-
ments such as surgery, chemotherapy and radiation [5]. Fe type and size of the tumor and 
the extent of pressure on or invasion into bones, nerves and other organs constitute prin-
cipal determinants of the pain severity and phenotype. Apart from tumor characteristics, 
patient characteristics are also likely to explain the observed diKerences in pain experience 
[6, 7]. Fe female sex is overrepresented in chronic pain conditions, where women tend to 
have a lower pain threshold, but, paradoxically, are more sensitive to morphine eHcacy [8]. 
Fis gender eKect is probably due to diKerences in anatomical and physiological composi-
tions in the central nervous system circuits between males and females [9]. Ethnicity also 
seems the inXuence the pain expression, with the diKerences in pain most likely caused 
by language obstacles and low socioeconomic status in minority groups, although cultural 
background can also inXuence self-reports of pain [7, 10].
Finally, the individual genetic make-up is contributing to observed diKerences in pain 
experience and analgesic responsiveness [11], and may in fact partly explain previously 
mentioned associations with sex and ethnicity. Most of the studies that addressed this 
topic were performed in the postoperative setting using a candidate gene approach or 
a genome wide analysis. Recently, a meta-analysis with 4,607 postoperative patients 
showed that the genetic variation 118A>G in the µ-opioid receptor (MOR), encoded by 
the OPRM1 gene, was associated with higher postoperative opioid dose requirement [12]. 
Studying a genetic contribution in cancer pain patients is more complicated. Indeed, in 
this particular condition, pain is confounded by even more factors, with more diHculties 
in proving the genetic contribution of selected candidate single nucleotide polymorphisms 
(SNPs) to its severity.
Investigating a large cohort (n  =  1,000) of female breast cancer patients, Cajanus et 
al. illustrated 33 % higher postoperative oxycodone requirement in 118GG genotyped 
individuals [13]. In the large EPOS trial consisting of 2294 European cancer pain patients 
the researchers demonstrated an eKect of CYP3A4/5 SNPs on fentanyl PK in 620 patients 
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[14], of COMT rs2020917 on constipation in 1568 patients [15], of a HTR3B genetic variant 
on opioid-induced nausea/vomiting in 1579 patients [16] and dyspnea in the total cohort 
(n = 2294) [17]. Yet, none of the SNPs correlated with opioid requirement in this cohort 
[18].
Fe aim of this study was to determine if polymorphisms in the candidate genes ABCB1, 
ARRB2, COMT, GCH1, IL1RN, KCNJ6, OPRM1, RHBDF2, SCN9A, and Stat6 are associ-
ated with opioid requirement in patients with advanced clinical cancer who were referred 
to a pain consultation service due to inadequate analgesia. Our prospectively recruited 
cohort is unique as it represents moderate-severe cancer pain patients, who were treated 
according to a uniform algorithm in a single center.
M ETHODS
Patients with advanced clinical cancer, for whom the multidisciplinary Palliative Care 
Team (PCT) of Erasmus University Medical Center was consulted to treat pain, between 
October 2008 and December 2012, were eligible for inclusion. Clinical data were pro-
spectively collected from a structured data collection sheet (demographical data, type of 
cancer, metastases, pain intensities and medication) and from the electronic health record 
(type of pain). Fe type of pain (nociceptive versus mixed nociceptive-neuropathic pain) 
was established by a clinical neurologist, using the de#nition of (a) neuropathic pain 
(component) of the ‘International Association for the Study of Pain’ and the algorithm 
described by Treede et al. [19], which is in accordance with previous literature on the clini-
cal distinction between nociceptive and mixed pain [20]. Pain intensity (numerical rating 
score, NRS) and opioid requirement were assessed at time of #rst consultancy (T = 0 days) 
and after the patient was switched to another analgesic or alternatively, after the dose was 
changed (T = 3 days). Dose modi#cations and opioid rotations were done in accordance 
with the institutional pain protocol of Erasmus MC, which was based on the Dutch 
national Guideline “Cancer Pain” [21].
Fe morphine equivalent dose (MED) was expressed as amount of opioid in mg paren-
teral morphine/24h. Conversion factors were according to the Dutch consensus guideline 
“Cancer Pain” [21]. Fe conversion factors used for calculating MED were 6.67, 0.07 and 
0.05 for parenteral hydromorphone, oral tramadol and oral codeine, respectively [22]. 
For parenteral buprenorphine the same conversion factor as for fentanyl was used [23]. 
MED was calculated by combining the sustained release and continuous intravenous 
opioid medication. Although information on all rescue medication for individual patients 
was not collected, the maximum daily dosage of oral and intravenous rescue medication 
(opioids) as a rule consisted of 100 % of the sustained release or continuous intravenous 
opioid dosage. When patients were using more than 50 % of the rescue doses, sustained 
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release or continuous intravenous opioid dosage was increased. Fus, the calculated MED 
represents 67–100 % of the actual MED. Fe study was approved by the institutional 
review board of Erasmus MC (MEC2008–166) and registered at www.clinicaltrials.gov 
(NCT00956878). All patients gave written informed consent for DNA analysis.
Study outcomes
Morphine equivalent dose (MED) at T = 3d and the relative increase in MED between 
T = 3d and T = 0d (∆MED/MED T = 0d) were the primary outcome measures for this 
study. By adjusting the change in dose for the dose received at baseline, the large variability 
between patients was reduced and we thus corrected for baseline analgesia. Free days 
was chosen as it corresponds to the median time point at which we have previously dem-
onstrated adequate analgesia with 48h after consultation of the PCT [24]. As secondary 
outcome measure, the use of ketamine as an adjuvant analgesic (indicating extreme pain 
phenotypes) was assessed.
Genotyping
Whole blood was obtained by venous puncture and DNA was isolated and frozen at 
-800C until further analysis. Fe genomic DNA was isolated with the MagNA Pure LC 
2.0 instrument (Roche Diagnostics®) according to the ‘MagNA Pure LC DNA Isolation 
Kit Large Volume’ protocol. DNA concentrations were measured on the NanoDrop 1000 
Spectrophotometer (Fermo Fisher Scienti#c®) and diluted to 10 ng/µl if concentrations 
exceeded this threshold. Fe selected candidate polymorphisms for this study were: ABCB1 
rs1128503, rs2032582, rs1045642, ARRB2 rs1045280, COMT rs4680, 4818, 4633, GCH1 
rs8007267, rs10483639, rs3783641, IL1RN*2 (86 VNTR), KCNJ6 rs6517442, rs2070995, 
METTL21A rs2952768, OPRM1 rs1799971, RHBDF2 rs12948783, SCN9A rs6746030 and 
Stat6 rs841718.
All SNPs, except IL1RN*2, have been genotyped with the TaqMan allelic discrimina-
tion method. Fe predesigned or custom made SNP assays have been designed by the 
manufacturer (Life Technologies, Bleiswijk, Fe Netherlands). Fe patients were analyzed 
on a 96-well plate with the 7500 Real-Time PCR System (software version v2.0.5; Life 
Technologies). Fe IL1RN*2 (86-bp tandem repeats) variation has been performed with 
PTC-200 Fermal Cycler, DNA Engine (Biorad®) and examined with gel-electrophoresis 
[25].
Fe catechol-O-methyltransferase (COMT) and guanosine triphosphate cyclohydrolase 
(GCH1) haplotype were estimated with R version 3.1.1 haplo.stats package. Fe haplo-
types included in this analysis were estimated with a posterior probability > 0.98. Fe 
original study describing the COMT haplotypes by Diatchenko et al. (2005) used SAS 
Proc haplotype for haplotype construction [26]. Both software packages make use of the 
expectation-maximization (EM) logarithm. By analyzing rs4680, rs4818 and rs4633 the 
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COMT haplotype was determined with an accuracy of approximately 98 % [26]. Patients 
genotyped GGC were categorized in the low pain sensitivity (LPS) group, ACT in average 
pain sensitivity (APS) group and GCC in high pain sensitivity (HPS). Fe following 
groups have been compared (LPS/LPS + LPS/APS vs. APS/APS + LPS/HPS vs. HPS/HPS 
+ APS/HPS) in the analysis.
Analysis of the 3 GCH1 SNPs leads to a sensitivity and speci#city of 100 % of the ‘pain-
protective’ haplotype, where non-carriers, carriers and homozygous carriers have been 
compared [27]. In addition to this haplotype, we are also interested in the combined allelic 
genotypic eKect of OPRM1 rs1799971 and COMT rs4680, as reported earlier [28]. Patients 
carrying the OPRM1 118G allele and the COMT Val158Val genotype or these genotypes 
alone were considered the high risk group for pain, while patients with the OPRM1 118AA 
genotype and COMT 158Met allele carriage were the low risk genotype.
Statistical analysis
Current data were analyzed with the statistical software package SPSS version 21.0 for 
Windows. Fe categorical demographic and clinical data were analyzed with Pearson’s 
chi2 test or Fisher’s exact test when appropriate. Continuous data were assessed with 
a non-parametric tests (Mann-Whitney or Kruskall-Wallis) or with a parametric test 
(students t-test or ANOVA) when normal distribution was not violated. Normality was 
tested numerically with the Shapiro-Wilk test. Fe genotype frequencies were assessed for 
violation of the Hardy-Weinberg equilibrium with the Chi2 test. In the SNP analysis the 
additive model was used when the genotype count into groups were separately ≥ 10. When 
this criterion was not met a dominant model was used.
Multiple linear regression was used for assessment of the correlation between the SNPs 
with MED (T = 3d) and relative ∆MED. Fe independent factors type of pain (nocicep-
tive vs. mixed), pain intensity (T = 0d) (only used for MED (T = 3d) outcome), gender, 
age, type of cancer and treatment have been included as confounding factors. Fe associa-
tion with ketamine use (extreme pain phenotypes) was assessed with logistic regression, 
in which the same independent variables have been used. Multicollinearity between the 
independent factors was excluded since none of the factors had a variation inXation fac-
tor (VIF) > 3. Metastasis was not included in the model because no evidence exists on 
higher pain intensities for this group compared with primary cancer patients. Besides, 
since almost 80 % of the population had a metastasis at time of inclusion, the cohort could 
be considered homogenous for this factor. Fe two-sided p-values in the multiple linear 
and logistic regression were adjusted for multiple testing with the Bonferroni correction 
(p < 0.0029).
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R E SU LTS
Patient characteristics
Two-hundred and forty three cancer patients were included in this prospective observa-
tional study. Free patients were not using opioids at baseline and after consultation PCT. 
Fese patients were consequently excluded from further analysis. From the remaining 240 
patients, demographic and clinical characteristics are reported in Table I. As illustrated 
in this Table, 72 % of the patients were diagnosed with nociceptive pain, 79 % had me-
tastasized cancer, 9 % required ketamine as an adjuvant analgesic and fentanyl was most 
frequently used at T = 0d (52.1 %) and T = 3d (73.3 %). Gastrointestinal, urological, lung 
and gynecological were the most prevalent tumor types. Twenty-six % of the patients were 
treated with radiotherapy, 14.2 % with chemotherapy and 7.5 % underwent elective surgery. 
Forty-#ve % of the patients had supportive (e.g. stents) or no cancer treatment at all at 
time of inclusion.
Outcome measures
Fe median MED was 20 mg/24 h [IQR: 10 – 53] at T = 0d and 40 mg/24 h [IQR: 20 – 
80] at T = 3d. In parallel, the pain intensity numerical rating score (NRS) score decreased 
from 6 [IQR: 4–8] to 4 [IQR: 2–5], reXecting a statistically (p < 0.0001) and clinically 
signi#cant improvement in pain. From the 240 patients the MED was decreased by the 
PCT in 18 (7.5 %) individuals and in 48 (20 %) cases the MED remained the same. From 
the latter group, 3 patients were rotated to an alternative opioid. In the total cohort 84 
patients were rotated to an alternative opioid.
Several outliers have been identi#ed within the outcomes MED (T = 3d) and relative 
∆MED with the formulas Q3+(3.3*(Q3-Q1)) and Q1-(3.3*(Q3-Q1)). After LOG transfor-
mation no outliers were found within the MED (T = 3d) outcome and 4 outliers in the 
relative ∆MED outcome. None of these outliers had extreme genotypes that could explain 
the high increase/decrease in dose between T = 0d and T = 3d. Because absence of outli-
ers is one of the assumptions in regression analysis these 4 outliers were removed. From 
the clinical factors age, gender, type of pain, type of cancer, type of treatment and pain 
intensity at baseline (T = 0d) only age (p = 0.019) and pain intensity at T = 0d (p = 0.010) 
were related with MED at T = 3d. Whereas none of these clinical factors were related with 
relative ∆MED.
Genetic associations
Fe genotype and haplotype frequencies of all assessed polymorphisms, except the 
METTL21A SNP, met the Hardy-Weinberg (HW) equilibrium. Ferefore, this SNP was 
removed from the statistical analysis to avoid any spurious associations. All allelic frequen-
cies were in line with the frequencies reported in the SNP database (HAPMAP) on the 
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Table I. Demographic and clinical characteristics
  n = 240
Age (years) 62 [54 – 68]
Gender (%)  
Male / Female 138 (57.5) / 102 (42.5) 
Type of pain (%)  
Nociceptive / Mixed 173 (72) / 67 (28) 
Type of cancer (%)  
Gastrointestinal 90 (37.5) 
Urological 36 (15) 
Lung 34 (14.2) 
Gynecological 22 (9.2) 
Other 14 (5.8) 
Primary unknown 14 (5.8) 
ENT 13 (5.4) 
Breast 9 (3.8) 
Hematological 8 (3.3) 
Metastasis (%)  
Yes/No 189 (79 / 51 (21) 
Treatment (%)  
None or supportive 108 (45) 
Radiotherapy 63 (26.3) 
Chemotherapy 34 (14.2) 
Surgery 18 (7.5) 
Radiotherapy and chemotherapy 11 (4.6) 
Surgery and radiotherapy 5 (2.1) 
Surgery and chemotherapy 1 (0.4) 
Ketamine use (%)  
Yes/No 21 (9) / 219 (91) 
Pain intensity T = 0d 6 [4 – 8]
Pain intensity T = 3d 4 [2 – 5]
Opioid T = 3d (%)  
Fentanyl 176 (73.3) 
Oxycodone 43 (17.9) 
Hydromorphone 11 (4.6) 
Morphine 5 (2.1) 
Buprenorphine 5 (2.1) 
Morphine equianalgesic dose (T = 0d) 20 [10 – 53]
Morphine equianalgesic dose (T = 3d) 40 [20 – 80]
All values are expressed in median with corresponding interquartile range (IQR), unless stated otherwise.
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National Center for Biotechnology Information (NCBI) website. Fe observed genotype 
frequencies of the determined genetic variants and haplotype overview are displayed in 
Table II.
Fe relative ∆MED was signi#cantly associated with COMT rs4633 (p = 0.007), COMT 
rs4680 (p = 0.012) and combined OPRM1/COMT genotype (p = 0.001) in the univariate 
analysis. After correction for clinical factors and Bonferroni correction only the eKect be-
tween the relative ∆MED with combined OPRM1/COMT genotype remained signi#cant 
(p < 0.0029). As displayed in Figure 1, cancer patients having the OPRM1 118G allele with 
the COMT Val158Val genotype or these genotypes alone require a higher median percent-
age increase in dose (after normalization to baseline dose) (95.2 % [32.8–345]) compared 
to OPRM1 118AA in combination with the 158Met allele (48.5 % [0–98.8]). None of the 
Table II. Genotype frequencies (n = 240)
Gene rs number Wild type allele Heterozygous allele Variant allele Undetermined
ABCB1
 
 
rs1128503 84 115 40 1
rs2032582 84 112 42 2
rs1045642 60 105 73 2
ARRB2 rs1045280 30 94 112 4
COMT
 
 
rs4680 51 130 59 0
rs4818 82 124 34 0
rs4633 52 132 56 0
GCH1*
 
 
rs8007267 144 88 7 1
rs10483639 153 77 9 1
rs3783641 143 87 8 2
KCNJ6
 
rs6517442 28 115 96 1
rs2070995 10 81 147 2
IL1RN *2 131 83 11 15
METTL21A rs2952768 43 89 103 5
OPRM1 rs1799971 192 45 1 2
RHBDF2 rs12948783 159 74 7 0
SCN9A rs6746030 169 63 6 2
STAT6 rs841718 42 124 69 5
COMT haplotype
 
  LPS+LPS or
LPS+APS
APS+APS or
LPS+HPS
HPS+HPS or
APS+HPS
 
  144 69 25 2
GCH1 haplotype
 
  Non-carrier Heterozygous carrier Mutant carrier  
  160 78 0 2
All values are expressed in median with corresponding interquartile range (IQR), unless stated otherwise.
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selected SNPs and haplotypes (ABCB1 rs1128503, ABCB1 rs2032582, ABCB1 rs1045642, 
ARRB2 rs1045280, COMT rs4680, COMT rs4818, COMT rs4633, COMT haplotype, 
GCH1 haplotype, IL1RN*2, KCNJ6 rs6517442, KCNJ6 rs2070995, OPRM1 rs1799971, 
RHBDF2 rs12948783, SCN9A rs6746030, Stat6 rs841718, OPRM1/COMT combined) were 
associated with MED at T  =  3d after correction for confounding factors and multiple 
testing. Also no correlation with ketamine use was found.
DISCUSSION
Our study illustrates that the combined OPRM1(rs1799971)/COMT(rs4680) genotype is 
related with a 50 % higher relative increase in opioid dose required for su@cient analgesia 
after PCT consultation. We found that patients carrying the OPRM1 118G allele with the 
COMT Val158Val genotype or these genotypes alone need a higher increase in dose, after 
correction for baseline dose. Bese results are in line with a previous report in 207 cancer 
patients showing the highest morphine dose in OPRM1 118G allele carriers and COMT 
158Val allele carriers [29].
Be COMT enzyme, mainly expressed in the prefrontal cortex and striatum [30], is 
responsible for the degradation of catecholamine’s (e.g. dopamine, noradrenaline). 
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Figure 1. Logarithmic function of relative ∆MED (%) and OPRM1/COMT genotype
Be combined OPRM1/COMT genotype is signiUcantly associated with relative ∆MED (%) in the univariate 
analysis (p = 0.001) and after correction for gender, age, type of cancer, treatment and pain (p = 0.0016). Be 
corrected relative ∆MED values for the previously mentioned clinical factors are displayed in this Ugure. Bis as-
sociation also remained after Bonferroni correction (p < 0.0029). Patients genotyped OPRM1 118AG/GG with 
COMT Val158Val (Group 2) or these genotypes alone require higher dose increase (95.2 % [32.8–345]) compared 
to patients genotyped OPRM1 118AA and COMT Val158Met/Met158Met, (Group 1) (48.5 % [0–98.8]).
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Induced changes in dopamine signaling system aZect the opioid system [31, 32]. An in 
vivo study illustrated that COMT knock-out mice experienced an increased anxiety and 
stress response [33] but paradoxically an increased morphine response [34]. Be COMT 
polymorphism rs4680 (Val158Met) leads to a decreased thermostability and reduced 
COMT activity [35]. In healthy volunteers it was demonstrated using positron emission 
tomography (PET) scans that AA genotyped individuals have lower MOR signaling upon 
pain challenge and a higher MOR binding potential [36]. Be opposite eZects of this 
variant on pain (increased) and analgesia (lower demand) can be explained by the presence 
of more ‘available’ receptors but not enough endogenous agonists to bind, as illustrated in 
animal models [37]. Bis is in line with our Unding where we report that the COMT GG 
(Val158Val) genotyped patients with the OPRM1 variant are predisposed to higher dosage 
step increase for su@cient analgesia.
Be OPRM1 118A>G SNP has been related with reduced opioid eZect as illustrated by 
means of an increased opioid requirement and reduced risk for adverse events [12, 38]. 
Whether this eZect is caused by a decrease in protein expression or decreased binding 
a@nity/potency for exogenous opioids remains inconclusive [39]. Independent of the 
functional consequence, the 118G allele will counteract the ‘beneUcial’ eZect of a person 
that carries the COMT 158Met allele. Bis could explain why diZerent studies addressing 
the genetic variants in these genes were unable to illustrate an eZect on pain sensitivity 
[40–42] or opioid demand [43].
A challenge of the current study is that information on opioid use before admission 
was missing in our cohort. Because of a chance of development of opioid tolerance, the 
length of prior opioid use is a potential confounder in the analysis of opioid requirement. 
Another limitation of this cohort is the heterogeneous nature of the population. However, 
none of our tumor type groups had a su@cient sample size in order to assess individually 
with adequate statistical power. Alternatively, we chose to adjust for known factors when 
possible and to correct our tests for multiple testing. On the other hand, one could argue 
that an eZect seen in such a heterogeneous population is more likely to have real clinical 
meaning and has application potential as it overcomes the background noise of confound-
ing factors.
In conclusion, we found that the combined OPRM1 118A>G and COMT Val158Met 
variants or these genotypes alone were related with 50 % higher dosage increase of opioids 
in patients with advanced cancer. Bese genetic biomarkers may be helpful in identify-
ing cancer pain patients with decreased opioid sensitivity and to relieve their pain more 
quickly and more adequately. Indeed, based on genetic information, the opioid dose could 
be adjusted proactively, with the ultimate goal to avoid excessive pain in these vulnerable 
and seriously ill patients.
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A BSTR ACT
Pain sensitivity is an inherited factor that varies strongly between individuals. We inves-
tigated whether genetic polymorphisms in the candidate genes COMT, OPRM1, OPRD1, 
TAOK3, TRPA1, TRPV1, and SCN9A are contributing to experimental pain variability 
between children. Our study included 136 children and adolescents (8–18 years). Cold 
and heat pain thresholds were determined with a Bermal Sensory Analyzer. Women and 
young children were signiUcantly more sensitive to pain (P < 0.05). After correction for 
age, gender, reaction time, and correction for multiple testing, OPRM1 118A>G G-allele 
carriers (AG and GG) rated the hot stimulus as signiUcantly less painful than did OPRM1 
118A>G AA genotyped individuals (2[1–5] vs 7 [3–9], respectively; P = 0.00005). Addition-
ally, OPRM1 118G allele carriers reached more frequently the minimum temperature limit 
(44 % vs 17 %, respectively; P  =  0.003) and maximum temperature limit (52 % vs 24 %, 
respectively; P = 0.0052), indicative for lower pain sensitivity. Be combined genotype, 
based on expected pain sensitivity, OPRM1 118AA/COMT 472 GA or AA genotyped 
children, was associated with lower pain thresholds (ie, higher pain sensitivity) than were 
the OPRM1 118GA or GG/COMT 472GG genotyped children. Bis is the Urst study 
reporting on genetic variants and experimental thermal pain in children and adolescents. 
OPRM1 rs1799971 and the combined OPRM1/COMT genotype could serve as biomarkers 
for pain sensitivity.
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INTRODUCT ION
Be amount of pain expressed by an individual is mediated true a complex interplay 
between biological, psychological, sociocultural and environmental factors [21; 48]. Bis 
interplay is responsible for major variability in pain severity and thus analgesic dose 
requirements between individuals. One of these factors, gender, has been related with dif-
ferences in pain perception in a study in which adult females showed lower thermal pain 
thresholds (i.e. higher pain sensitivity) than males. Be higher pain sensitivity observed in 
females seems to be mediated by increased pain-related fear [20]. A recent meta-analysis 
in pediatrics conUrmed the increased pain sensitivity to thermal stimuli in females only 
in cohorts with a mean age of 12 years or older [6]. Ethnicity, with diZerent underlying 
mechanisms, is also contributing to diZerences in pain experience as shown in a systematic 
literature review reporting increased pain responsiveness in African-American individuals 
[36]. Studies on the relative contribution of environment versus genetics pointed out that 
heritable components can explain 12–70 % of the variability in pain intensity, depending 
upon the pain modality [2; 16; 31; 32]. In line with this genetic in|uence, speciUc variants 
within the mu-opioid receptor (OPRM1)[38] and catechol-O-methyltransferase (COMT) 
[4] gene have been associated with pain and analgesic treatment with opioids.
An experimental setting is ideal to assess associations between candidate polymorphisms 
and pain sensitivity, as such a setting excludes major confounders that are present in the 
clinic and hamper a genotype-phenotype correlation. Be method of thermal quantitative 
sensory testing is often used to assess pain sensitivity in children and adults in a controlled 
and non-invasive fashion. Although experimental pain is often not directly translatable to 
the clinical situation, a good correlation has been reported between thermal pain thresh-
olds and opioid response in healthy volunteers [15], the postoperative setting [1; 27; 35] 
and chronic pain [14]. Several studies have reported that speciUc genetic variants seem to 
be associated with pain sensitivity in the experimental setting – at least in adults [19]. Bis 
has, however, never been investigated in children.
For this study candidate genes previously associated with pain sensitivity in adults were 
selected for which there is evidence on either: a) thermal pain thresholds: OPRD1 [23], 
TRPV1 [23], TRPA1 [22]; b) pain and/or analgesic requirement: OPRM1 [38], COMT 
[20], SCN9A [37; 42]; or c) variants found in a genome wide association study involving 
morphine requirement in pediatrics: TAOK3 [10]. A prerequisite for the probability of 
establishing associations was su@cient frequency of the variant allele in the population 
(> 5 %). Be aim of our study was to determine whether the selected genetic variants are 
associated with thermal pain sensitivity in a cohort of children previously admitted to the 
hospital during their neonatal period and in healthy controls without previous hospital 
admissions.
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M ETHODS
Bis candidate gene association study was approved by the Institutional Review Board of 
Erasmus University Medical Centre in Rotterdam (Be Netherlands) as an addendum to 
our ‘Long term consequences of neonatal pain study’ (at age 8–18 years) (MEC-2010–299) 
[45; 46]. All parents and children participating in this long-term outcome study (n = 171) 
were asked to provide consent for DNA analysis on left-over saliva material from this 
study. Saliva had been collected at the child’s age of 8–18 years and was stored between 
2 to 4 years at -20°C until the current DNA analysis for this candidate gene association 
study. An information letter with informed consent forms was sent to the home address. 
Written informed consent was obtained from the parents of each child prior to participa-
tion. Co-consent in writing was also obtained from children 12 years of age and older, in 
accordance with Dutch law.
Participants
Be participants (8–18 years) had participated in a trial on the possible long-term eZects of 
pain and opioid/sedative administration during the prenatal or neonatal period on brain 
morphology, brain functioning, neuropsychological functioning and pain sensitivity. Six 
groups were distinguished on the basis of the neonatal medical history: 1) children receiv-
ing neonatal extracorporeal membrane oxygenation (ECMO) treatment [45] who had 
been exposed to a median pain intensity in combination with high continuous opioid 
and sedative exposure; 2) preterm born children who were mechanically ventilated in the 
Urst weeks of life [46] with low exposure to pain and opioids; 3) children operated upon 
in the Urst months of life to remove a giant congenital melanocytic naevus (GCMN), 
with extreme pain and high opioid and sedative exposure; 4) children undergoing major 
surgery in the Urst month of life (e.g. abdominal, thoracic incision) with relatively high 
pain intensity and high opioid and sedative exposure; 5) children who prenatally had 
been exposed to opioid related substances (morphine, methadone, heroin) through their 
mothers; and 6) a control group of healthy children without a history of neonatal pain 
and opioid exposure.
Experimental thermal pain
Bermal detection and pain thresholds were assessed with the Bermal Sensory Analyzer 
(TSA; type II Medoc®, Ramat Yishai, Israel). Our research group has ample experience 
with this method [43–46]. Be thermode stimulating surface was placed on the thenar 
eminence of the non-dominant hand. Be applied temperature ranged from 0°C to 50°C, 
which was safe and non-damaging for the skin [29]. Assessment was according to a stan-
dardized protocol. Be Urst step was explaining the test to the children, after which the 
detection and pain thresholds for cold and heat were determined with the reaction time 
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dependent Method of Limits (MLI). Next, the detection thresholds for cold and heat were 
examined by gradually decreasing or increasing, respectively the baseline temperature of 
32°C at a rate of 1°C/sec. Be child had been instructed to press the button as soon as the 
cold or heat stimulus was felt, upon which the temperature of the thermode returned to 
baseline temperature. Two tests served as rehearsals, and the detection thresholds were 
calculated as the means of the 4 following tests. Be cold and heat pain thresholds were 
assessed almost in the same way, but now the child had been instructed to press the button 
as soon as the thermode started to feel painful, with the temperature reversing at a rate of 
10.0°C/sec after the button was pressed. If a child did not press the button before 0°C or 
50°C was reached, the test was automatically terminated. In this case the pain thresholds 
were set at 0°C and 50°C, respectively. All TSA test outcomes were corrected for the child’s 
average reaction time, determine with the short base-line speed task of the Amsterdam 
Neuropsychological Tasks (ANT) [12]. Lastly, perception of the intensity of pain evoked 
by a hot stimulus (46°C), applied with the TSA apparatus, was determined with a self-
reported score on a Numerical Rating Scale (NRS) with the extremes 0 (no pain at all) 
and 10 (worst imaginable pain).
Genotyping
DNA was isolated from surplus saliva (registered at Dutch internet portal (NL33603.078.10)), 
either manually with the “QuickExtractTM – DNA Extraction Solution (Epicentre®)” 
or automated with the “DNA Isolation Kit - Large volume” on the MagNA Pure LC 
2.0 instrument (Roche®). Be following candidate genetic polymorphisms were selected: 
COMT rs4680, rs4818, rs4633, OPRM1 rs1799971, OPRD1 rs2234918, TRPA1 rs11988795, 
rs13255063, TRPV1 rs2234918, TAOK3 rs795484 and SCN9A rs6746030. All genetic variants 
were analyzed with the allelic discrimination method using “TaqMan® SNP Genotyping 
Assays” on the 7500 Fast Real-Time PCR System (software version 3.0.0; Applied Biosys-
tems, Bleiswijk, the Netherlands).
Genotype frequencies were checked for agreement with the Hardy-Weinberg equilib-
rium and MAFs from literature (HapMap, National Centre for Biotechnology Infor-
mation). When a genotype group within a SNP consisted of less than 10 participants, 
heterozygotes and homozygotes variants were combined. COMT haplotype was estimated 
with R (version 3.1.1) haplo.stats package using a posterior probability limit of 90 %, with 
GGC (rs4680, rs4818, rs4633 resp.) genotype coding for low pain sensitivity (LPS), ACT 
for average pain sensitivity (APS) and GCC high pain sensitivity (HPS) [13]. Participants 
with LPS/LPS and LPS/APS alleles were categorized in the LPS group, APS/APS and LPS/
HPS in the APS group and HPS/HPS and APS/HPS alleles in the HPS group. In addition 
also the combined eZect of OPRM1 and COMT rs4680, suggested in previous reports, was 
assessed [28; 39]. To this aim children with the 118AA genotype with 472A allele carriage 
were compared with children with the 118G allele carriage with/or 472GG genotype.
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Statistical analysis
Data were analyzed in IBM SPSS Statistics version 21. Normal distribution was judged 
visually (Q-Q plot, histogram) and tested with the Kolmogorov-Smirnov test. Associa-
tions of normally distributed data were analyzed with a T-test or ANOVA, whereas skewed 
data was analyzed with Mann-Whitney U or Kruskal-Wallis test. Before assessment of the 
genetic factors, clinical factors such as age, gender and cases vs. control were analyzed for 
their in|uence on thermal pain. Be association between the genetic variants and pain 
thresholds, NRS pain scores and number of children who reached the minimum and 
maximum temperature was tested univariate and multivariable either by multiple linear or 
binary logistic regression. Be association between the selected genetic variants with TSA 
outcomes was corrected for age, gender and reaction time, by including these factors as 
covariates in the multivariable linear regression. All other outcomes were solely corrected 
for age and gender in the multivariable regression. In the univariate analysis p-values 
below 0.05 were considered statistically signiUcant. Associations with the selected genetic 
variants from multivariable regression were considered signiUcant if p-value was below 
0.0056, which was after adjustment for multiple testing by Bonferroni correction. Data 
are presented as median with corresponding interquartile range, unless stated otherwise.
R E SU LTS
From the 171 participants from the previous trial, 136 parents and/or children (79.5 %) gave 
written informed consent for DNA analysis on surplus saliva material and were recruited 
in this current study. Figure 1 shows the inclusion rate broken down for the medical his-
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Figure 1. Overview inclusion rate participants according to medical history.
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tory subgroups. Participants (n = 136) and non-participants (n = 35) did not signiUcantly 
diZer in age (11.2 [10.1–14.2] versus 11.2 [10.2–13.9; p = 0.63) and gender (52.9 % versus 40 % 
female; p = 0.19). Clinical characteristics are listed in Table 1.
Be Unal analysis included TSA test results of 133 children. One child refused to perform 
the test, the results of two other children were considered unreliable due to presence of 
attention deUcits. Girls rated the heat stimulus of 46°C signiUcantly more painful than 
did boys (NRS: 7 [3–9] versus 4 [1–7]; p = 0.004). Bis signiUcant correlation between 
gender and pain sensitivity was conUrmed by the higher pain thresholds (tolerating more 
extreme temperatures) in boys for cold ((°C): 5.74 [0.57–16.9] versus 14.6 [4.21–21.6]; 
p = 0.0004) and heat ((°C): 49.1 [44.5–50] versus 45.1 [40.8–48.2]; p = 0.0002). Also more 
boys than girls reached the upper (54.8 % versus 26.4 %; p = 0.003) and lower temperature 
limits (48.4 % versus 22.2 %; p = 0.032). Although younger children reported higher NRS 
scores for the stimulus of 46°C (r= -0.182, p = 0.034), age was not signiUcantly correlated 
with thermal pain thresholds. Be medical history had no in|uence on the pain sensitivity 
and no associations in this respect were between all cases combined versus the controls. 
Considering the absence of an eZect of medical history on thermal pain sensitivity we 
performed genetic analysis on the total cohort. Be associations with the clinical factors 
are shown in Supplementary Table 1.
Table 1. Descriptive data cohort
  n = 136  
Age (yrs.) 11.2 [10.1–14.2]
Male/Female (%) 47.1/52.9  
Medical history group (n)    
Group I: Extracorporeal Membrane Oxygenation 32  
Group II: Pre-term birth 17  
Group III: Giant congenital melanocytic naevi 12  
Group IV: Major surgery 9  
Group V: Neonatal Abstinence Syndrome 10  
Group VI: Controls 54  
Reaction time (ms) 307 [272–339]
Skin temperature (°C) 36.2 [36–36.9]
Environmental temperature (°C) 23 [22–24]
Parents present Yes/No (%) 88.1/11.9  
Cold detection threshold (°C) 30.8 [30–31.1]
Heat detection threshold (°C) 33.7 [33.2–34.7]
Cold pain threshold (°C) 10 [1.08–19.2]
Heat pain threshold (°C) 47.0 [42.8–50]
NRS (stimulus 46°C) 6.0 [2.0–8.75]
Data are presented as median with IQR, unless stated otherwise
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Genetic factors
Genotype results are displayed in Table 2. Observed MAFs were in agreement with the 
frequencies reported in literature, although two single nucleotide polymorphisms (SNPs) 
were not in HW-equilibrium in univariate analysis (COMT rs4818; p = 0.03 and OPRM1 
rs1799971; p  =  0.02). When corrected for multiple testing (p  =  0.0056)[47], all SNPs 
where in Hardy Weinberg equilibrium. Since for OPRM1 and SCN9A polymorphisms 
the homozygous variant group was < 10 individuals, this group was combined with the 
heterozygous genotyped children. In view of the undetermined results for some of the 
individual COMT SNPs (rs4680, rs4818 and rs4633) the COMT haplotype was success-
fully constructed in 88 participants, with 46 participants having LPS, 29 APS and 13 HPS 
COMT haplotype.
Supplementary Table 2 summarizes the associations between the genetic variants and 
thermal pain sensitivity. In the univariate analysis, OPRM1 rs1799971 A>G was associated 
with the NRS score for the applied heat stimulus (p = 0.001), with G-allele carriers rating 
the heat stimulus as less painful compared to wild type participants (NRS: 2 [1–5] versus 
7 [3–9]). In line with their lower pain sensitivity, G allele carriers also had higher cold 
and heat pain thresholds (p = 0.006 and 0.012, respectively). Be eZect size for cold pain 
thresholds was larger than that of heat thresholds (-4.91 (95 %CI: -8.74;1.09) versus 2.19 
(95 %CI: 0.543;3.83)). Also, as illustrated in Figure 3, the G allele carriers reached more 
frequently the minimum and maximum temperature limits (p  =  0.002 and p  =  0.006 
resp.). After adjusting for age, gender, reaction time and false positives, OPRM1 rs1799971 
Table 2. Results genotyping
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A>G remained signiUcantly associated with NRS (p = 0.00005) and the number of chil-
dren reaching the minimum and maximum temperature limits (p = 0.003 and 0.0052), 
illustrated in Figures 2 and 3.
Children genotyped TRPA1 rs11988795 TT had signiUcantly lower cold pain thresholds 
compared to CT and CC individuals (18.8 [9.45–26] versus 10.1 [1.51–18.9] and 6.45 
[0.49–17.9], p = 0.020). Correspondingly, the heat pain threshold was also lower in the TT 
genotyped group compared with the heterozygotes and wild type children (43.1 [40.2–49] 
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Figure 2. NRS score heat stimulus (46°C)
Numerical Rating Score (NRS) given by the children, indicating pain intensity for the applied heat stimulus (46°C). 
After stratiUcation according to gender, the eZect of OPRM1 118A>G genotype remained signiUcant* (p < 0.001) 
in both groups (multiple linear regression, corrected for age).
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Figure 3. Minimum and maximum temperature limits
Children who reached minimum (0°C; indicative for lower cold pain sensitivity) and maximum temperature limit 
(50°C; indicative for lower heat pain sensitivity). Be horizontal y-axis displays the percentage of males/females 
(blue and red bars) that reached the min./max. temperature within the OPRM1 118AA and 118G allele carrier 
genotype group (upper and lower panel). Gender and OPRM1 genotype were signiUcantly associated with min. 
(p = 0.017 vs. p = 0.003, respectively) and max. temperature limit (p = 0.003 vs. p = 0.005, respectively) in a logistic 
regression with correction for age.
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versus 47.1 [44.1–49.9] versus 47.7 [42.6–50], p = 0.022). Although the associations re-
mained after correction for gender, age and reaction time, the Bonferroni threshold was 
not reached. TRPV1 rs8065080 TT genotyped children had increased pain sensitivity to 
heat (p  = 0.046) but not against cold pain (p  = 0.12). In addition, after correction for 
confounding factors, the TT genotyped children in general reported the hot stimulus as 
not painful. Nevertheless, all these associations were not signiUcant after correction for 
false positives.
Be combined OPRM1/COMT genotype was associated with the thermal pain thresh-
olds. Children with the OPRM1 118AA genotype combined with COMT 472A allele 
carriage seemed more sensitive to pain as they had lower thermal pain thresholds and 
reached the minimum and maximum limits less frequently compared with OPRM1 118G-
allele carriers with the COMT 472GG genotype. Be associations with the thermal pain 
thresholds remained signiUcant in the multivariable analysis and after correction for false 
positives (p < 0.0056). Be other pain parameters remained signiUcant with the OPRM1/
COMT combined genotype after correction in the multivariable analysis but did not pass 
Bonferroni correction. None of the other polymorphisms were associated with thermal 
pain sensitivity, neither in the univariate nor in the multivariable regression.
DISCUSSION
Our study demonstrates that OPRM1 118A>G and the combined OPRM1/COMT genotype 
are associated with experimental thermal pain sensitivity in a pediatric population. Be 
children and adolescents who carried the OPRM1 118G allele seemed less sensitive to pain, 
as they rated the stimulus of 46°C lower than did OPRM1 wild type genotyped children 
and reached the minimum and maximum temperature limits of 0°C and 50°C in the TSA 
test more frequently. We did not Und a correlation between OPRM1 genetics and pain 
thresholds. Regarding the combined OPRM1/COMT genotype higher pain sensitivity was 
seen in children with the OPRM1 118AA genotype who also carried the COMT 472A allele.
DiZerent molecular mechanisms have been linked to the OPRM1 118A>G variant, as 
reviewed recently [24]. As summarized in this review, reduced expression in 118G allele 
carriers could be the consequence of a change in mRNA stability, an additional methyla-
tion site [33] or loss of a N-glycosylation site [25]. A study assessing the a@nity of endog-
enous and exogenous opioids for the mu-opioid receptor showed increased β-endorphin 
a@nity and potency in the 118G variant [7] but this Unding could not be replicated by 
others [3; 5; 25]. However, results of experimental studies in healthy adult volunteers are 
in line with our Undings and support the hypothesis of an increased a@nity and potency 
of β-endorphin for the mu-opioid receptor. To illustrate this, a study with 167 healthy 
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subjects showed higher pressure pain thresholds in carriers of the 118G allele and lower 
heat pain ratings for a 49°C stimulus in males carrying the minor G allele [17].
We also found a lower heat pain sensitivity in 118G allele carriers after correction for 
gender, indirectly conUrming increased binding and potency of the endogenous agonist. 
In addition, a study showing decreased thermal pain sensitivity in non-Hispanic whites 
carrying the 118G allele suggests the existence of a gene-ethnicity interaction [18]. Be 
authors link this interaction to the ethnicity-speciUc haplotype structure and gene-gene 
interactions. We did not analyze this interaction because the ethnicity in our cohort was 
not proactively documented. Experimental pain in relation to the OPRM1 SNP has also 
been assessed in approximately 800 women prior to breast surgery [8], without any cor-
relation with thermal pain sensitivity. Confounding factors, such as prior opioid use for 
cancer pain, are likely obscuring a genotype-phenotype correlation in the latter case.
In line with our Unding of a larger eZect size of OPRM1 118A>G on cold pain thresholds 
than on heat pain, a study comparing monozygotic and dizygotic twins concluded that 
genetics contributed 60 % to cold pain sensitivity and 26 % to heat pain sensitivity [31]. 
Although the larger spread in cold pain thresholds between the children most likely leads 
to increased eZect size of this genetic variant compared to heat pain, the extent of genetic 
contribution is highly dependent on the chosen pain phenotype and comparison between 
pain modalities might lead to contradicting conclusions. Our previous Undings illustrated 
that mechanically ventilated preterm neonates receiving placebo were more likely to 
require (rescue) morphine when carrying the OPRM1 118G allele with or without the 
COMT 472GG genotype [24]. Bis seems to contradict with the higher cold and heat pain 
thresholds reported in the current study for these genotypes.
However, the eZect of the OPRM1 variants might be more complex than simply a 
change in a@nity for endogenous peptides or decreased receptor expression in 118G car-
riers. A recent study in 50 healthy volunteers supports our initial contradictive Undings 
by documenting the opposite eZect of this SNP on dopamine (DA) release in the nucleus 
accumbens [34]. OPRM1 118G carriers had, compared to 118AA individuals, higher DA 
release in the nucleus accumbens during the painful stimulus, whereas during placebo 
intervention DA release in this brain area was lower in 118G carriers [34]. Be discrepancy 
in Undings between our studies might also be related to the developmental pattern of the 
involved receptor (OPRM1) and enzyme (COMT). However, although human studies are 
lacking, in vivo animal data suggest no diZerence in OPRM1 transcription between 10, 20 
postnatal days and adult rats [26]. In contrast, the COMT protein expression and activity 
in humans showed a developmental pattern, with maximum levels reached in adults [41].
Even though no associations were found with TRPA1 and TRPV1 SNPs after Bonferroni 
correction it is still worthwhile discussing these variants. Be transient receptor potential 
(TRP) V1 ion channel is known to be activated by chemical stimuli such as capsaicin or 
by temperatures exceeding 43°C [9]. Although on average the heat pain threshold in our 
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cohort exceeded 43°C and the painfulness was assessed at 46°C, the found association be-
tween the TRPV1 variant and heat pain sensitivity did not survive Bonferroni correction. 
As anticipated no association was found with cold pain sensitivity in our cohort, whereas 
other researchers reported increased cold withdrawal time in carriers of the TRPV1 variant 
allele [19]. While TRPV1 is activated by noxious heat temperatures, the TRPA1 ion chan-
nel is activated by temperatures < 15°C [40], though this has been contradicted [11]. In 
the present study we found a correlation between TRPA1 rs11988795 variant and thermal 
pain thresholds, with a larger eZect size for cold pain. Bis is in line with a previous 
report showing higher cold pain sensitivity in rs11988795 AA compared to GG genotyped 
individuals [22]. However, this association did not remain after Bonferroni correction.
Be method used to measure pain sensitivity could be considered a limitation, since 
quantitative sensory testing is highly depending on environmental factors, methodological 
factors, cooperation and attention of participants tested [30]. However, in our cohort 
environmental factors were kept as stable as possible and the tests were protocolized and 
performed by one and the same researcher in the same room [45; 46]. Also the levels of 
cooperation and attention could be questioned in young children. Still, the feasibility 
was assessed twice per detection threshold and once per pain threshold test, which were 
the previously mentioned rehearsals. Almost all children showed good understanding of 
what was expected from them. Lastly, even though it would be interesting to assess if the 
found associations for thermal pain could be replicated for the clinical pain and analgesic 
requirements documented during their neonatal hospital admission, a grouped analysis 
was not possible due to the diZerences in study set-up and documentation of the data for 
groups 1–4. Sample sizes of these groups were too small for separate analysis in all but the 
preterm, mechanically ventilated cohort, as we discussed before [28].
In conclusion, our study illustrates that children carrying the OPRM1 minor 118G allele 
or the combined OPRM1/COMT 118G allele and/or 472GG genotype are signiUcantly less 
sensitive to thermal experimental pain. Bis might have important implications for the 
prediction of clinical pain states and thus the pharmacological and non-pharmacological 
treatments in the pediatric population.
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A BSTR ACT
Aim: Assess association between UGT2B7 polymorphism -900G>A (rs7438135, also 
known as -842G>A) with morphine kinetics in preterm newborns undergoing mechanical 
ventilation.
Materials & methods: Birty-four infants were enrolled in a randomized clinical trial and 
allocated to rapid sequence intubation with remifentanil (1 µg/kg) or morphine (0.3 mg/
kg). Be latter group was included in our study.
Results: Morphine plasma concentrations at 20 min post intubation were associated with 
postnatal age (p = 0.017) and UGT2B7–900G>A (p = 0.036). UGT2B7–900A allele carri-
ers (n = 13) had lower morphine levels compared with UGT2B7–900G/G patients (n = 2). 
Morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations were only 
found to be associated with gestational and postnatal age. However, -900A allele carriers 
had a higher morphine-3-glucuronide:morphine metabolic ratio compared with patients 
genotyped as -900G/G (p = 0.005), as determined by linear regression.
Conclusion: Our small pilot study illustrates that in addition to gestational and postnatal 
age, the UGT2B7–900G>A polymorphism signiUcantly alters morphine pharmacokinet-
ics in preterm infants.
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INTRODUCT ION
In newborn infants undergoing intensive care treatment, opioid administration for pain 
relief is used in many institutions despite insu@cient pharmacokinetic (PK) and phar-
macodynamic (PD) data. Newborns and especially preterm infants with fast developing 
and vulnerable brains are highly sensitive to both pain experience and drug-related side 
eZects [1]. Adverse eZects, such as cognitive dysfunction, have been suggested to occur 
based mainly on cross-sectional studies [2] but warrant long-term longitudinal follow-up 
[3]. A recently published study was not able to illustrate this negative eZect on cognitive 
dysfunction at an age of 8–9 years of follow-up [4]. With improving means to assess in-
dividual genetic constitution, personalized dosing strategies can be developed for speciUc 
drugs such as opioids with a narrow therapeutic window.
Be role of pharmacogenetics (PG) in opioid dosing has received some attention in 
the adult population [5,6]. To our knowledge only two PG studies have been published 
during the neonatal period, one study regarding tramadol PK [7] and the other on in 
utero exposure to methadone and buprenorphine [8]. In the PK–PG analysis of tramadol 
a relationship was found between CYP2D6 genetics and O-demethylation activity. Be 
latter study has evaluated the impact of three genes (i.e., COMT, OPRM1 and ABCB1), 
in which OPRM1 and COMT polymorphisms were found to be associated with a shorter 
hospitalization time and lower requirement for postpartum treatment in term newborn 
infants with neonatal abstinence syndrome. However, besides our own work, concerning 
genetic variation in OPRM1 and COMT on morphine requirement [9], no data are avail-
able on morphine PG in the (pre)term neonatal period.
Along with the PDs, the kinetics of morphine is a major determinant of the treatment 
outcome. Morphine is predominantly subject to conjugating phase II reactions such as 
glucuronidation, which is catalyzed by UDP-glucuronyltransferase (UGT). UGT2B7 has 
been identiUed as the major conjugating enzyme for morphine. Be ontogeny of UGT 
enzymes in humans has not been fully explored, but early studies have demonstrated 
glucuronidation of morphine during the mid-trimester in fetal liver [10] and kidneys [11]. 
Be glucuronidation capacity in the newborn period is poorly developed [12] but partly 
compensated by sulfate conjugation [13]. Whereas glucuronidation capacity increases 
rapidly after birth, sulfation capacity is slowly decreasing. UGT2B7 activity towards 
morphine starts at approximately 15 weeks of fetal age and is 10–20 % of adult activity in 
mid-trimester [10] while adult enzymatic activity is not reached until sometime between 
2 months to 2.5 years [14]. Be observed variability in morphine PK during the neonatal 
period and early infancy is not only the result of maturation of the metabolizing en-
zymes but is also partly determined by the genetic predisposition. As UGT2B7 has been 
identiUed as the major conjugating enzyme, polymorphisms in the UGT2B7 gene may 
have relevance and important implications for the disposition of morphine in newborns. 
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UGT2B7 metabolizes morphine primarily to morphine-3-glucuronide (M3G), whereas 
approximately 10 % is converted to morphine-6-glucuronide (M6G), which is an active 
metabolite.
Several studies have assessed the eZect of the -900G>A (rs7438135) SNP in UGT2B7 
on PK and tolerance of morphine. In a young adult population with sickle cell disease, 
carriers of the -900G allele had a signiUcantly lower M6G:morphine ratio than AA car-
riers, suggesting a decreased UGT2B7 activity associated with the G variant allele [15]. 
In line with this observation, the 802T>C (rs7439366) SNP has been associated with low 
morphine glucuronidation rate and reduced occurrence of side eZects [16,17]. Bis poly-
morphism is in complete linkage disequilibrium (LD) with the -900G>A genetic variation 
[18]. Nevertheless, albeit under diZerent clinical conditions, other research groups have 
failed to replicate these Undings for 802T>C [19–23].
Other polymorphisms can also occur in combination with SNP 802C>T. Be so called 
*2g allele consists of 802C>T and -79G>A, as depicted in the study of Duguay et al. 
Be promoter SNP -79G>A gives a 2.5- to 7-fold decrease in transcriptional activity in 
colon and hepatic cells, respectively [24]. Although the UGT2B7*2g allele occurs in 5 % 
of Caucasian individuals and our cohort primarily consists of white infants, we are not 
able to analyze the consequence of this allele on morphine kinetics due to the sample size. 
Besides, the low variant allele frequency of this SNP will only explain a small part of the 
observed variability in morphine plasma concentrations.
Be aim of this study was to explore whether the highly investigated polymorphism in 
adults, UGT2B7–900G>A (rs7438135), is associated with altered morphine PK in preterm 
newborns.
M ETHODS
Bis candidate gene association study was embedded in a study evaluating optimal drug 
dosing during endotracheal intubation conducted at the tertiary level neonatal intensive 
care unit (NICU) at Skåne University Hospital in Lund, Sweden [25]. Be Regional Ethics 
Committee in Southern Sweden and the Medical Products Agency in Sweden approved 
the research protocol. Be trial was registered as EUDRACT (no. 2004–001583) and at 
www.clinicaltrials.gov (NCT00216944). Written informed consent for DNA analysis was 
obtained from both parents.
Study design
Birty-four preterm infants were included in a randomized controlled trial on two dif-
ferent intravenous premedication strategies for semi-urgent intubation during neonatal 
intensive care [25]. Inclusion criteria were gestational age of < 37 weeks and no analgesic 
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or sedative drugs administered during 24 h prior to the intubation. Exclusion criteria were 
asphyxia, major malformations and postoperative care [25]. Be present study focused 
on the 17 infants who received morphine (0.3 mg/kg) and atropine (0.01 mg/kg) prior to 
intubation (Table 1). Be administration of drugs was blinded, and given within 5 min 
directly followed by the intubation [25]. Blood was sampled for PK analysis before drug 
administration (baseline), and 20 min, 6 h and 24 h after the termination of intubation. 
During a follow-up period of 24 h, the children’s pain/stress was scored every 30 min 
with the Astrid Lindgren and Lund Children’s Hospital Pain assessment Scale for preterm 
and sick newborn infants (ALPS-Neo, score 1–10) [26] and every 4 h with the Echelle 
Douleur Inconfort Nouveau-Ne (EDIN) scale [27]. According to an algorithm based on 
pain assessment results, a morphine injection dose (0.15 mg/kg) or infusion (10–20 µg/
kg/h) was administered if nonpharmacological support was insu@cient. In this study we 
have assessed the relationship between genetic variation in UGT2B7 with morphine and 
its metabolites. Be study outcomes were concentrations of morphine, M3G and M6G, 
and also morphine metabolites:morphine plasma ratios at 20 min after intubation. Be 
morphine plasma concentrations at 6 and 24 h were not included in this analysis because 
of the multiple morphine injections and/or infusions administrated after 20 min. Buccal 
swab samples for DNA isolation were obtained in all 17 infants.
Table 1. Characteristics of the diZerent UGT2B7–842G>A genotype groups in preterm infants re-
ceiving morphine as premedication before intubation.
Characteristics
GG† GA AA
p-value(n = 2) (n = 6) (n = 7)
Gestational age (days) 174; 218 183 (177–197) 187 (177–226) 0.49
Postnatal age (days) 0.14; 6 4.5 (1.11–9.82) 7.4 (0.25–16) 0.49
Sex (male/female) 2/0 4/2 2/5 0.18
Weight (g) 950; 1700 975 (890–1270) 825 (648–1993) 0.75
Duration intubation (s) 47; 502 53 (43–196) 249 (49–451) 0.25
Morphine bolus (yes/no) 0/2 4/2 4/3 0.41
Morphine bolus (n) 1; 1 1 (0–1.25) 0.5 (0–1.75) 0.32
Morphine infusion (yes/no) 0/2 0/6 2/5 0.60
Total morphine dose (μg) 290; 510 295 (270–368) 250 (200–600) 0.69
ALPS-Neo score at baseline 3; 7 3.5 (0.75–4.0) 4 (2.5–7.8) 0.41
Be continuous variables are presented as median with their interquartile range.
†In this column the values of the two -900G/G genotyped patients are shown. ALPS-Neo: Astrid Lindgren and 
Lund Children’s Hospital Pain Assessment Scale.
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Bioanalytical method
Morphine and its metabolites were analyzed using LC-MS/MS. Be method, with some 
modiUcations, has been described before [28]. Whole blood was sampled in heparin-
ized tubes and the samples were centrifuged within 30 min. Be plasma was collected, 
transported on ice and immediately frozen to -70°C. Sample preparation was performed 
according to an earlier reported procedure [29]. In brief, 50 µl of plasma were precipitated 
with 100 µl acetonitrile containing denatured internal standards. Be supernatants were 
evaporated to dryness and reconstituted in 10 µl of 0.1 % aqueous formic acid.
Be instrument used was an ACQUITY UPLC system connected to a Quattro Premier 
XE tandem mass spectrometer (Waters, MA, USA). Be analytical column used was an 
ACQUITY UPLC HSS T3, 2.1 × 100 mm, 1.8 µm particle size, kept at 60°C. A gradient 
elution was used with mobile phase A: 0.1 % aqueous formic acid and mobile phase B: 
methanol. Be |ow rate for morphine and its metabolites was 0.2 ml/min. Be total 
run time was 6.5 min and the injection volume was 3 µl. Be tandem mass spectrometer 
was operated in the positive electrospray mode using selecting reaction monitoring. Be 
instrumental setting for morphine and the metabolites is described in a previous method 
[28]. A linear relationship was observed for morphine, M3G and M6G in the range of 
2–1000 ng/ml. Be intra-assay precision was studied at 10, 200 and 800 ng/ ml for mor-
phine and its metabolites. For morphine, coe@cients of variation (CV) were 6.69, 1.12 and 
4.15 % (n = 5). CV for M3G was 6.59, 2.52 and 2.00 % (n = 8) and for M6G CV was 7.42, 
2.07 and 2.55 % (n = 8). Limit of detection was estimated to 0.6 ng/ml for morphine, M3G 
and M6G. In order to collect su@cient number of patients in the PG analysis, samples 
that were below this limit of detection were all set to 0.5 ng/ml. Morphine and metabolite 
concentrations between 0.6–2 ng/ml were set to 1.3 ng/ml.
Genotyping procedure
DNA isolation was performed at the Skåne University Hospital in Malmö (Sweden) ac-
cording to the protocol DNA Purication from Buccal Swabs (Spin Protocol) obtained 
from the QIAamp DNA mini and blood mini handbook 04/2010 (Qiagen AB, Sollen-
tuna, Sweden) manual. e DNA isolate volume was 140 µl for each sample and the mean 
DNA concentration from the buccal swabs was 17.4 ng/µl (range: 1–109 ng/µl). e DNA 
isolates were all used undiluted in the SNP analysis.
e selected UGT2B7 SNP, -900G>A (rs7438135; also know in literature as -842G>A) 
was assessed at the Erasmus MC Clinical Chemistry Department, Rotterdam, e Neth-
erlands. e genetic variation 802T>C was assessed in order to conrm the previously 
reported complete LD between the two SNPs. Polymorphism -900G>A and 802T>C 
were genotyped according to the TaqMan® allelic discrimination assay (Life Technologies 
Europe BV, Bleiswijk, e Netherlands). e reaction solution was prepared using 6.26 µl 
of the TaqMan GTXpress™ Master Mix (Life Technologies), 0.313 µl of the SNP specic 
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assay mix and 3.44 µl RNAse free water. e probes in the 900G>A assay mix are labeled 
reverse: wild-type allele on the y-axis and variant allele on the x-axis, while the 802T>C 
assay mix contained a normal calling.
e PCR program started with denaturation of the DNA strand at 95°C for 20 s, fol-
lowed by hybridization of the primers and probes at 92°C for 40 s. After hybridization 
the elongation was begun at 60°C for 30 s. e whole process was run for 45 cycles. e 
post-PCR detection was performed on the 7000 Real-Time PCR System (software ver-
sion v2.0.5; Applied Biosystems). Both polymorphisms were assessed with the same PCR 
program and on the same machine.
Statistical methods
Statistical analyses were performed using IBM SPSS Statistics Software, version 21.0 for 
Windows (IBM Corporation, IL, USA). Owing to the small sample size, nonparametric 
tests (Kolmogorov–Smirnov, Kruskal–Wallis) have been applied for the demographic and 
clinical characteristics (Table 1). All data are presented as median with their correspond-
ing interquartile range (IQR) unless stated otherwise. Di+erences between groups were 
assumed signicant for p-values < 0.05.
Multiple linear regression with the use of stepwise backward elimination was performed 
in order to assess and correct for the impact of potential non-genetic confounders. A 
codominant inheritance pattern was used for the -900G>A SNP in the linear regression. 
Next to the UGT2B7 SNP, gestational age (GA), postnatal age (PNA), gender, weight 
and time required for intubation were also forced into the model. e latter independent 
variable was included since morphine was administered before the intubation and the 
time required for intubation varied among the newborns and thus might have caused 
di+erences in morphine concentration at 20 min after the end of the intubation. e 
independent variables were checked for multicollinearity. e variance in0ation factor 
did not exceed the threshold of 3, excluding multicollinearity between the independent 
variables GA, PNA, weight and time required for intubation.
R E SU LTS
Seventeen preterm infants randomized to morphine premedication were included in 
this candidate gene pilot study. All patients were successfully genotyped for the selected 
UGT2B7 SNP; four patients were genotyped as -900G/G, six -900G/A and seven -900A/A. 
e frequency of the G allele (29 %) in this cohort deviated from the frequency described 
in the literature for Caucasians (50 %) [30], which could be caused by the relatively small 
population. Nevertheless, the allelic distribution met the Hardy–Weinberg equilibrium 
(χ2 =  1.3; p  =  0.26). SNP 802T>C analysis conrmed the complete LD between these 
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genetic variations. All patients genotyped as -900G/G were also 802T/T, while all infants 
with the -900A/A genotype were carrying the 802C/C alleles (results not shown). Two 
newborns, both -900G/G carriers, were excluded from the analysis because of detectable 
morphine and M6G concentrations at baseline. e characteristics of the remaining 15 
newborns are shown in Table 1.
From the 15 patients that were eventually included in the analysis, nine newborns, all 
A allele carriers at position -900, received additional morphine injections and/or infusion 
after the premedication. Seven infants received one additional morphine injection, one 
four additional morphine injections followed by a morphine infusion and one infant 
received only a morphine infusion. Both infants who received additional morphine as 
an infusion were -900A allele homozygous. Additionally, although not statistically dif-
ferent, the -900A/A and G/A infants had more additional morphine injections compared 
with G/G patients (0.5; 0–1.75 and 1.00; 0–1.25 vs n = 1.00 morphine injection for both 
infants, respectively). e median time required for intubation was longer in the two G/G 
genotyped patients (47.0 and 502 s) compared with the A heterozygous and homozygous 
patients (53.0, IQR: 43.0–193; and 249, IQR: 49.0–451 s, respectively), but this di+erence 
was not signicant (p = 0.25).
Genetic association with UGT2B7 SNP
e morphine, M3G and M6G plasma concentrations in relation to the SNP -900G>A 
are displayed in Figure 1 and the metabolic ratios (MRs) for morphine are shown in Fig-
ure 2. After correction for confounding factors in the multiple linear regression, morphine 
plasma concentrations at 20 min post intubation were signicantly di+erent between 
the G/G (180 and 363 ng/ml), G/A (145 ng/ml; 107–173 ng/ml) and A/A (122 ng/ml; 
84.0–146 ng/ ml) genotyped newborn infants (p = 0.036). Also PNA was correlated with 
morphine concentrations (p = 0.017), whereas higher levels were found with decreasing 
PNA. e model with the genetic variation in UGT2B7, PNA and time needed for intuba-
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Figure 1. Morphine, morphine-3-glucuronide and morphine-6-glucuronide plasma concentrations 
stratied by UGT2B7–900G>A genotype.
M3G: Morphine-3-glucuronide; M6G: Morphine-6-glucuronide.
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tion explained 63.3 % (adjusted 53.3 %) of the variability observed in morphine plasma 
concentration.
Although the M3G plasma concentration was lower in -900G allele homozygous new-
borns (4.1 and 10 ng/ ml) compared with the G/A (14 ng/ml; 1.9–23 ng/ ml) and A/A (26 
ng/ml; 8.1–43 ng/ml) genotyped patients, this di+erence was not signicant after correc-
tion (p = 0.28). Conversely, GA (p = 0.007) and PNA (< 0.0001) were strongly associated 
with the M3G plasma concentration and accounted for 80.6 % (adjusted 77.3 %) of the 
observed variability. Also with regard to M6G plasma concentrations no signicant di+er-
ences have been found between G/G (0.50 and 1.3 ng/ml), G/A (1.3 ng/ml; 1.1–3.9 ng/ml) 
and A/A (4.0 ng/ml; 1.3–14 ng/ml) allele carriers (p = 0.20). M6G plasma concentrations 
were also found to be related with the GA and PNA (p = 0.034 and 0.001, respectively) 
but also with the intubation time (p = 0.028). ese three independent variables explained 
83.7 % (adjusted 79.2 %) of the variability in M6G plasma levels.
e MRs for morphine are shown in Figure  2. All included independent variables 
(GA, PNA, weight, gender, intubation time and -900G>A), were signicantly associated 
with the M3G:morphine MR (p = 0.001, p < 0.001, p = 0.003, p = 0.02, p = 0.005 and 
p = 0.005, respectively). is model explained 97.5 % (adjusted 95.6 %) of the variability in 
M3G:morphine MR between newborns. An allele dose-e+ect was observed between the 
variation -900G>A and M3G:morphine MR. With regard to the M6G:morphine MR at 
20 min post intubation, only a trend was observed for -900G>A (p = 0.071). Also here, 
GA, PNA, weight and intubation time were signicantly correlated to M6G:morphine 
MR (p = 0.003, p < 0.001, p = 0.015 and p = 0.009, respectively). ese variables combined 
contributed to 94.1 % (adjusted 91.0 %) of the observed variability in M6G:morphine MR.
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Figure 2. Morphine-3-glucuronide:morphine and morphine-6-glucuronide:morphine metabolic ra-
tio stratied according to UGT2B7–900G>A genotype.
M3G: Morphine-3-glucuronide; M6G: Morphine-6-glucuronide; MR: Metabolic ratio.
140 Part III: Genetics, Pain and Analgesia in Pediatrics
DISCUSSION
We have demonstrated an association between the UGT2B7 polymorphism -900G>A 
(-842G>A) and morphine PK after administration of a single dose of morphine in preterm 
newborns prior to tracheal intubation for mechanical ventilation. To our knowledge, this 
is the rst study assessing the role of genetic variation in UGT2B7 on morphine PK in 
this specic population. Carriers of the -900A allele had signicantly lower morphine 
plasma concentrations compared with -900G homozygous patients, as determined using 
backward linear regression analysis, suggesting that the conversion from G to A most 
likely leads to an increased UGT2B7 activity. is assumption is conrmed in the MR 
analysis, where A allele carriers had a higher M3G:morphine MR, again using backward 
linear regression analysis. Because of the small number of subjects, we also performed 
forward linear regression analysis to verify our results. e lower morphine concentrations 
in -900A allele carriers was conrmed with this approach (p = 0.017), but the e+ect on 
M3G:morphine MR was now not signicant (p = 0.12).
Our ndings are in line with the results found in adults with sickle cell disease, in 
which a reduced formation of morphine glucuronides was observed in -900G allele car-
riers [15]. However, there are also ndings that are contradictory [16]. For the genetic 
variation 802T>C, which is in complete LD with the -900G>A mutation, it was found 
that 802C/C genotyped patients had signicantly lower morphine glucuronide levels. We 
have conrmed the existence of the complete LD in our preterm infants. Owing to the 
existence of complete LD between these SNPs, this would mean that -900A genotyped 
patients should have lower metabolite levels.
In contrast to the association found for morphine plasma concentrations and 
M3G:morphine MR, no signicant associations were observed for M6G concentration or 
MR. is could be due to the fact that the formation of M6G is catalyzed by UGT1A1 to a 
great extent, and to a lesser extent by UGT1A8 instead of solely UGT2B7 [31]. e relative 
contribution of UGT1A1 and UGT1A8 next to UGT2B7 has been recently assessed in an 
adult population with advanced cancer [32]. Two haplotypes for UGT1A1/1A8 were weak 
predictors of M6G:morphine and M3G:morphine MRs, whereas UGT2B7 haplotypes were 
not associated. Our study had insu4cient power to also assess variations in these genes.
Contradicting results exist regarding the a4nity of M6G for the µ-opioid receptor 
compared with morphine, although in vivo results have shown up to fourfold higher 
analgesic potency for M6G [33]. Studies assessing the relationship between morphine and 
M6G concentrations with the analgesic and side e+ects of the drug have also showed 
inconclusive results [34,35]. Our data speculate that -900A allele carriers with lower 
morphine plasma concentrations will experience lower morphine potency compared with 
G/G genotyped patients, due to the requirement of additional morphine. Namely, all 
homozygous A genotyped patients required rescue morphine and both infants with ad-
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ditional infusion were genotyped -900A/A. Considering the small cohort it is necessary to 
determine if this e+ect on PK will indeed in0uence the morphine requirement, a clinically 
relevant outcome.
In spite of a low glucuronidation activity during the neonatal period, large interindi-
vidual variability is observed in newborn infants [36]. is variability is the consequence 
of an interplay between genetic and non-genetic factors, whereas GA and PNA seem to 
play central roles. Our ndings indicate that in addition to these non-genetic factors, 
genetic variation in UGT2B7 is also likely to explain the di+erences in morphine PK. 
Our results suggest that the genotype–e+ect association is not confounded by ontogeny. 
Although the GA of the -900G/G genotyped patients is lower compared with the GA of 
-900A allele carriers, inclusion of this variable in the multiple linear regression still showed 
the genetic e+ect on morphine PK.
One limitation of this clinical study, which is common when recruitment is performed 
in urgent situations, is that few infants were included. e fact that two infants had to be 
excluded because of detectable morphine and metabolite concentrations in plasma under-
scores the variability in PK. ese infants had received their previous dose more than 24 
h before recruitment. is emphasizes that morphine elimination is very slow in preterm 
infants, in particular in -900G/G genotyped patients, which is in line with our ndings, 
and illustrates that children with a recent prior history of morphine administration should 
be excluded. However, despite the small cohort we have observed an association between 
genetic variation in UGT2B7 and morphine PK, which was signicant after correction for 
confounding factors.
CONCLUSION & FUT UR E PER SPECT I V E
Large interindividual variability exists in morphine plasma concentrations in the preterm 
population. We have shown that the polymorphism -900G>A, leading to altered UGT2B7 
activity, a+ects morphine PK in the immature and growing population. Premature infants 
that carry the -900A allele have an increased breakdown of morphine. Our study illustrates 
that the observed consequence of this polymorphism in adults is also visible in preterm 
infants, implying that genetics might play a role next to ontogeny in drug metabolism.
Since these results are based on small numbers of infants (n = 15), and we only had two 
UGT2B7–900G/G subjects, these ndings warrant further validation in a larger cohort. e 
following step would be to assess in a prospective setting whether carriers of the -900A allele 
have a worse analgesic response and thus require additional morphine doses when in need 
of this drug during mechanical ventilation. Since large variability is seen in the genotype 
groups, the nal goal would be to determine what the relevance of this SNP is next to other 
UGT2B7 SNPs and polymorphisms in other genes a+ecting the morphine pathway.
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A BSTR ACT
Background: is study determined whether the SLC22A1 [encoding the organic cation 
transporter 1 (OCT1)] genotype could explain, in addition to the postmenstrual age 
(referring to gestational plus postnatal age) and CYP2D6 genotype, the tramadol (M) 
pharmacokinetic variability in early infancy.
Methods: Fifty infants, median postmenstrual age 39.5 (interquartile range: 36.8–41.3) 
weeks, received an i.v. M loading dose (2 mg/kg) followed by a continuous infusion (5–8 
mg·kg·24 h). Blood was sampled from 4 to 24 hours after start of the M treatment, which 
generated 230 observations. M and O-desmethyltramadol (M1) concentrations were 
measured by high-performance liquid chromatography.
Results: Linear mixed-model analysis illustrated that the SLC22A1/OCT1 genotype was 
independently associated with a log-transformed M1/M ratio (P  = 0.013), with carriers 
of <  2 SLC22A1/OCT1 functional gene copies having a higher M1/M ratio (2.25; 95 % 
CI, 2.01–2.48) than infants with 2 functional gene copies (1.86; 95 % CI, 1.66–2.06). e 
CYP2D6/SLC22A1 combined genotype was associated with 57.8 % higher M1/M ratio in 
carriers of ≥ 2 CYP2D6 functional gene copies and < 2 SLC22A1/OCT1 functional gene 
copies compared with infants with < 2 active CYP2D6 functional gene copies and SLC22A1/
OCT1 normal activity (P < 0.001).
Conclusions: ese ndings highlight the additional role of SLC22A1/OCT1 genetics in 
M1 exposure in neonates. ey also suggest that OCT1 is already active early after birth, 
which may have impact on the disposition of other OCT1 substrates in this population.
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INTRODUCT ION
Critically ill infants commonly receive opioids for alleviation of postsurgical pain or pain/
distress provoked during stressful procedures in the neonatal intensive care unit. e dos-
ing of opioids is ideally guided by regular assessment of pain with the use of validated 
pain scores [1]. Tramadol (M), as one of the opioids used in the treatment of pain, has 
a relatively wide therapeutic range and low incidence of adverse events [2]. Nonetheless, 
a large variation in pharmacokinetics (PK) of M is observed in the neonatal population, 
which is mainly caused by the extensive maturational changes during the neonatal period 
[3]. e ultimate goal of infant pain therapy for the future would therefore be to individu-
alize pharmacotherapy based on age, weight, disease-status, co-medication and genetics.
M is metabolized in the liver and converted into its active metabolite, O-desmethyl-
tramadol (M1) by the cytochrome P450 enzyme 2D6 (CYP2D6) and into its inactive 
metabolite N-desmethyltramadol (M2) by CYP3A4 and CYP2B6 [4]. M1 is formed more 
extensively compared to M2, although their relative formation will also depend on the 
genetic variability of the metabolizing enzymes [4,5]. M1 has a higher a4nity (Ki = 3.4 
nM) for the mu-opioid receptor compared to the parent compound (Ki = 2.4 µM) [6], 
highlighting the importance of M conversion by CYP2D6. e relevance of CYP2D6 
genetics for M has been established in the adult population [4, 7, 8] and in neonates 
[9], implicating decreased concentrations of the active metabolite and an absence of 
analgesia. However, the variation in disposition of M extends beyond this conversion in 
M1. After demethylation, M1 is either transported from the hepatocyte into the central 
circulation via an unidentied transporter or further metabolized by the phase II UDP-
glucuronosyltransferase 2B7 (UGT2B7) enzyme [4], followed by renal elimination. M1 
can also be transported from the blood/plasma compartment back into the hepatocyte 
by the organic cation transporter (OCT1). OCT1, encoded by the solute carrier family 22 
member 1 (SLC22A1) gene, is highly expressed on the sinusoidal membrane of hepatocytes 
in humans [10, 11] and is responsible for the uptake of positively charged molecules, such 
as metformin, acyclovir and irinotecan [12]. A transporter is crucial for M1 to cross cell 
membranes since removal of the methyl group from M by CYP2D6 exposes a hydroxyl 
group, thereby decreasing the membrane permeability of M1 [13].
Loss-of-function SLC22A1/OCT1 polymorphisms have been associated with increased 
M1 exposure in adult volunteers receiving single oral dose of M [13]. In addition to the 
adult data, these SLC22A1/OCT1 polymorphisms have been associated with a 20 % mor-
phine clearance reduction in 146 children (6–15 years) undergoing adenotonsillectomy 
[14]. However, as illustrated in two recently published reviews the relevance of SLC22A1/
OCT1 genetics has been assessed in a wide age-range of populations except the neonatal 
population [15, 16]. Immaturity of OCT1 activity in neonates may obscure a genotype-
specic e+ect. Should OCT1 activity in neonates be at or close to adult levels, SLC22A1/
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OCT1 genotype might add to the variation in M disposition and would have consequences 
for individualized M dosing in neonates. To date, no data exist on OCT1 maturation, 
therefore this knowledge also may add to our understanding on the interplay of SLC22A1/
OCT1 genotype and age. is information could be extrapolated for the dosing of other 
OCT1 substrates that are used in the neonates [16] and for which associations have been 
found with SLC22A1/OCT1 genetics in adults. ese OCT1 substrates with illustrated 
genotypic e+ect in adult data include morphine [14, 17], tropisetron/ondansetron [18] and 
imatinib [19] Additionally, all drugs positively charged at pH 7.4 (weak bases with pKa> 8) 
are potential OCT1 substrate candidates [20].
Although the assessed genetic variants are not highly prevalent or even absent in specic 
Asian and African-American populations, approximately 8 % of the European population 
and up to 87 % of individuals with South American Indian background have two non-
functional gene copies [21]. ese individuals are genetically predisposed to complete lack 
OCT1 activity. Moreover, the previously discussed study in healthy adults illustrated that 
the extent of the e+ect per 1 SLC22A1/OCT1 non-functional gene copy on M1 plasma 
concentrations is roughly in the same range as that with one CYP2D6 non-functional 
gene copy [13]. is observation deserves to be validated as the current CYP2D6 genotype-
guided dosing recommendations for M may have to be updated to also include SLC22A1/
OCT1 genotype. A recent review highlighted SLC22A1/OCT1 as a relevant candidate 
gene, in addition to CYP2D6, for M metabolism and clinical response [8]. erefore the 
present study aimed to determine if any e+ects of SLC22A1/OCT1 genotype on M1 levels 
are observable in the rst months of postnatal life.
PAT IENTS A ND M ETHODS
is is a retrospective analysis of data on 50 (pre)term critically ill neonates (1–28 days) and 
infants (29 days – 5 months) treated with intravenous M for pain relief [9]. e aim of the 
primary and previously performed study was to determine clinical and genetic predictive 
factors for the observed variability of M PK in this population. Local IRB approval (reg-
istration number ML3791) was received from the University Hospital Leuven, Belgium 
and national approval (registration number B32220071629) from the ‘Federaal Agentschap 
voor Geneesmiddelen en Gezondheidsproducten’, Belgium. Written informed consent 
for deoxyribonucleic acid (DNA) and PK analysis was obtained from parents of eligible 
neonates and infants.
Study design
Infants who underwent a surgical procedure either with or without mechanical ventilation 
and non-surgical children on respiratory support who required M treatment were eligible. 
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Ventilated infants who underwent a surgical procedure received fentanyl (loading dose 
3–5 µg/kg, infusion 3 µg/kg/h) followed by add-on M (loading dose 2 mg/kg, infusion 5–8 
mg/kg/24 h) and propacetamol (4 times daily 10–20 mg/kg/24 h) within 24 hours post-
operatively. Non-ventilated post-surgical infants received only continuous M with add-on 
propacetamol. Non-surgical children on respiratory support received fentanyl or M based 
on the standard procedures on analgesia and sedation in the Leuven Neonatal Intensive 
Care Unit (NICU) [22]. During analgesia with M known CYP2D6 and OCT1 inhibitors 
or inducers were not administered. If an arterial or venous line was available, 200 µL 
blood was collected at multiple occasions between 4 and 24 hours after initiation of M 
bolus. As shown previously, the M and M1 plasma concentrations were stable in this time 
window [9]. As the half-life of M in neonates is approximately 4 hours and steady state 
is not reached, the loading dose might have lled the gap until steady state. e number 
of blood collections and the timing of sampling depended on the child’s weight (max 1 
ml/kg/study) but blood sampling from a central venous catheter for study purposes was 
performed only in conjunction with collection of samples for clinical indication. Every 
24 hours the Intensive Care (IC) team was allowed to alter the continuous perfusions in 
line with the child’s analgesic needs. M and M1 plasma concentrations were determined 
by high performance liquid chromatography (HPLC) according to the method described 
previously [23, 24].
Genotyping
e DNA analysis was performed at the Department of Clinical Chemistry, Erasmus 
University Medical Centre Rotterdam, Netherlands. e methods of DNA extraction 
from ethylenediaminetetraacetic acid whole blood and CYP2D6 genotyping have been de-
scribed previously [9]. e selection of assessed CYP2D6 variants (*3, *4, *5, *6, *9, 10, *41 
and XN) covers the most frequent polymorphisms in the Caucasian population. Analysis 
of the SLC22A1/OCT1 genetic variants Met420del (rs72552763), Arg61Cys (rs12208357), 
Gly401Ser (rs34130495), Gly465Arg (rs34059508) and Cys88Arg (rs55918055) was per-
formed on the ABI PRISM® 7500 Real-Time PCR system (Applied Biosystems®, Bleiswijk, 
Netherlands). e SLC22A1/OCT1 haplotype (expressed as Normal Function, Interme-
diate Function and Poor Function) consisting of these genetic variants was estimated 
with the haplo.stats package (R, version 3.1.1), which uses the expectation-maximization 
logarithm and a posterior probability > 0.98. Violation of Hardy-Weinberg equilibrium 
was tested for each individual genetic variant with the Chi2 test, leading to removal from 
the statistical analysis if p-values < 0.05. In addition, the observed minor allele frequency 
(MAF) was compared with the frequency reported in the literature for Europeans [21]. e 
assay used was validated by direct sequencing of wild type, heterozygote and (if available) 
homozygote samples. Five percent of samples were reanalyzed to check data consistency.
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Due to low frequencies in the extreme CYP2D6 phenotypes, children with Poor Me-
tabolizer (PM) and Intermediate Metabolizer (IM) phenotypes were analyzed combined 
as the ‘low activity’ group versus Extensive Metabolizer (EM) and Ultra-rapid Metabolizer 
(UM) phenotype in the ‘normal activity’ group. Infants with 0 (poor function) and 1 (de-
creased function) functional gene copy of SLC22A1/OCT1 were analyzed combined as the 
OCT1 ‘low activity’ group against 2 SLC22A1/OCT1 functional gene copies (normal func-
tion) dened as the ‘normal activity’ group. In addition to the genotypes of the separate 
genes also the combined genotypic e+ect was assessed. Combinations were made based 
on the theoretical background, where CYP2D6 ‘low activity’ was combined with OCT1 
‘normal activity’ (lowest M1 plasma concentrations expected), CYP2D6 ‘low activity’ with 
OCT1 ‘low activity’, CYP2D6 ‘normal activity’ with OCT1 ‘normal activity’ and CYP2D6 
‘normal activity’ with OCT1 ‘low activity’ (highest M1 plasma concentrations expected).
Statistical analysis
All statistical analyses were conducted using IBM SPSS Statistics (software version 21.0 
for Windows; IBM Corporation, IL, USA). Unless stated otherwise, data are reported 
as median with corresponding interquartile range (IQR). Violation of normal distribu-
tion was judged visually and mathematically with Shapiro-Wilk and skewness as well as 
kurtosis value. Depending on the shape of the distribution, parametric or non-parametric 
tests were performed accordingly, for (Log)-Gaussian or non-Gaussian distributions, 
respectively.
As our data consists of multiple measurements per subject a restricted maximum likeli-
hood (REML) linear mixed-model analysis was performed to assess the relation between 
CYP2D6 and SLC22A1/OCT1 genotypes with M1/M metabolic ratio, with time of sampling 
as repeated measurements. e metabolic ratio M1/M of the measured concentrations was 
the dependent variable. Sampling had been performed at 90 di+erent time points between 
4 and 24 hours after start infusion. In order to simplify the software iteration process in 
the linear mixed model and to run properly, the time points were rounded to the nearest 
half hour. e autoregressive structure was chosen for the repeated covariance matrix since 
the further M1/M measurements within the subject were separated the less correlated they 
were. PMA and subject ID were entered as random factors in the model, while CYP2D6 
and SLC22A1/OCT1 genotypes were set as xed factors (without interaction term).
R E SU LTS
e 50 children included in the analysis had a median postmenstrual age (PMA) of 39.5 
weeks (range 27–54 weeks), with 14 (28 %) born premature. Forty ve children have a 
Caucasian ethnicity, whereas 5 individuals have Mediterranean backgrounds (Tunisia, 
Chapter 8: Tramadol & OCT1 genetics newborns 153
8
Morocco). e most frequent reason for M administration was postoperative analgesia. 
e surgical indications included congenital diaphragmatic hernia, congenital oesophageal 
or duodenal atresia, coarctation of the aorta, or other cardiac surgical procedures such as 
banding of the pulmonary artery. See Table 1 for a summary of other patient demograph-
ics. For more background information of the patients see previous publication [9]. Data 
on 230 plasma samples collected between 4 and 24 hours after initiation of M dose were 
available. An overview of the M and M1 plasma concentrations is also reported in Table I.
Steady state (4 hours after M loading dose was started) was conrmed by lack of correla-
tion between M or M1 plasma concentrations and the time of sample collection (rs=-0.002, 
p = 0.97 and rs=-0.033, p = 0.62). As expected a strong positive correlation was conrmed 
between PMA and weight (r = 0.866, p < 0.001), resulting in exclusion of weight from 
the mixed model to avoid any collinearity problem in the nal model. Although weaker, 
weight was also correlated to gestational age (GA) and postnatal age (PNA) (rs = 0.648, 
p < 0.001 and rs = 0.419, p < 0.002). PMA and PNA were strongly, negatively correlated 
with M concentration (rs=-0.689; p < 0.001 and rs=-0.745; p < 0.001), while the correla-
tion between these variables with M1 was in the opposite direction and weaker (rs = 0.399; 
p  < 0.001 and rs  = 0.226; p  = 0.001). Regarding the M1/M metabolic ratio (MR), the 
strongest correlation was observed with PMA (rs = 0.676; p < 0.001). One subject was 
identied as an extreme outlier (signicant with Grubbs’ test) due to high M1 concentra-
tions (1.89–2.29 µM) and low M concentrations (0.0418–0.414 µM). is large deviation 
could not be explained by extreme low/high age (GA 40.9 weeks; PNA 1 day), weight (3.26 
kg), genotype (1 SLC22A1/OCT1 functional gene copy and 1 CYP2D6 functional gene 
copy) or clinical diagnosis (pneumothorax). Since the data of this subject were considered 
to have a too large in0uence on the results, they were removed from further analysis.
Table 1. Clinical characteristics of the cohort
  N = 50
Postmenstrual age (weeks) 39.5 [36.8–41.3]
Gestational age (weeks) 37.7 [35.4–39.0]
Postnatal age (days) 7.0 [2.0–27]
Preterm (%) 28
Weight (kg) 3.05 [2.34–3.51]
Ethnicity
Caucasian (n) 45 
Non-Caucasian (n) 5 
Tramadol plasma concentration (µM) 1.55 [1.07–2.19]
O-desmethyltramadol plasma concentration (µM) 0.201 [0.112–0.345]
*Values are displayed as median [interquartile range], unless stated otherwise.
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Genotype results
Table 2 shows a summary of the CYP2D6 and SLC22A1/OCT1 genotype results. e ob-
served MAFs for SLC22A1/OCT1 SNPs Met420del (rs72552763), Arg61Cys (rs12208357), 
Gly401Ser (rs34130495), Gly465Arg (rs34059508) and Cys88Arg (rs55918055) are in line 
with previously reported frequencies for a European population [21]. Carriers of the 
genetic variant Cys88Arg (rs55918055) were not found in our cohort. In total, the num-
ber of individuals with 2 inactive SLC22A1/OCT1 alleles was 4 %, where Tzvetkov et al. 
[13, 18] reported 9–12 %. However, statistical testing shows that our frequency does not 
signicantly deviate from the numbers reported by Tzvetkov et al. (p = 0.52). As shown 
previously, the CYP2D6 polymorphisms were also in agreement with MAFs reported in 
the literature [9]. None of the polymorphisms violated HW-equilibrium (p < 0.05). More 
information is provided in Supplementary Table 1.
e linear mixed model analysis illustrated that both CYP2D6 and SLC22A1/OCT1 
genotypes were signicantly associated with the log M1/M MR (p = 0.001 and p = 0.013). 
As previously described, infants carrying fewer than 2 functional CYP2D6 copies had 
lower log M1/M MR (1.76; 95 %CI 1.58–1.94) than infants with 2 or more functional 
gene copies (2.35; 95 %CI 2.09–2.61). For the SLC22A1/OCT1 genotypes the opposite ef-
fect was found as carriers of 1 or zero functional gene copies had higher M1/M MR log 
(2.25; 95 %CI 2.01–2.48) than carriers of 2 functional gene copies (1.86; 95 %CI 1.66–2.06). 
Figures 1 and 2 illustrate the e+ect of CYP2D6 and SLC22A1/OCT1 genotype on the mean 
log M1/M per subject, with the colors indicating the PMA of the child.
After combining the CYP2D6 and SLC22A1/OCT1 genotypes, the association with the 
M1/M ratio became highly signicant (p = 7.51*10–27). While the lowest M1/M MR log 
was observed in infants carrying fewer than 2 functional CYP2D6 copies in combination 
with normal SLC22A1/OCT1 genotype (1.52; 95 %CI 1.27–1.76), the highest M1/M MR 
log was observed in subjects carrying 2 or more functional CYP2D6 copies combined 
with 1 or zero SLC22A1/OCT1 functional gene copies (2.40; 95 %CI 2.00–2.81). Although 
the geometric means of the M1/M MR were di+erent, the two other groups (<  2 ac-
tive CYP2D6 functional gene copies and 2 SLC22A1/OCT1 functional gene copies vs. 2 
functional CYP2D6 copies and 2 SLC22A1/OCT1 functional gene copies) had marginally 
Table 2. Overview genotype results of the cohort
 
CYP2D6 functional gene copies (n)
  0 0.5 1 1.5 2 > 2
SLC22A1 
functional 
gene copies 
(n)
0 - - 1 - 1 -
1 - - 8 6 7 -
2 1 2 11 3 8 2
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more overlap in values (2.02; 95 %CI 1.74–2.30 vs. 2.25; 95 %CI 1.91–2.58). e e+ect of the 
combined genotypic groups on the M1/M MR with the PMA of the child are shown in 
Figure 3. When the M levels were not taken into consideration CYP2D6 was signicantly 
associated with M1 concentrations (p = 0.019), whereas SLC22A1/OCT1 showed only a 
trend with M1 concentrations (p = 0. 06).
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Figure 1. MR O-desmethyltramadol (M1)/tramadol (M) in relation to CYP2D6 2 or more functional 
gene copies versus CYP2D6 < 2 functional gene copies.
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Figure 2. MR O-desmethyltramadol (M1)/tramadol (M) in relation to SLC22A1/OCT1 2 functional 
gene copies versus SLC22A1/OCT1 < 2 functional gene copies.
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DISCUSSION
Our data suggest that OCT1 activity in early infancy is at a level that can be a+ected by 
genotype. e subjects in this study who carried one or no functional SLC22A1/OCT1 gene 
copies had a higher M1/M ratio, which is indicative of higher plasma concentration of the 
active metabolite M1. is is in line with the role of OCT1 as a transporter of substrates 
into the hepatocyte. ese ndings also conrm the relationship between SLC22A1/OCT1 
polymorphisms with M1 exposure observed in vitro and in healthy adult volunteers [13].
Recently OCT1 protein expression in human livers from organ donors was found to be 
stable in a cohort ranging from 9 to 70 years of age [25]. According to recent reviews, data 
on the ontogeny of human OCT1 activity are still lacking [15, 16]. As SLC22A1/OCT1 
genotype a+ected M disposition in our study population, this suggests that OCT1 matures 
very soon after birth, in both term and preterm infants. Our data are also indirectly show-
ing this ‘early’ impact of CYP2D6 genotype on activity. In vivo data have shown a CYP2D6 
genotype-phenotype correlation after 2 weeks PNA [26]. Stevens et al. reported no detect-
able CYP2D6 activity in up to 87 % of the samples in the rst and second trimesters, while 
the undetectable activity ranged 29–38 % for the third trimester until 1 week of postnatal 
age. After the rst post-partum week, CYP2D6 activity could not be detected in 13 % of 
the liver samples, re0ecting the CYP2D6 PM frequency in a Caucasian population [27].
CYP2D6 genotype-guided dosing recommendations are available for M [28], i.e. de-
creasing the dose to 30 % in UMs and use of an alternative analgesic is suggested for 
PMs. Pre-emptive genotyping for CYP2D6 could be considered in specic populations 
(e.g. breastfeeding mothers, children undergoing tonsillectomy for obstructive sleep apnea 
syndrome (OSAS)) with an increased risk for adverse events. Adverse events such as severe 
respiratory depression induced by opioids should be prevented at all costs, especially in the 
vulnerable critically ill neonatal population. As not all CYP2D6 UMs will develop severe 
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Figure 3. MR O-desmethyltramadol (M1)/tramadol (M) in relation to the combined SLC22A1/
CYP2D6 genotype. LA, < 2 functional gene copies; NA, 2 (or more in the case of CYP2D6) functional 
gene copies.
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respiratory depression, other factors such as kidney function, co-morbidity and SLC22A1/
OCT1 genetic variants could potentially increase this risk. Particularly simultaneous 
occurrence of 3 or more functional CYP2D6 gene copies with carriage of two inactive 
SLC22A1/OCT1 gene copies might increase the susceptibility to adverse events because of 
a combination of increased M1 formation and a decrease in OCT1-mediated hepatocel-
lular uptake of M1 from the central compartment for subsequent elimination.
Severe respiratory depression in a 5-year-old child undergoing adenotonsillectomy for 
OSAS after 20 mg oral M was recently reported [29]. is adverse event, which is in 
general less prominent with M use than with use of other opioids, was not caused by renal 
impairment but most likely by the combination of underlying respiratory illness with the 
presence of three functional CYP2D6 copies. Since SLC22A1/OCT1 genotype was not 
reported here, it would be of high relevance to assess in future studies the relevance of 
carrying two loss-of-function SLC22A1/OCT1 copies in CYP2D6 ultra-rapid metabolizers 
experiencing adverse events. We were unable to analyze what the e+ect would have been 
on M1 plasma concentration for this specic group because this genotypic combination 
was not found in our population.
Several limitations of this study need to be addressed. Firstly, body weight was excluded 
from the mixed model due to collinearity between this variable and PMA. We chose 
PMA as the preferred parameter as for most critically ill neonates, weight is not measured 
frequently enough to re0ect accurate weight at the time of M administration. Second, 
because the initial study design focused on pharmacokinetics of di+erent and multimodal 
analgesics, we were unable to address the relationship between SLC22A1/OCT1 genotype 
and clinical outcomes such as pain scores, dose required for su4cient analgesia or occur-
rence of adverse events. Although our ndings support further research on the pharmaco-
dynamics and SLC22A1/OCT1 genetics, at this stage it is not possible to implement this 
information in the clinical setting when dosing neonates. eoretically we would expect 
the requirement of lower M doses in neonates carrying loss-of function SLC22A1/OCT1 
alleles due to increased exposure.
CONCLUSION
Our study emphasizes that in addition to PMA and CYP2D6 genetics, carriage of loss-of-
function SLC22A1/OCT1 polymorphisms explains additional variability in M PK in the 
developing pediatric population. Genotyping of CYP2D6 and SLC22A1/OCT1 might shed 
light on unexplained side e+ects of M. Future research with larger sample sizes should 
validate prospectively the e+ects of CYP2D6 and SLC22A1/OCT1 genotypes on clinical 
outcomes before implementing genotyping of CYP2D6 and OCT1 pre-emptively in 
clinical practice. Besides, the genetic component should be expanded in larger studies 
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by addressing the additional value of polymorphisms in other important genes such as 
drug metabolizing enzymes (CYP2B6, CYP3A4 and UGT2B7), transporters (ABCC3) and 
opioid pharmacodynamics related genes (OPRM1). is will increase our understanding 
of the genetic make-up and its in0uence on the M detoxication process. Our study 
suggests that OCT1 is already active soon after birth, but, however, does not provide any 
information on the development of this expression. Our ndings may help understand the 
variation in disposition of other OCT1 substrates in neonates, in addition to ontogenetic 
studies that need to be performed.
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A BSTR ACT
Aim: Determine whether SNPs of OPRM1 118A>G (asn(40)asp), COMT 472G>A (val(158)
met) and ARRB2 8622C>T are associated with morphine rescue in newborns on mechani-
cal ventilation.
Materials & methods: is is a pharmacogenetic analysis of a randomized controlled 
trial in (pre)term newborns (n = 64) at a level III Neonatal Intensive Care Unit (NICU) 
who received placebo infusion and for whom need and dose for rescue morphine was 
documented.
Results: For OPRM1 and COMT separately, the expected risk for rescue morphine or 
morphine dose was not signicantly increased. However, the combined OPRM1/COMT 
‘high-risk’ genotype lead to a signicant association with the need for rescue (OR: 5.12; 
95 % CI: 1.12–23.3; p = 0.035). No association was found between OPRM1/COMT ‘high-
risk’ genotype and total morphine dose administered.
Conclusion: Combined OPRM1 118A>G and COMT 472G>A genotype might serve as a 
predictor for the need of rescue morphine in premature and term newborns on mechanical 
ventilation.
Chapter 9: Rescue morphine ventilated newborns 165
9
INTRODUCT ION
Neonatal intensive care treatment is related to frequent painful procedures and continu-
ous distress from ventilatory support [1]. Adequate analgesia is needed not only because 
of ethical considerations, but also because of short- and long-term negative e+ects of 
neonatal pain exposure [2]. e use of morphine in newborns has been reduced in the 
past years because of fear for adverse e+ects [3,4]. Neonates on mechanical ventilation are 
not routinely treated with morphine anymore in our institution, but only as needed [5–7]. 
Also postoperative morphine use is reduced by applying intravenous paracetamol [8].
Analgesia with morphine in newborn infants is complicated by the existence of large 
interindividual di+erences in both morphine pharmacokinetics as in analgesic require-
ments [6,9]. erefore, it would be worthwhile to have objective biomarkers that may aid 
to personalize morphine dosing. e eld of pharmacogenetics predicts individual dosing 
of drugs based on genetic di+erences a+ecting disposition and e+ect. Genetic polymor-
phisms in several genes have been associated with pain sensitivity and opioid response in 
both adults [10,11] and children [12]. More recently, genetic variation in newborns with 
the neonatal abstinence syndrome (NAS) caused by in utero opioid exposure has been 
related to treatment requirement and length of hospitalization [13].
Pain perception is amongst others modulated by μ-opioid receptor (MOR) activity in 
the central nervous system, encoded by the OPRM1 gene, which is the main target for 
morphine. Over 700 SNPs have been described, but only few have been found relevant 
for analgesic e4cacy [14]. One of these variants is the well-documented A118G, asn40asp 
(rs1799971) SNP, with functional consequences on protein expression and conformational 
changes [15], a relatively high variant allele frequency (VAF) of 15 % in the Caucasian 
population [16]. In adult clinical studies, this genetic variant has been associated with 
reduced morphine e4cacy [17–26].
Another highly investigated protein is COMT, which is involved in pain perception 
by regulation of MOR expression [27]. e common genetic variant 472G>A, val158met 
(rs4680) leads to a 3- to 4-fold reduced COMT activity due to changes in thermo-stability 
[28]. e 158met variant has been associated with decreased release of endogenous opi-
oid in response to sustained experimental pain and an increase in the concentration of 
μ-opioid receptors in human subjects [29]. e distribution of genotype groups in the 
Caucasian population are 29 % 472GG (val158val), 46 % 472GA (val158met) and 25 % 
472AA (met158met) [16].
e genetic contribution in the perception of pain and the variability in opioid re-
quirement for su4cient analgesia is most likely not explained by polymorphisms in one 
single gene. Potential associations between genetic factors and pain sensitivity or need for 
analgesia might only appear when polymorphisms from multiple genes are combined, 
especially when DNA variants lead to opposite clinical e+ects. In the adult population two 
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independent studies have been published that emphasize the relevance of the combined 
OPRM1 A118G and COMT val158met genotype with analgesic response [20,30].
A third potential pharmacogenetic candidate gene in predicting morphine requirement 
is ARRB2, encoding the β-arrestin 2 protein. MOR signaling is terminated through inter-
nalization of the receptor by β-arrestin 2 after the receptor has been phosphorylated by 
G-protein-coupled receptor (GPCR) kinases [31]. In ARRB2(-/-)-decient mice, a higher 
potency and prolonged analgesic duration of single dose morphine has been shown [32]. 
A study in patients with moderate to severe cancer pain illustrated that the ARRB2 8622T 
allele (rs1045280) was more frequently found in patients that switched from morphine to 
another opioid [33].
In the adult population, studies have been performed with the previously mentioned 
pharmacodynamics (PD)-related candidate genes on morphine e4cacy and toxicity [33,34]. 
However, the contribution of these variations on the analgesic potency of morphine in 
preterm newborns, who undergo major developmental changes, has not been analyzed yet. 
erefore, the aim of this study is to determine the role of the OPRM1 118A>G, COMT 
472G>A (val158met) and ARRB2 8622C>T polymorphisms on the morphine requirement 
in (pre) term newborns on mechanical ventilation. Morphine requirement was expressed 
as rescue morphine needed (yes/no) and in case of morphine administration the dose in 
μg/kg/h.
M ETHODS
is pharmacogenetic study is based on a randomized, double-blind, placebo-controlled 
trial in newborns investigating the value of continuous morphine, as described previously 
[6]. e local ethical committee approved the current study as an amendment to the origi-
nal study protocol. Separate written informed consent for DNA collection and analysis 
was obtained from parents of eligible newborns. All newborns that required mechanical 
ventilation were suitable for inclusion. Additional inclusion criteria were postnatal age 
(PNA) < 3 days, articial ventilation < 8 h, and an indwelling arterial catheter. Neonates 
with severe asphyxia (Apgar-score after 5 min of <  4 or cord blood pH <  7.0), severe 
intraventricular hemorrhage grade III or intraventricular hemorrhage plus apparent peri-
ventricular hemorrhagic infarction), major congenital and/or facial malformations, neuro 
logic disorders or continuous/intermittent neuromuscular blockers were excluded from 
the trial. Please see Simons et al. [6] for a more detailed description of the inclusion and 
exclusion criteria. All newborns were admitted to the level III Neonatal Intensive Care 
Unit (NICU) of two centers in e Netherlands (Erasmus MC – Sophia, Rotterdam and 
Isala Clinics, Zwolle).
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e patients in the randomized controlled trial were allocated to either loading dose 
morphine (100 μg/kg) followed by continuous morphine infusion (10 μg/kg/h) or to con-
tinuous placebo infusion. Both groups were treated for a maximum of 7 days. Occurrence 
of pain in the newborn during any medical action was treated with additional open label 
morphine, independent of the randomization group. e rescue morphine, consisting of 
50 μg/kg bolus, was followed by 5–10 μg/kg/h continuous infusion, whereas patients’ pain 
for additional morphine was performed as described previously [6]. Because the outcome 
of the randomized controlled trial showed no di+erence in morphine requirement be-
tween the two randomization groups, our institution now refrains from using continuous 
morphine as standard care in mechanically ventilated newborns. For this reason, we chose 
to analyze the placebo arm, in order to obtain the possible additional value of pharmaco-
genetics in the standard of care setting in our hospital.
e primary outcome measures of this pharmacogenetic study were rescue morphine 
requirement as a dichotomous variable (yes/no) and total morphine amount required as 
a continuous variable, expressed in μg/kg/h. As a secondary outcome measure we have 
analyzed the sensitivity, specicity, positive predictive value (PPV) and negative predictive 
value (NPV). e sensitivity of the genetic test is dened as the number of patients that 
required rescue morphine with the mutation divided by total number of patients that 
required rescue. e specicity was calculated by dividing the number of patients that did 
not have rescue morphine nor the mutation divided by total number of patients that did 
not require rescue. For the PPV of the test the patients with the mutation and rescue were 
divided by total number of patients with the mutation. Whereas the NPV was calculated 
by dividing patients without mutation and rescue by total number of patients without the 
mutation.
DNA isolation & genotyping
DNA was isolated using buccal brushes (Master-Amp™, Epicentre). Tissue was collected 
by rolling the buccal brush on the inside of the patients’ cheek, approximately 20-times 
on each side. Brushes were stored in the original packaging at room temperature for maxi-
mally 7 days before extracting the DNA, whereas the extraction was performed according 
to the protocol of the manufacturer. PCR amplication was performed in 50 μl reaction 
volume, containing 10 ng of genomic DNA, 1× PCR Bu+er II (Perkin Elmer), 1.5 mM 
MgCl2, 2 nM dTNPs (Roche), 1.25 U of Amplitaq Gold (Perkin Elmer) and 40 pmol each 
of forward and reverse primer.
To detect variation OPRM1 118A>G, forward primer 5´-GCTTGGAACCC-
GAAAAGTCT-3´ and reverse primer 5´-GTAGAGGGCCATGATCGT-GAT-3´ were 
used. Amplication consisted of an initial denaturation step (7 min at 94°C), followed 
by 35 cycles of 1 min at 94°C, 1 min at 55°C and 1 min at 72°C, ending with one extension 
cycle (7 min at 72°C). Two μl of 1:100 diluted PCR product was used as template in 
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a nested PCR, nal volume of 50 μl, containing 1× PCR Bu+er II, 1.75 mM MgCl2, 
0.2 mM dNTPs 1.25 U of Amplitaq Gold and 40 pmol forward primer 5´-GCTTG-
GAACCCGAAAAGTCT-3´ and reverse primer 5´-ACCGCATGGGTCGGAAACGT-3´. 
Mismatches (underlined) were used to create a restriction site for Psp1406I. e PCR cycle 
conditions were identical to those described above, except for an annealing temperature of 
53°C. For restriction analysis, 10 μl of the nested PCR amplication was digested for 2 h 
at 37°C in a nal volume of 15 μl with 10 U of Psp1406I (MBI Fermentas). For genotyping 
the val158met SNP of the COMT gene, forward primer 5´-CTCATCACCATCGAGAT-
CAA-3´ and reverse primer 5´-CAGTGAACGTGGT-GTGAACAC-3´ were used. 
Amplication consisted of an initial denaturation step (7 min at 94°C), followed by 45 
cycles, each consisting of 1 min at 94°C, 1 min at 58°C and 1 min at 72°C, ending with an 
extension cycle (7 min at 72°C). For restriction analysis, 10 μl from the 185 base pairs (bp) 
PCR amplication prod-uct was digested for 2 h at 37°C in a nal volume of 15 μl with 10 
U of NlaIII (New England Biolabs).
Both digested fragments were separated by electrophoresis on a 3 % agarose gel with 
ethidium bromide staining. SNP 118A>G existed of fragments of 188 and 19 bp for the 
wild-type sequence, 207, 188 and 19 bp for heterozygous sequences and a single band of 
207 bp for homozygous variant sequences. e fragments produced for val158met were 87, 
54 and 44 bp for the wild-type sequence, 87, 69, 54, 44 and 18 bp for heterozygotes and 
69, 54, 44 and 18 bp for homozygous variants. All PCR-RFLP analyses were performed in 
duplicate.
Polymorphism 8622C>T in the ARRB2 gene was analyzed with the TaqMan allelic 
discrimination analysis. e assay, with ID number C__8718195_20, was obtained at Ap-
plied Biosystems and was analyzed on the 7000 Real-Time PCR System (software version 
v2.0.5; Applied Biosystems). e PCR amplication started with denaturation at 95°C 
for 20 s, followed by hybridization of the primers and probes at 92°C for 40 s. After 
hybridization the elongation was begun at 60°C for 30 s. e whole process was run for 40 
cycles, in which three control samples (wild-type, heterozygous and mutant) and a blank 
sample has been included.
Statistics
All data were analyzed using SPSS version 21.0 for Windows. Results are shown as median 
values with their interquartile range (IQR) when variables violated normal distribution, 
which was judged using the Q-Q plot and Kolmogorov–Smirnov test. e categorical 
variables included in Table 1 and the Hardy–Weinberg equilibrium in the genotype fre-
quencies are assessed with either the Pearson chi-square or Fisher’s exact test, depending 
on the expected count in the cells. e continuous variables were analyzed either using the 
independent samples t-test or the Mann–Whitney U test, depending on distribution of the 
variable. All p-values in this manuscript are two-sided. e e+ects of the OPRM1, COMT 
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and ARRB2 genotypes (autosomal dominant model) on the requirement of rescue mor-
phine (yes/no) were analyzed in an univariate logistic regression model. e relationship 
between the combined OPRM1 and COMT genotype and morphine requirement (yes/no) 
was also assessed using logistic regression. For the combined allelic e+ect the dominant 
model as well was used. Newborns that have either the OPRM1 118G risk allele and/or the 
COMT 472GG (val158val) genotype have been compared against newborns with ‘low-risk’ 
genotype, which is composed of newborns that are wild-type for the OPRM1 SNP (118AA) 
and carriers of the COMT 472A (158met) allele. High and low risk indicates the level of 
pain and therefore the level of requirement for opioids.
e above mentioned logistic regression models are consisting of the following in-
dependent variables: gestational age (GA), birth weight, sex, allocation center, Visual 
Analogue Scale (VAS) at baseline and co-medication for analgesia and/or sedation. PNA 
was not included in the analysis as a confounding factor because all newborns received the 
randomized treatment within 72 h after birth. e VAS score at base-line was included 
in the regression models, since this could imply worse clinical situation of the newborn 
and therefore possibly confound the requirement of rescue morphine. VAS is an one-
dimensional pain scale that is represented by a 10-cm line, ranging from ‘no pain’ at the 
left end to ‘extreme pain’ at the extreme right. is is a validated scale for self-report of 
pain in adults and children with an age > 5 years [35,36]. Additionally, this method is also 
used by the physician/nurse for the judgment of pain experience in nonverbal patients, 
representing the observational VAS. In our study VAS was measured at the bedside of the 
Table 1. Baseline characteristics of placebo-allocated newborns.
 
Rescue morphine
(n = 25)
No rescue morphine
(n = 39) p-value
Sex, male/female (n) 14/11 25/14 0.52
Gestational age (weeks) 28.7 (27.3–31.4) 30 (29.1–32.1) 0.14
Preterm/term (n) 23/2 38/1 0.56
Weight (g) 1165 (867.5–1478) 1410 (1050–1715) 0.083
Ethnicity, Caucasian/non-Caucasian (n) 21/4 32/7 0.84
Location, Sophia Children’s hospital/Isala Clinic Zwolle (n) 13/12 26/13 0.24
Pain/sedation medication, yes/no (n) 4/21 4/35 0.70
VAS pain score, baseline 0.95 (0.50–1.75) 0.50 (0.30–1.60) 0.091
VAS pain score, average 1.74 (1.32–2.56) 1.43 (0.92–2.54) 0.29
COMFORT pain score, average 16.0 (15.0–17.6) 15.7 (14.1–16.8) 0.16
SSS/CRIB 4.0 (1.0–8.0) 2.0 (1.0–4.0) 0.061
Successful DNA analysis, yes/no (n) 19/6 31/8 0.84
All data are presented as median (interquartile range), unless stated otherwise.
CRIB: Clinical Risk Index for Babies; SSS: Surgical Stress Score; VAS: Visual Analogue Scale.
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patient and via recorded videotapes [6]. e chosen independent variables GA and birth 
weight forced into the regression model were assessed for multicollinearity, in which the 
analysis illustrated a variance in0ation factor < 3. In neonates who have received rescue 
morphine, the cumulative morphine dose (μg/kg/h) in relation with the genetic variations 
was analyzed with multiple linear regression. e same independent variables as described 
previously were included in this analysis.
R E SU LTS
From the 150 patients included in the original study [6], parents of 133 newborns gave 
written informed consent for DNA analysis. From these 133 infants, 11 were lost to follow-
up. is resulted in 122 newborns in the study, from which 64 newborns were allocated to 
placebo. Table 1 shows the baseline characteristics of the newborns that were randomized 
to placebo treatment. e median GA of the included patients in the placebo group with-
out rescue morphine (n = 39) was 30.0 (IQR: 29.1–32.1) weeks, with 97.4 % of the patients 
born preterm. e patients requiring rescue morphine (n = 25) had a median age of 28.7 
(IQR: 27.3–31.4) weeks of gestation, with 92 % born preterm (p = 0.14). e majority of 
the newborns had a Caucasian ethnicity. In total, 18 % in the group without additional 
morphine and 16 % in the ‘rescue morphine’ group were of non-Caucasian origin or the 
information on ethnicity was missing. e baseline and average values of pain scores did 
not di+er signicantly between the two groups.
e OPRM1 118A>G (VAF 16 %), COMT 472G>A (VAF 40 %) and ARRB2 8622C>T 
(VAF 70 %) allele distributions all met the Hardy–Weinberg equilibrium (p = 0.27; p = 0.73 
and p = 0.20, respectively) and the observed VAFs were comparable with those reported by 
the National Center for Biotechnology Information (NCBI) [16]. In 16 (25 %) newborns 
one of the SNP assays failed, probably due to poor quality DNA, with no signicant 
di+erences between groups (Table 1). Since only to patients have been genotyped 8622CC 
for the ARRB2 gene this SNP was omitted from the statistical analysis. With regard to the 
combined OPRM1/COMT genotype, 27 newborns had the ‘high-risk’ genotype and 24 
newborns the ‘low-risk’ genotype.
Relation OPRM1 & COMT with morphine rescue & dose
Although carriers of the OPRM1 118G allele seem to indeed have an increased risk for 
requiring additional morphine (OR: 1.85; 95 % CI: 0.494–496.90), this di+erence was not 
signicant (p = 0.36). In addition, from the newborns that did require res-cue morphine 
carriers of 118G allele needed on average 5.63 (2.22–29.36) μg/kg/h morphine and 118AA 
newborns 3.12 (0.96–95.84) μg/kg/h morphine (p = 0.096). A similar e+ect was observed 
for COMT 472G>A (val158met); patients with the 472GG (val158val) wild-type geno-
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Figure 1. Odds ratio plot on a logarithmic scale for OPRM1 118A>G, COMT 472G>A (val158met) 
in gure shown as 472A>G (met158val), and combined OPRM1/COMT genotype in relation to 
morphine requirement (yes/no). For the combined allelic e+ect, patients with the ‘high-risk’ genotypes 
(118G allele carriage and/or 472GG [val/val] genotype) are plotted against newborns with the ‘low-
risk’ genotypes (118AA and 472A [met] allele carriage).
Table 2. Relation between morphine requirement (yes/no) and total morphine administered (μg/
kg/h) with OPRM1 118A>G, COMT 472G>A (val158met) and OPRM1/COMT combined genotype.
 
Rescue morphine
yes/no, n (%)
Total morphine (μg/kg/h)
median (IQR)
OPRM1    
118AA (n = 44) 16/28 (36.4) 3.12; 0.96–5.84 (n = 16)
118AG/GG (n = 18) 8/10 (44.4) 5.63; 2.22–9.36 (n = 8)
OR (95 % CI) 1.85 (0.494–6.90) –
p-value 0.36 0.096
COMT    
472GA/AA (val/met, met/met) (n = 37) 12/25 (32.4) 3.69; 1.40–9.72 (n = 12)
472GG (val/val) (n = 15) 8/7 (53.3) 5.66; 1.71–7.22 (n = 8)
OR (95 % CI) 3.33 (0.780–14.2) –
p-value 0.10 0.93
OPRM1/COMT    
118AA+472A carrier (met carrier) (n = 24) 6/18 (25) 2.85; 1.13–9.64 (n = 6)
118G carrier and/or 472GG (val/val) (n = 27) 13/14 (48.1) 5.26; 1.42–8.80 (n = 13)
OR (95 % CI) 5.12 (1.12–23.3) –
p-value 0.035 0.58
e given p-values are corrected for gestational age, birth weight, sex, allocation center, Visual Analogue Score at 
baseline and co-medication for analgesia and/or sedation.
Statistically signicant values are in bold.
172 Part III: Genetics, Pain and Analgesia in Pediatrics
type were trending towards an increased risk of requiring morphine (OR: 3.33; 95 % CI: 
0.780–714.2), as expected, but again not signicant (p = 0.10; Figure 1). Newborns with 
the 472GG (val158val) genotype needed on average 5.66 (1.71–77.22) μg/kg/h morphine 
and 472A (158met) allele carriers 3.69 (1.40–49.72) μg/kg/h morphine (p = 0.93).
However, the combination of OPRM1 and COMT yielded a signicant association 
with the need for rescue morphine. Newborns with the ‘high-risk’ genotype (dened by 
having the OPRM1 118G allele and/or the risk genotype COMT 472GG [val158val] have 
an increased risk for requiring rescue morphine: OR: 5.12; 95 % CI: 1.12–23.3; p = 0.035) 
compared with the 118AA combined with being a 472A (158met) carrier (Figure 1). With 
regard to the total morphine dose, no associations were found with the genotypes analyzed 
(Table 2).
Sensitivity, specicity, PPV & NPV
e PPV was 44.4 %, 32.4 %% and 48.2 % for OPRM1, COMT and the combined genotype 
respectively, while the NPV was 63.6 %, 46.6 % and 75 % in the same order. e analysis 
showed a sensitivity of 33.3 % and 60 % for OPRM1 and COMT respectively, while the 
specicity was 73.6 % and 21.8 %. Combination of the 2 SNPs in one allelic genotype gave 
an sensitivity of 68.4 % and specicity of 56.3 %.
DISCUSSION
To our knowledge, this is the rst study exploring the role of genetic variants in PDs 
related genes on morphine requirement for pain in (pre)term newborns on articial 
ventilation. When analyzed separately, neither OPRM1 118A>G (asn40asp) nor COMT 
472G>A (val158met) were signicantly associated with morphine requirement or total 
morphine dose, although OPRM1 and COMT genotypes did yield an odds ratio greater 
than 1. Combining the OPRM1 and COMT SNPs in one allelic genotype, as suggested 
in the literature, generated a signicant association with morphine rescue requirement 
(p = 0.035).
In line with the results for OPRM1 and COMT on rescue morphine requirement, the 
patients with the ‘high-risk’ genotype also had a twofold higher total morphine dose, 
although this association did not reach statistical signicance (p = 0.83). Since only the 
newborns that required rescue morphine were included in this linear regression analysis, 
the power decreased by a reduction from 44 to 17 patients, which might explain the lack of 
statistical signicance. e relation between the analyzed SNPs in OPRM1 and COMT on 
morphine requirement has also been illustrated in di+erent adult studies with postopera-
tive [19,21–25,37] and cancer related pain [38–40], although others failed in nding these 
associations [41–43]. is failure is most likely caused by the polygenic aspect in pain 
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[10], as discussed in the introduction. Our results on the combined genotypic e+ect are 
in line with two previously performed studies, in which is concluded that OPRM1 118AA 
in combination with COMT 158met have the lowest requirement whereas vice versa (118G 
and COMT 158val) have a higher risk for more pain and thus more opioid consumption 
[20,30].
Assessment of the genetic contribution in opioid disposition and response is particularly 
challenging in newborns due to confounding by developmental changes, such as matura-
tion of the hepatic enzymes and changes in renal function, both of which are related to 
gestational and PNA [44]. Yet, genetic polymorphism have been shown to play a role also 
in the developing child. For example, CYP2D6 genetic polymorphisms impact tramadol 
metabolism in the neonatal period [45]. And, well know, the impact of the *28 allele of the 
UGT1A1 phase II enzyme that has been associated specically with jaundice in neonates: 
Gilbert’s syndrome [46,47].
Recently, Wachman and colleagues have analyzed the genetic variations in OPRM1 
and COMT in newborns [13], but with the focus on NAS. ey have demonstrated that 
118G allele carriers and 472GG (val158val) genotyped newborns had a shorter hospital 
admission and lower risk for requiring treatment. Although our study di+ers in the type 
of opioid exposure, both ndings point toward the same direction with a negative e+ect 
on sensitivity to endo- and exogenous opioids for the 118G allele and 472GG (val158val) 
genotype. New-born babies on mechanical ventilation with the 118G allele in combina-
tion with the 158val allele are speculated to be less sensitive to endogenous opioids, with 
the consequence of experiencing more pain while being exposed to the same procedure 
and thus requiring morphine rescue. NAS infants are less sensitive to exogenous in utero 
exposure of methadone or buprenorphine. is may lead to the observed e+ect of being 
less prone to abstinence, as shown by a shorter hospitalization and lower requirement of 
the treatment of NAS.
ese clinical e+ects from both studies should also be compared with the ndings from 
in vitro studies. e studies addressing the molecular consequences of the 118A>G genetic 
variation have retrieved inconclusive results. is polymorphism has been associated with 
an decreased protein expression while others did not found this e+ect and instead showed 
conformational changes leading to higher a4nity of endogenous opioids and the opposite 
e+ect on exogenous opioids [15]. When comparing the clinical data from our and the 
NAS study we would expect a changed protein expression instead of alternations in the 
3D structure of the receptor because the same clinical e+ect is observed for both endo- and 
exogenous opioids.
Combining the two SNPs had a relatively large e+ect on the PPV and NPV compared 
with the sensitivity and specicity. Since in the case of the last two parameters also other 
non-genetic factors will deter-mine whether newborns will require morphine rescue, this 
could explain the low sensitivity and specicity percentages. Although, the combined 
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allelic genotype did increase the PPV and NPV, the predictive value of the test is still 
not high enough. Based on these percentages, application of this genotyping strategy in a 
clinical setting seems of limited value at this moment, although it could be taken as one of 
the determinants of need for morphine rescue in a multimodal treatment strategy.
One of the limitations of this study is that DNA was extracted from buccal swabs 
which has a lower quantity and quality when compared with DNA from saliva or whole 
blood samples [48]. Due to poor quality of the isolated DNA less newborns could be 
included in the nal analysis, which has decreased the power of the study, especially for 
the COMT polymorphism. However, in the case of newborns this method of DNA col-
lection is an appropriate option because of the restriction in amount of blood that they 
can provide and in the case of saliva samples which are only suitable for older children. 
Another restriction of our study is that newborns treated with a continuous morphine 
infusion were not considered appropriate for this pharmacogenetic analysis. is decision 
has reduced the power, but despite the relatively small number of newborns included 
signicant associations have been found. In addition, considering the current treatment 
protocol for presumed pain during articial respiration in newborns, where continuous 
morphine infusion is not given on a routine base [5], our ndings from infants allocated 
to the placebo group are therefore more relevant for the neonatal clinical practice.
In conclusion, we present, to our knowledge, the rst data on the in0uence of genetic 
variation in the OPRM1 and COMT genes on morphine rescue medication in (pre)term 
newborns on mechanical ventilation. e combined allelic ‘high-risk’ OPRM1/COMT 
genotype was found to be signicantly related with requirement for rescue morphine in 
premature neonates on mechanical ventilation.
FUT UR E PER SPECT I V E
Neonates at the intensive care are exposed to frequent painful procedures, including 
continuous distress from ventilatory support. Adequate analgesia with morphine is com-
plicated by the existence of large interindividual di+erences in both morphine pharmaco-
kinetics and requirement. Biomarkers that predict the need for morphine may be valuable 
tools in tailoring analgesia, thereby reaching better analgesia in those patients needing it 
and reducing negative e+ects. In our study, we have shown that genetic information on 
COMT and OPRM1 may facilitate in predicting neonates that would need additional 
morphine. Yet, the predictive power is still low for use in clinical practice. e search for 
additional factors, both genetic as non-genetic, is needed to be able to tailor morphine 
analgesia even further.
Future research on genetics could focus on studying these polymorphisms in a larger 
cohort. Also the potential contribution of other candidate genes should be considered 
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because of numerous genes involved in pain and the analgesic response to opioids. A key 
requisite in these studies would be to include a su4cient number of patients, in these cases 
newborn children, which can be a hurdle to collect due to di4culties involving sampling 
and informed consent of the vulnerable infants.
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GENER A L DISCUSSION
Pain needs to be adequately treated from a clinical, ethical and economical perspective. 
Currently pain is dened as “a distressing experience associated with actual or potential 
tissue damage with sensory, emotional, cognitive, and social components.” [1]. Abnormal 
sensory input without a clear sign of tissue damage is occurring in neuropathic pain, 
which is outside the scope of this thesis. Di+erent factors are contributing to the vari-
ability in pain expression, which can be explained with the generally accepted biopsy-
chosocial model of pain. Biological characteristics such as the primary disease, eventual 
comorbidities, drugs and genetics, but also psychological aspects (e.g. personality, coping 
mechanism) and social factors caused by the environment (e.g. household, family, work, 
culture) all contribute to the nal expression of pain. e studies outlined in this thesis are 
focused on the biological aspect of pain and analgesia by addressing the genetic variability. 
We rst aimed to give an overview with the most potential candidate genes that alter 
opioid therapy for application in clinical practice. Additionally, we have validated the 
relevance of these candidate genes in relation with opioid response in adult postoperative 
and cancer cohorts. As opposite to adults, data on the role of PGx with opioids in the 
pediatric population is very limited. Additionally, identied genotype-phenotype associa-
tions in adults are not directly applicable in (the youngest) children, due to the in0uence 
of developmental changes on the phenotypic activity. erefore the majority of the studies 
described in this thesis have aimed to address this information gap. In this discussion we 
synthesize the results of these studies and place them in context while providing future 
guidance for clinical care and research.
C A NDIDATE GENE S
In the case of acute pain several genes have been identied to play a role in the nocicep-
tive insult triggered by tissue damage to the processing of this signal in the brain. e 
genetic components of pain and its e+ect on pain sensitivity has been extensively studied 
by Je+rey Mogil (McGill University, US) by use of transgenic knockout mice [2]. is 
work resulted in a freely available online ‘Pain Genes Database’, which is mainly based on 
behavioral measures on pain sensitivity [2, 3]. Although we did not evaluate the genetic 
vulnerability to pain systematically in all studies, it is important to highlight that analgesic 
therapy is complicated a priori due to the extensive variability in pain sensitivity among 
individuals. Young children, especially neonates and infants di+er in their communication 
of pain. Whereas adults and adolescent children can adequately describe and rate their 
pain intensity, this self-report (golden standard) is impossible in the lower age groups. In 
very young children this has to be monitored observationally for which several scales have 
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been developed and validated [4]. Moreover, the developmental aspects of the expression 
of proteins and enzymes has to be taken into account when assessing the consequences of 
genetic variability on pain sensitivity.
Next to the variability in pain sensitivity patients also display major variation in opioid 
response. Nowadays, a trial-and-error approach is followed to reach adequate analgesia, a 
method which could be improved if biomarkers predicting opioid response were available. 
A promising  eld in this perspective is pharmacogenetics (PGx), in which genetic analysis 
of drug metabolizing enzymes, drug transporters and drug receptors is performed in order 
to predict the metabolism or transport (pharmacokinetics) and e+ ects (pharmacodynam-
ics) of drugs. See Figure 1 for an simpli ed overview of the pharmacokinetics of opioids, 
in which genes are depicted in italic that are coding for either drug metabolizing enzymes 
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Figure 1. Overview pharmacokinetics-related candidate genes
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or transporters in this process. Additionally, genetic variants of e! ector proteins and recep-
tors can also lead to a diminished or induced opioid response. Important genes involved in 
this pharmacodynamics route are shown in Figure 2. " e pediatric population, especially 
in the neonatal and infant age range, is highly subjective to developmental changes that 
a! ect drug metabolism and transport. For a good correlation between genotype and 
phenotype the activity of the involved protein has to be su#  ciently expressed to make 
distinctions between genotypic groups apparent [5].
Guiding opioid treatment based on PGx markers is not hampered by the lack of po-
tential candidate genes. In contrast, the literature is ”full” of potential biomarkers. " is 
extensive amount of information makes it di#  cult for healthcare practitioners to interpret 
the relevancy of a particular marker. We started with a systematic literature search, exam-
ining publications in several databases that are describing genetic markers with respect to a 
#
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Figure 2. Overview pharmacodynamics-related candidate genes
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correlation with opioid pain treatment e#cacy and toxicity (Chapter 2). With this search 
in 5 databases 4,257 unique citations were retrieved, eventually resulting in 852 signicant 
articles covering 24 genes. After extensive review of this data we created a shortlist with 
10 candidate genes: CYP2D6, OPRM1, COMT, SLC22A1, UGT2B7, KCNJ6, CYP3A4/A5, 
ABCB1 and ABCC3. Based on this shortlist genes were selected for assessment in the 
studies described in this thesis (Chapter 3 – 10).
Although genetic variability within the cytochrome P450 2D6 (CYP2D6) enzyme on 
opioid response is not assessed in this thesis, based on its role in opioid metabolism and 
evidence from literature it is worthwhile to mention its relevance before proceeding with 
other PK-related genes. CYP2D6 plays a major role in the biological activation of codeine 
and tramadol, and to a lesser extent for oxycodone and hydrocodone. CYP2D6 genetic 
variability is well characterized with an open source database reporting genetic variants and 
their consequence in vitro and/or in vivo on enzyme activity [6]. Additionally, CYP2D6 
genotype has been translated to actionable genotype-predicted phenotypic groups in 
the Netherlands as well as in the United States [7, 8]. Based on the extensive clinical 
evidence, CYP2D6 genotype-based codeine guidelines for healthcare practitioners have 
been published [9]. Furthermore, the CYP2D6 ultra-rapid metabolizer status is added 
as a contra-indication in the Summary of Product Characteristics of codeine [10]. Our 
literature search (Chapter 2) conrms the importance of genetic variability within this 
gene for codeine and tramadol response.
OPIOID PH A R M ACOK INET IC R EL ATED GENE S
UGT2B7
#e UDP-glucuronosyltransferase 2B7 (UGT2B7) enzyme is involved in the glucuronida-
tion of codeine, tramadol, and buprenorphine but is mainly of importance for morphine 
glucuronidation to morphine-3-glucuronide and morphine-6-glucuronide [11] (Figure 1). 
As demonstrated (Chapter 2), the most investigated UGT2B7 single nucleotide polymor-
phism (SNP) in relation to opioids is -900G>A (-842G>A). We have observed in that 
preterm newborns with the -900GG genotype had higher morphine levels, re%ecting lower 
enzymatic activity (Chapter 7). #is is the rst study to report an association between 
UGT2B7 genotype and morphine PK in neonates. With regards to the developmental pat-
tern of UGT2B7 various studies have been performed and illustrate that full maturation of 
this enzyme is reached between 2 and 6 months [12]. Despite that our group was younger, 
an e&ect of the genotype was observed. Apparently, di&erences in UGT2B7 activity and 
consequently substrate concentrations between the genotype groups can be found with 
lower overall activity. As this was a small pilot cohort, replication is warranted, preferably 
addressing also the e&ect on clinical outcome. Other studies have also addressed this vari-
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ant or polymorphisms that are in linkage disequilibrium with this variant on morphine 
disposition and response (Table 1, see end of this chapter).
From Table 1 it is evident that quite some contradictive results have been retrieved on 
the -900G>A variant or other SNPs in linkage disequilibrium. Although our results are in 
line with a previous study reporting reduced glucuronidation of morphine in -900G allele 
carriers [13], other studies in oncology patients did not demonstrate this e&ect [14–17]. 
Co-medication in cancer patients could have diluted the genetic e&ects. Also, since 
treatment of the tumor by radio- or chemotherapy could lead to hepatotoxicity [18, 19], 
genetic e&ects having functional consequences on hepatic enzymes could be irrelevant in 
these populations. In 759 patients with advanced cancer no e&ect was found of UGT2B7 
genetics on morphine metabolism. Instead, the combined UGT1A1/1A8 haplotype was 
associated with reduced M3G/morphine and M6G/morphine concentrations after oral 
ingestion [14]. A recent study in children in the postoperative setting was unable to dem-
onstrate the e&ect of SNP -900G>A on morphine clearance [20]. #e distinction between 
-900G>A genotype groups could only be made in children with normal OCT1 (SLC22A1 
gene) function.
Based on these studies, polymorphisms within other genes (UGT1A1, UGT1A8, 
SLC22A1) seem to be more relevant with regards to morphine PK than that of UGT2B7. 
Since our pilot study has included a low number of neonates and literature data is con-
tradicting, validation of these results in a larger cohort with the assessment of additional 
genes, as discussed, is mandatory.
SLC22A1
Transporters facilitate the passage of hydrophilic compounds across the lipid cell mem-
brane. #e Organic Cation Transporter (OCT1) has been implicated in the uptake of mor-
phine (active metabolite codeine) and O-desmethyltramadol (active metabolite tramadol) 
from the circulation into the hepatocyte in adults [21] (Figure  1). Inactivating genetic 
variants in the SLC22A1 gene, encoding OCT1, are thus expected to lead to a decreased 
elimination of codeine, morphine and tramadol. We found in very young infants with 
SLC22A1 loss-of-function alleles (*2-*6) increased O-desmethyltramadol plasma levels, 
after correction for CYP2D6 genotype (Chapter 8). Our results in this young popula-
tion re%ect adult data on tramadol (Table 2, see end of this chapter), pointing towards 
increased O-desmethyltramadol exposure [22, 23] and consequently decreased postop-
erative demand [22]. Currently no negative or con%icting studies have been published 
on SLC22A1 variants and tramadol. OCT1 is expressed from the rst postnatal day and 
increases quickly in the following months [24, 25]. Our study in infants suggests that 
full maturation of OCT1 in this young pediatric population is not needed for making a 
distinction between SLC22A1 genotypic groups.
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In contrast to tramadol, the impact of OCT1 genotype on codeine and morphine dis-
position was not replicated by all studies (Table 2). #is lack of e&ect can be explained by 
the results of in vitro study characterizing 19 non-synonymous SLC22A1 variants in their 
capacity to transport 10 substrates (e.g. morphine, tramadol, metformin, tropisetron). 
#ree groups of SLC22A1 loss-of-function alleles were established; 1) total loss of activity 
independent of substrate (*5, *6, *12, *15), 2) strong loss of activity but not complete, also 
independent of substrate (*3, *4, *14) and 3) substrate specic loss of activity ranging from 
0 % to 90 % (*2, *7, *10, *11, *14) [26]. #is study demonstrated that the *2 allele should be 
considered as a reduced function allele towards morphine, instead of total loss of function 
[26]. However, the *2 allele has zero activity towards O-desmethyltramadol, which further 
supports our nding in Chapter 8.
Before SLC22A1 genetics could be incorporated in the updated CPIC guideline of 
CYP2D6 genotype and codeine (tramadol, morphine) therapy [9], future research should 
focus more on the clinical impact. #is research should keep in mind that CYP2D6 UMs 
and PMs on tramadol or codeine (morphine) therapy already have an increased toxic-
ity risk and lack of analgesia, respectively. On the contrary, where studies have failed to 
demonstrate CYP2D6 genotypic e&ect on tramadol and codeine disposition or response, 
unidentied SLC22A1 genetics could have confounded these results. #e rst study ad-
dressing the clinical impact demonstrated that SLC22A1 loss-o&-function allele carriers 
required lower postoperative tramadol doses [22]. However, su\ciently powered studies 
should analyze if CYP2D6 EM individuals also have increased risk for toxicity when car-
rying SLC22A1 inactive alleles, and how large the risk is per inactive allele. Special atten-
tion should be given to the high toxicity risk group of genotype-predicted CYP2D6 UM 
patients that also carry 2 inactive SLC22A1 alleles. #is group is exposed to high morphine 
and O-desmethyltramadol plasma levels when treated with codeine and tramadol due 
to rapid formation of these metabolites and decreased clearance. Data on this specic 
Table 3. CYP2D6/OCT1(SLC22A1) risk genotype frequency in di&erent ethnicities
 
Africans
(%)
Asians
(%)
Caucasians
(%)
CYP2D6 UM 40 2 5
OCT1 poor function 0 0 8 
CYP2D6/OCT1       
(toxicity risk) 0 0 0.4 
CYP2D6 UM 40 2 5
OCT1 intermediate function 12 2 38 
CYP2D6/OCT1       
(toxicity risk) 4.8 0.04 1.9 
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‘high risk’ group are lacking. In order to investigate this, large numbers of individuals are 
required (Table 3).
A challenge in the clinical application of this genotyping strategy would be to demon-
strate that pre-emptive genotyping of all individuals on codeine and tramadol would be 
cost-e&ective, even with these low numbers of individuals at risk for toxicity (Table 3). In 
the assessment of the cost-e&ectiveness aspect it is of importance to demonstrate that the 
identication of these subjects would not only prevent respiratory depression or other life 
threating e&ects but also decrease opioid-related hospital admissions.
OPIOID EFFECTOR GENE S
Two important candidate SNPs from literature are OPRM1 118A>G and COMT 472G>A 
(Chapter 2), encoding the mu-opioid receptor (MOR) and catechol-O-methyltransferase 
enzyme (COMT). Figure 2 displays the role of these and other pharmacodymanic-related 
genes. We conrmed that the e&ect of these SNPs in adult cancer patients on opioid re-
sponse (OPRM1/COMT, Chapter 5) and in children on pain sensitivity (OPRM1/COMT, 
Chapter 6) was more relevant than variants in other candidate genes that were assessed 
concordantly. In other smaller cohorts, we choose to only determine these OPRM1 and 
COMT genetic variants. Using this approach, we found an association with postoperative 
morphine consumption (COMT, Chapter 3), the need for morphine rescue in neonates 
on the ventilator (OPRM1/COMT, Chapter 9) and an e&ect on withdrawal severity in 
children (OPRM1, Chapter 10).
For the MOR no studies addressed the in%uence of ontogeny in humans. Data from rat 
indicate no di&erence in number of mRNA transcripts of the MOR between 3 age groups 
[27]. #is re%ects the fact that we were able to demonstrate the e&ect of the OPRM1 variant 
on experimental pain in children from 8–18 years (Chapter 6), procedural pain in neonates 
(preterm and term) (Chapter 9) and an association on the severity of withdrawal (Chapter 
10) in children across the whole age range. In contrast to the MOR, COMT activity appears 
to change with age. In neonates (n = 8) the COMT enzyme protein content, determined 
with the Bradford method, and activity (Western Blotting) in the human prefrontal cortex 
was 50 % of adult values (n = 7). In the same study the COMT enzyme activity increased 
gradually to 75 % of adult value in young adults (20–24 years) [28].
#erefore it is unlikely that the absence of an association between the COMT Val158Met 
SNP with withdrawal in our pediatric cohort (Chapter 10) is due to immature COMT 
activity. Additionally, as we found associations for the COMT genotype in neonates on 
pain sensitivity during mechanical ventilation (Chapter 9), this indirectly suggest that 
50 % protein expression is su\cient to nd the distinctive e&ect of the genotype on pain 
and analgesia.
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Pain sensitivity (OPRM1)
#e consequence of the OPRM1 118A>G SNP on pain sensitivity has been assessed in 
adults (Chapter 3), children (Chapter 6) and neonates (Chapter 9). We found that 
children carrying the 118G allele are less sensitive to thermal pain. Data from this pediatric 
cohort (47 % boys, 53 % girls) t well with adult literature data, in which also a decreased 
sensitivity to experimentally induced thermal and pressure pain was observed [29, 30]. 
Further supporting our pediatric study, the endogenous opioid beta-endorphin has a 
higher a\nity and potency for the 118G variant of the MOR [31]. Others were unable to 
replicate this increased a\nity and potency [32, 33].
Interestingly, neonates randomized to placebo or morphine during articial ventilation 
carrying the 118G allele in combination with the COMT SNP require more frequently 
opioids (Chapter 9). #e fact that we found more pain in these infants ts well with the 
studies showing increased pain with the 118A>G variant in other clinical settings, such as 
migraine, hernia, bromyalgia and diabetic foot ulcer [34–37]. #is sounds counterintui-
tive when comparing these results with the decreased risk of the 118G allele to thermal 
pain. Two hypotheses may explain this contradictive observation. First, distinctive endog-
enous opioid peptides could be involved across di&erent stimuli evoking pain, and hence 
the functional consequence of the 118A>G SNP was found to be substrate dependent 
[31]. Alternatively, the 118A>G variant has been related with opposite e&ects on dopamine 
(DA) release in the nucleus accumbens (NAc) [38]. Placebo administration resulted in 
decreased DA release in NAc whereas during painful stimuli the release was increased [38]. 
As dopamine has been linked to the endogenous opioid system, di&erences in DA levels 
will in%uence the expression of endogenous opioid peptides [39].
In contrast to the pediatric data, no associations were found with (thermal) pain sen-
sitivity in adults (Chapter 3). We speculate that this could be caused by anxiety in the 
adult cohort, because these patients were tested shortly before the cardiac surgery. #e 
anxiety may have overwhelmed the genotype e&ect. Also, this cohort existed of mostly 
males. Di&erences between sexes have been observed, where females are more likely to 
su&er from a chronic pain condition (e.g. migraine, musculoskeletal pain, osteoarthritis) 
[40] while responding better to morphine [41]. #is ‘gender’ e&ect is highly dependent 
on socio- cultural (gender role expectations) and biological (gender hormones) di&erences 
between males and females [40]. Since the adult cohort existed of primarily male individu-
als (91 %), unlike other cohorts examined in this thesis, the gender role expectations could 
have biased our results.
Opioid response (OPRM1)
In our adult cancer cohort OPRM1 118G carriers in combination with the COMT Val158Val 
genotype had higher increase in dose after being seen by the palliative care team (Chapter 
5). #is is in line with two meta-analysis that have demonstrated in 118G allele patients 
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undergoing surgery increased opioid demand and lower risk to side e&ects [42, 43], with 
most solid evidence for morphine [42]. Unfortunately we were unable to demonstrate 
the e&ect of the 118G allele in our cohort of mostly males undergoing cardiac surgery 
(Chapter 3). It could be questioned in these patients if the administration of remifentanil 
and fentanyl intraoperatively a&ected the activating potential at the MOR and thereby 
omitting this genetic e&ect on morphine demand in the postoperative period. Moreover, 
we have observed an association between this OPRM1 SNP and withdrawal severity. #is 
implies that this genetic variant e&ect on MOR activity could predispose patients to more 
severe withdrawal symptoms.
While the literature shows more uniformity for this variant with postoperative pain 
phenotypes, this is not the case with cancer related pain [44] and chronic non-malignant 
conditions [45, 46]. One of the factors most likely eliminating the genetic e&ect in these 
chronic pain phenotypes is the development of tolerance to opioids. #e increase in opi-
oid demand over time mirrors progression of the disease, PK-related changes (increased 
metabolic activity), but it is assumed that this dose escalation is mostly a consequence 
of desensitization and down-regulation at MOR level [47]. #is desensitization of the 
receptor can abolish the OPRM1 genotype e&ect. Moreover, co-medication interfering 
with the metabolism of opioids can disturb a genotype-phenotype association. #is aligns 
with our results from Chapter 4 and 5, where this variant (nor any others) was not related 
with absolute morphine consumption the need to rotate from opioids, respectively.
Other OPRM1 SNPs have been associated with opioid demand and side e&ects [48–53], 
but without replication. #is could be indicative for false positive ndings. Rare OPRM1 
SNPs might have even more impact on MOR function and thus opioid response. A rare 
but very interesting OPRM1 variant (Arg181Cys, rs799910351) in this perspective was 
reported in the Scandinavian population [54]. #e patient that was homozygote vari-
ant had no analgesic e&ect from opioids and two patients carrying one allele required 
extremely high doses (400 and 550 mg/24 hours). In an attempt to uncover if this variant 
could explain the individual with extreme morphine equivalent dose in our cancer cohort 
(Chapter 5), the whole cohort (n = 239) was genotyped. Yet, it seems that this variant 
is region bound, as it was not detected in our cohort with mainly Europeans (data not 
published). Unfortunately, although the e&ect size is larger and as a result the consequence 
for the clinic of more importance with these type of SNPs, these variants are unlikely to 
enter the pre-emptive setting as the number needed to genotype (NNG) is extremely high.
COMT
Most studies have addressed the isolated e&ect of the Val158Met (rs4680) variant. While 
others have assessed more variants (rs4680, rs4818, rs4633) composing the COMT haplo-
types low pain sensitivity (LPS), average pain sensitivity (APS) and high pain sensitivity 
(HPS). #ese haplotypes have been related to interindividual di&erences in pain sensitiv-
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ity [55]. #e studies described in this thesis analyzed either the e&ect of the individual 
Val158Met variant (Chapter 9, 10) and when studies had su\cient sample size also the 
COMT haplotypes (Chapter 3, 4, 5, 6).
Pain sensitivity (COMT )
#e role of the Val158Met variant on pain sensitivity has been conrmed in our studies. As 
demonstrated in the pediatric population, 158Met allele carriers in combination with the 
OPRM1 118AA genotype were more sensitive to thermal pain (Chapter 6). #ese results 
are in line with published data from healthy subjects and also t with theoretical explana-
tion. COMT activity is decreased by 3–4 fold due to the 158Met allele. #is reduced activ-
ity has been related with a decrease in µ-opioid system activation, as demonstrated with 
positron emission tomography and a MOR-selective radiotracer in healthy subjects [39]. 
Less endogenous opioids are available to suppress the pain induced by the experimental 
stimulus. However, as is the case for the OPRM1 118A>G SNP, opposite e&ects are seen 
between pain phenotypes. We have observed lower baseline pain in neonates carrying the 
158Met allele in combination with the OPRM1 118AA genotype, re%ected by the fact that 
these children were less likely to require rescue morphine administration during mechani-
cal ventilation (Chapter 9).
When looking at the previously mentioned COMT haplotypes, the initial study from 
literature reporting on these COMT haplotypes found the e&ect in an experimental 
pain setting [56]. We conrm this nding, in our adult population with thermal pain 
data (Chapter 3). Carriers of the HPS group were more sensitive for pain, although this 
association did not remain after correction for multiple testing. In contrast, the e&ect 
of these COMT haplotypes was not found on thermal pain in our pediatric population 
(Chapter 6). #is might have been caused by a power issue, as from the 136 included 
children the COMT haplotype was only successfully constructed in 88 children. #erefore 
based on these studies it remains inconclusive which approach to choose (single variant or 
haplotypes) when relating COMT genetic variability to pain sensitivity.
Opioid response (COMT )
Cancer patients with the COMT Val158Val genotype in combination with the OPRM1 
118G allele had a larger increase in opioid dosage after palliative care team consultation 
(Chapter 5). Although also from literature the 158Val is linked to decreased opioid po-
tency, the ndings are not uniform (Table 4, see end of this chapter). #is variant was not 
found to be predictive of opioid induced withdrawal or the severity in pediatric patients 
(Chapter 10). #is implies that reduced opioid potency due to changes at the level of 
COMT activity do not a&ect the development of withdrawal. Also, in adult patients 
no e&ect was established of the Val158Met variant on postoperative opioid consumption 
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(Chapter 3). Instead, we found that the COMT haplotype APS was associated with the 
highest postoperative opioid requirement. Based on the e&ect of these haplotypes on pain 
sensitivity, as discussed previously, high opioid consumption is expected in carriers of the 
HPS (high pain sensitivity) haplotype. Instead HPS carriers required the lowest amounts 
of postoperative opioids in this study. #is haplotype was, however, again not predictive 
for opioid rotation in cancer patients (Chapter 4). As is the case with pain sensitivity, the 
e&ect of COMT genetic variability on opioid response remains inconclusive.
GENE- GENE INTER ACTIONS
Epistasis, describing interactions between genes, is an important factor to consider for 
pharmacogenetics in analgesia with opioids. #e e&ect of one allele on a particular pheno-
type can mask or alter the e&ect of another allele located at a di&erent locus on the same 
phenotype [57]. #e e&ect of the individual OPRM1 118A>G or COMT Val158Met SNPs 
was not evident on the requirement of morphine in adult cancer patients (Chapter 5) and 
the need for rescue morphine in newborns during mechanical ventilation (Chapter 9). 
Only after combination of these genotypes, a signicant association was found. #is in-
teraction was also found on thermal pain thresholds in children (Chapter 6). #e OPRM1 
118A>G variant has been linked to reduced opioid e\cacy in adults [42, 43], while the 
individuals with the COMT 158Met allele require lower amounts of opioids for pain relief 
[58–63]. #erefore, carriers of the OPRM1 118G allele should be grouped together with 
the COMT 158Val allele carriers. Others have also highlighted an interaction between 
these 2 genes [63–65]. #e chance of an European individual having the OPRM1 118G risk 
allele (15 %) and the COMT 158Met protective allele (50 %) is approximately 8 %. Hence, 
determining solely the OPRM1 or COMT variant in clinical practice will generate invalid 
advice in 8 patients for every 100 individuals.
M ETHODS A ND TECHN IQUE S
Although the exploratory genotype-association design is relatively easily executed and 
powerful for analyzing the e&ect of (relative) common genetic variants, usually sample 
sizes are small. #is makes these type of studies inappropriate for assessing multiple genes 
and rare genetic variants leading to extreme phenotypes (e.g. non-response, severe toxic-
ity). In multi-center studies power and external validity is increased but, confounding is 
introduced by di&erences between sites in treatment guidelines or type of patients. #e 
latter factor is especially of importance when multiracial di&erences exist with background 
prevalence rates amongst the populations. #e exploratory, case-control or observational 
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study design with prospective sample collection for DNA analysis (Chapter 3, 4, 5, 7, 8, 
9) is a commonly accepted, feasible and valid approach [66]. In the studies described in 
Chapter 6 and 10, informed consent for PGx analysis was gathered retrospectively (Chap-
ter 6, 10). #is retrospective approach has the limitation of lower inclusion rates due to 
lost to follow-up (e.g. patient deceased, inaccurate contact information). Saliva and buccal 
swabs collection methods surpass the need for blood collection and thereby the need for 
subjects visiting the hospital, a higher inclusion rate could be reached. A limitation of 
this collection method is, however, that lower amounts of DNA are retrieved, which may 
complicate DNA analyses. See Table 5 for an overview of di&erent study designs with the 
advantages and disadvantages for PGx research [66–69].
An alternative and more e\cient approach for advancing the PGx research eld is by 
setting up a genomic biobank linked to the electronic health record (EHR). #is has al-
ready been realized by the electronic MEdical Records and GEnomics (eMERGE) network 
[70]. With this method a broad informed consent applies making the material suitable 
for multiple studies in the future. However, documentation in the EHR is subjective to 
input errors and incomplete information for answering specic study aims. Additionally, 
ethical concerns with respect to the unknown study aim during sample collection are 
raised. A more controlled setting reducing confounding and selection bias is reached with 
a randomized controlled trial. With such an approach, if su\ciently powered, the e&ect 
of PGx-guided dosing on clinical outcomes and cost-e&ectiveness can be demonstrated.
Table 5. Pharmacogenetics research: pros and cons study designs
Study design (this thesis) Advantages Disadvantages
Case-control t  'FBTJCMFFYFDVUJPO
t  1PXFSGVMGPSBTTFTTJOHDPNNPO
variants and common traits
t  $PNQBSJTPOPVUMJFST	DBTFT
WFSTVT
controls
t  4NBMMTBNQMFTJ[F
t  "DUJWFJODMVTJPOGPS%/"BOBMZTJT
Observational cohort t  'FBTJCMFFYFDVUJPO
t  1PXFSGVMGPSBTTFTTJOHDPNNPO
variants and common traits
t  4NBMMTBNQMFTJ[F
t  "DUJWFJODMVTJPOGPS%/"BOBMZTJT
Study design Advantages Disadvantages
Biobank linked to EHR t  *OGPSNFEDPOTFOUBWBJMBCMF
t  #SPBEJOGPSNFEDPOTFOU
t  *OëOJUFVTFNBUFSJBM
t  *ODPNQMFUFJOGPSNBUJPOGPSSFTFBSDI
purposes
t  &UIJDBMDPODFSOT
Randomized Clinical Trial t  $POUSPMMFETFUUJOH
t  $POGPVOEJOHSFEVDFE
t  4FMFDUJPOCJBTSFEVDFE
t  &YQFOTJWF
t  5JNFDPOTVNJOH
   (depending on follow-up period)
Genome wide approach t  )ZQPUIFTJTHFOFSBUJOH
   (novel discoveries)
t  -BSHFTBNQMFTJ[FSFRVJSFE
t  7BMJEBUJPODPIPSUSFRVJSFE
In vitro study t  $POUSPMMFETFUUJOH
t  'VODUJPO4/1PONPMFDVMBSMFWFM
t  %FQFOEJOHPODFMMMJOFTSFMFWBOU
proteins might not be expressed
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Besides the study design that is of relevance for PGx research, also the genotyping 
platform is of importance. See Table 6 for the advantages and disadvantages of the most 
frequently used techniques. In the case of only a handful of relevant genetic variants, 
the PCR-FLP and Real-Time PCR techniques are su\cient. In the case of pre-emptive 
genotyping, the micro-array based techniques, including pre-spotted variants from hun-
dreds of genes, are more cost-e\cient. #is strategy is applied in the PG4KDS protocol 
(St. Jude Children Research Hospital), where all children receiving care are pre-emptively 
genotyped for 230 genes [71]. While rare polymorphisms can be included in micro-arrays, 
the selection is always lagging behind due to the de novo genetic variants detected in 
individuals. Sequencing-based approaches such as next generation sequencing and whole 
exon sequence can overcome this issue [72], although these methods are so far accompa-
nied with high costs and SNPs with unknown functional e&ect. #is type of data requires 
software, which can be handled by skilled personal in transferring the data to clinical 
phenotypes and an infrastructure of high level bioinformatics facility.
M A IN CONCLUSIONS
Based on the research described in this thesis we conclude that:
Ⴜ OPRM1 118A>G and COMT Val158Met genetic variants are of importance for explain-
ing pain variability and opioid response. #ese genetic variants remain the only ones 
associated with pain sensitivity and need for analgesia despite testing also other genes 
concordantly. Furthermore also when these OPRM1 And COMT variants were selected 
Table 6. Pharmacogenetics research: pros and cons genotyping platforms
Analytical technique (this thesis) Advantages Disadvantages
PCR-RFLP t  -PXDPTU
t  &BTZEBUBJOUFSQSFUBUJPO
t  .BOVBM
t  5JNFDPOTVNJOH
t  *OEJWJEVBM4/1T
Real-Time PCR
(TaqMan)
t  "VUPNBUFE
t  -PXDPTU
t  &BTZEBUBJOUFSQSFUBUJPO
t  *OEJWJEVBM4/1T
t  5JNFDPOTVNJOHJGΉ4/1T
determined
Analytical technique
(literature)
Advantages Disadvantages
Micro-arrays t  5JNFFïDJFODZ
t  3FEVDUJPODPTUTQFSTPOBM
t  %JïDVMUEBUBJOUFSQSFUBUJPO
quali!ed personal required
t  /PEFOPWPWBSJBOUT
Sequencing t  'VMMDPWFSBHF4/1TJOJOEJWJEVBM t  &YQFOTJWF
t  4/1TXJUIVOLOPXOFêFDU
t  %JïDVMUEBUBJOUFSQSFUBUJPO
quali!ed personal required
230 Part IV: Discussion and Summary
beforehand, due to limited sample size for addressing more genes, often associations 
were found with pain sensitivity and opioid response. (Chapter 3, 5, 6, 9, 10).
Ⴜ "e OPRM1 118A>G and COMT Val158Met genetic variants should always be exam-
ined concordantly (Chapter 5, 6, 9).
Ⴜ Although the OPRM1 118A>G and COMT Val158Met SNPs are related with pain and 
opioid response, these variants are less likely to predict extreme phenotypes neces-
sitating opioid rotation (non-response or side e&ects) in adult cancer patients or the 
occurrence of withdrawal in children at the intensive care setting (Chapter 4, 5, 6, 9, 
10).
Ⴜ Based on literature the impact of OPRM1 118A>G is most evident for increased 
morphine demand in the acute pain setting (postoperative). We were unable to dem-
onstrate this e&ect on postoperative morphine consumption in our cohort of (mostly!) 
males undergoing cardiac surgery (Chapter 3).
Ⴜ In addition to the adult literature our studies demonstrate that UGT2B7 and SLC22A1 
genotypes can partly explain the variability in morphine and tramadol disposition in 
neonates.
Ⴜ UGT2B7, SLC22A1, OPRM1 and COMT genotype most likely can be translated to 
genotype predicted phenotype activity in the pediatric population, despite the fact 
that full activity of the enzymes, transporters and receptors is not reached for some of 
the proteins encoded by these genes (Chapter 6-10).
Ⴜ "e use of saliva and buccal swabs kits (Chapter 6, 10) are child-friendly and valid 
methods of material collection when no intravenous access is available (anymore). 
Although a lower amount of DNA is retrieved with these type of collections, and 
problems might be encountered when using highly sensitive genotyping techniques.
FUT UR E PER SPECT I V E S
Ideally, PGx-testing should be performed pre-emptively in order to have a bene!cial e&ect 
on opioid therapy. However, the question arises whether we are ready for pre-emptive 
clinical implementation? At this time the answer is NO. "ere are some steps that have to 
be taken to change this answer into YES.
Ⴜ While the OPRM1 118A>G and COMT Val158Met SNPs are frequently found to relate 
with more/less pain and more/less opioid consumption (this thesis), genotyping these 
variants as a stand-alone test seems of low clinical importance. Also when using the 
combination of this OPRM1 and COMT genetic variant.
Ⴜ Moreover, contradictory results have been retrieved for these genes related to di&erent 
pain phenotypes and opioids. While it is more complicated to assess the di&erences 
between pain phenotypes, future studies should address in an experimental setting in 
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healthy subjects if the response is a&ected equally using validated endpoints for all 
opioids in individuals carrying these variants.
Ⴜ PGx-markers that predict extreme reactions to opioids such as extreme high doses 
required for su*cient analgesia, the occurrence of severe adverse events or extreme 
withdrawal symptoms, would be more easily adapted in the clinical practice. Very 
recently genetic variants, including the OPRM1 118A>G SNP, have been related with 
respiratory depression in the pediatric population [73-75]. Replication is warranted 
since these studies were all assessed separately in the same cohort without correction 
for multiple testing. "is should be analyzed in independent cohorts with also other 
pain phenotypes and opioids. Moreover, also the consequence of OPRM1 118A>G on 
the risk for respiratory depression is so far inconclusive [76, 77].
Ⴜ "e evidence for genotyping OCT1 seems more solid, as no contradictory results are 
retrieved and the possible outcome (severe toxicity) is of more clinical importance. "e 
SLC22A1 genetic variants should always be determined concordantly with CYP2D6 
genetics for codeine and tramadol, whereas for morphine testing CYP2D6 is not 
required. In contrast with our study, which has included the SLC22A1*2-*6 alleles, 
this list should be extended to the *7-*15 alleles. "ese alleles also have a signi!cant 
impact on activity and are common in non-Caucasian populations [26]. Especially, in 
cities located in the Randstad (conurbation of Western Holland), which is inhabited 
by global ethnic populations.
Ⴜ Due to the contradictive !ndings, our small cohort in premature neonates and 
the large cancer cohort in relation to an e&ect of UGT2B7 genetics on morphine 
pharmacokinetics [14], testing of this gene does not seem to have an important role 
as stand-alone test in explaining morphine response. Future studies should always 
address concordantly other PK-related genes (ABCB1, ABCC3, SLC22A1, UGT1A1, 
UGT1A8), important for morphine disposition.
If we would wish to proceed to pre-emptive testing a set of ‘pain’ genes, the challenges that 
are in general applicable to PGx need to be overcome.
Ⴜ Robust data by means of for instance large RCTs, addressing genotype-based versus 
conventional dosing strategies, are often requested from clinicians upon clinical PGx 
implementation [78]. An adult study comparing historical controls (n  =  47) with 
PGx-guided analgesia (n  =  50) following major abdominal surgery demonstrated a 
50 % reduction in analgesic consumption and less narcotic-related side e&ects in the 
PGx-guided group [79]. However, in this relative small study the exact e&ect sizes 
per SNP could not be assessed. In order to address this, large numbers of subjects 
are needed. "e level of evidence needed for pre-emptive PGx implementation also 
largely depends on the e&ect size of the genetic variant. For example, genetic variants 
of the human leukocyte antigen (HLA), which have been related to hypersensitivity 
(severe cutaneous reactions, Steven Johnson syndrome) with abacavir, carbamazepine 
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and allopurinol [80], are one of the examples where the execution of RCTs would be 
highly unethical.
Ⴜ Cost-e&ectiveness remains an important issue when implementing diagnostic screen-
ing tests. Currently several health insurances in the Netherlands reimburse retrospec-
tive genetic testing, because it is related to the therapy of the patient. However, the 
extreme increase in costs with this pre-emptive strategy in large patient groups would 
have to be lower than the reduction of costs due to possible reductions in toxicity and 
consequently hospitalizations.
Ⴜ Clearly for a su*cient processing of PGx information in guiding pain therapy the 
health care systems should invest in the infrastructure and logistics. "e NIH Pharma-
cogenomics Research Network has set-up the Translational Pharmacogenetics Program 
(TPP) with the aim to implement PGx across 8 health care systems in the United 
States [81].
In the future, we will hopefully optimize opioid e*cacy and reduce adverse events based 
on pre-emptive testing of genetic variants in addition to the collection of other clinical 
characteristics that in<uence pain sensitivity (fear, previous experiences), opioid disposi-
tion (e.g. kidney function, drug-drug interactions) and opioid response (opioid history). 
In the meantime healthcare professionals should consider testing for both CYP2D6 and 
SLC22A1 genetics when toxic e&ects with codeine and tramadol are observed in individual 
patients, including the youngest pediatric age range. "erefore if the opioid, or another 
opioid metabolized or transported by the same route, will be required in the future and 
the patient is indeed genetically predisposed to toxicity ‘we don’t have to make the same 
mistake again’.
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SU M M A RY
Large interindividual variability in the experience of pain and the response to analgesic 
agents advocates towards a personalized treatment approach (precision medicine). "e re-
search described in this thesis aimed to analyze the potential impact of pharmacogenetics 
(PGx) in the analgesic treatment with opioids. PGx is a research !eld on the relevance of 
candidate genetic variants on pharmacological treatments. First, we assessed the literature 
for the highest potential candidate genes (Part I). We analyzed the signi!cance of these 
PGx makers in the adult postoperative and cancer related setting (Part II). "e main 
focus was, however, on PGx markers in the pediatric population. Due to the impact of 
growth and development on the disposition and e&ect of drugs, data from adults cannot 
be directly translated to this group (Part III). Finally all the !ndings are discussed, put in 
perspective and future directions are de!ned (Part IV).
Part I
In Chapter 2 a review is presented on PGx studies in the !eld of analgesia with opioids. 
4257 unique citations have been retrieved with a literature search in 5 databases (Embase, 
Medline (OvidSP), Web-of-Science, Cochrane and Google Scholar). After screening of 
the abstracts, 852 relevant citations were found. Eventually, based on our criteria a shortlist 
of 10 genes that seemed most promising for clinical use was made and discussed. "is re-
view concludes that most evidence is present for CYP2D6, SLC22A1, OPRM1 and COMT 
genes. Moreover, this literature search underscores the need for PGx studies in children as 
very limited data is available for this vulnerable population.
Part II
In this part we aimed to cover di&erent pain modalities (experimental, postoperative, 
chronic non-malignant and cancer related pain) in adults. "e role of OPRM1 118A>G, 
COMT Val158Met SNPs and the COMT haplotype on thermally-induced pain, postop-
erative pain after thoracic surgery and the development of chronic pain is elucidated in 
Chapter 3. We were unable to illustrate the genetic e&ect of OPRM1 or COMT variant 
on the di&erent pain phenotypes. However, the COMT haplotype was associated with 
postoperative pain, with patients having the ‘average pain sensitivity’ haplotype requir-
ing lowest postoperative morphine. No genetic associations were found in 356 oncology 
patients with opioid treatment failure (Chapter 4). Although the observed trend between 
treatment failure and the polymorphisms in RHBDF2 and OPRK1 requires further investi-
gation. In another oncological setting (n = 340) the association of genetic variants (ABCB1, 
ARRB2, COMT, GCH1, IL1RN, KCNJ6, METTL21A, OPRM1, RHBDF2, SCN9A, Stat6) 
with morphine equivalent dose, relative increase in dose after consultation by the Pallia-
tive Care Team and the requirement of ketamine was analyzed (Chapter 5). Patients with 
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the OPRM1 118G and COMT Val158Val genotype, or these genotypes alone, had higher 
relative dose escalation (median = 95.2 % [IQR: 32.8–345]) compared to the OPRM1 118AA 
genotype and COMT 158Met allele group (48.5 % [0–98.8]) (p = 0.0016).
Part III
In Chapter 6 the e&ect of genetic factors (COMT, OPRD1, OPRM1, TRPA1, TRPV1, 
TAOK3, SCN9A) on thermal pain sensitivity in children (n = 136, 8–18 years) was assessed, 
by exposing them to protocolized thermal stimuli with the so-called "ermal Sensory 
Analyzer. OPRM1 (rs1799971) 118G allele carriers had decreased pain sensitivity compared 
to the wild type group. "is was re<ected by scoring the hot stimulus as less painful 
and reaching more frequently the minimum and maximum temperature limit (0–50°C). 
Moreover, higher pain thresholds were seen in carriers of the OPRM1 118G allele in com-
bination with the COMT Val158Val genotype.
Due to developmental changes in drug metabolism or transport the e&ect of some 
genetic variants might not visible if the enzyme or transporter is not su*ciently expressed 
on tissue level. In order to address the interaction between this developmental variation 
and genetics, we have tested if genetic variants in UGT2B7 (Chapter 7) and SLC22A1 
(Chapter 8) alter opioid PK in the neonatal population. UGT2B7 and SLC22A1 genetic 
variants had an e&ect on morphine and tramadol pharmacokinetics (PK), respectively. It 
remains to be established if these genetic variants also in<uence the analgesic response on 
these medications or predispose neonates to adverse events.
We investigated the relation with genetics in neonates on the mechanical ventilator 
(Chapter 9) and the development of opioid withdrawal in neonates and older children 
(Chapter 10), with both groups admitted to the intensive care unit. "e combined OPRM1/
COMT genotype was associated with the need for morphine rescue in 64 mechanically 
ventilated newborns. Carriers of the OPRM1 118G allele that also carried the COMT Val-
158Val genotype required more frequently morphine rescue. In the cohort (n = 77) were we 
assessed the genetic e&ect on withdrawal these OPRM1 and COMT genetic variants were 
not related with the development of withdrawal. However, we observed an association 
with the severity of withdrawal, showing more withdrawal related symptoms in carriers 
of the 118G allele.
Part IV
When analyzing variants in several genes, OPRM1 118A>G and COMT Val158Met remain 
the only SNPs associated. Furthermore also when these OPRM1 And COMT variants 
were selected beforehand, due to limited sample size for addressing more genes, frequently 
associations were found with pain sensitivity and opioid response. Although these vari-
ants were associated with more or less pain and opioid demand, these genotypes are not 
predisposing patients to extreme clinical outcomes (need to rotate to alternative opioid, 
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risk factor for withdrawal). Due to this, these SNPs are unlikely to be implemented in the 
clinical practice as stand-alone tests. Besides quite some inconsistencies have been reported 
between pain phenotypes and opioids. "e relevance of these SNPs between opioids needs 
to be addressed in an experimental pain study with healthy subjects. Variants in other 
genes that have been assessed in this thesis concordantly with the OPRM1 and COMT 
variant seem to be less relevant in explaining the variability between pain sensitivity and 
opioid response or require validation (RHBDF2, OPRK1). "e genotype to phenotype 
translations of UGT2B7, SLC22A1, OPRM1 and COMT gene can be used in the pediatric 
population. Moreover, the use of saliva and check-swabs is a child-friendly method of 
material collection when no intravenous access is available. "e importance of genotyping 
SLC22A1, in addition to CYP2D6, for codeine and tramadol seems more solid, since the 
possible outcome (toxicity) is of more clinical relevance. "e assessed alleles should be 
extended to also common alleles in other non-Caucasian populations, which we did not 
include in our study. Clinicians should request genetic testing of CYP2D6 and SLC22A1 
when severe codeine and tramadol toxicity or lack of response is presented in a patient.
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SA M EN VAT T ING
Er zijn grote verschillen in het pijnstillend e&ect van opiaten, en daarom wordt gepleit 
voor een gepersonaliseerde behandelstrategie (precisiegeneeskunde). Het onderzoek dat 
in dit proefschrift is beschreven richt zich op de rol van de farmacogenetica (PGx) bij de 
precisiegeneeskunde van pijnbehandeling met opiaten. Dit onderzoeksveld probeert te 
verklaren, en te voorspellen, hoe bepaalde genetische variaties (erfelijke aanleg) de manier 
waarop iemand reageert op medicijnen kunnen beïnvloeden. Allereerst is aan de hand van 
de literatuur een lijst samengesteld met genen die voor de klinische praktijk het belangrijkst 
lijken (Deel I). Deze zijn vervolgens onderzocht bij volwassenen, zowel patiënten voor en 
na een hartoperatie als bij patiënten met kanker (Deel II). Echter, de hoofddoelgroep voor 
dit proefschrift waren kinderen (Deel III). Bevindingen bij volwassenen kunnen niet sim-
pelweg vertaald worden naar kinderen omdat er veel leeftijdsafhankelijke veranderingen 
plaatsvinden in de afbraak en respons op medicijnen. In het laatste hoofdstuk (Deel IV) 
worden alle bevindingen in perspectief geplaatst en worden aanbevelingen gedaan voor 
toekomstig PGx onderzoek bij de behandeling van pijn met opiaten.
Deel I
In Hoofdstuk 2 is de literatuurstudie opgenomen waarin is gekeken naar PGx onderzoek 
bij de behandeling van pijn met opiaten. De zoekstrategie resulteerde in 4257 citaties 
uit vijf literatuurdatabanken (Embase, MEdline (OvidSP), Web-of-Science, Cochrane, 
Google Scholar). Na het lezen van de samenvattingen zijn 852 relevante publicaties over-
gebleven. Uiteindelijk is een lijst met 10 genen met de meeste potentie voor implementatie 
in de klinische praktijk opgesteld. Het meeste onderzoek is gedaan naar genetische vari-
aties in CYP2D6, SLC22A1, OPRM1 en COMT. Ook is gebleken dat er nog maar weinig 
onderzoek op dit gebied is gedaan bij kinderen.
Deel II
Dit deel van het proefschrift betreft onderzoek bij volwassenen, en wel met verschillende 
vormen van pijn. In Hoofdstuk 3 gaat het om de invloed van de genetische varianten 
OPRM1 118A>G, COMT Val158Met en de COMT haplotype op pijn veroorzaakt door 
koude- of warmteprikkels, postoperatieve pijn na een hartoperatie en chronische pijn op 
de plek van de incisiewond. De enige relevante variant bleek het COMT haplotype te 
zijn, in de zin dat dragers van het ‘gemiddelde pijngevoeligheid’ haplotype postoperatief 
minder opiaten hadden gebruikt, wijzend op minder pijn. Uit een ander onderzoek, bij 
356 mensen met kanker, bleek dat op de basis van genetische veranderingen niemand een 
ander type opiaat nodig had (Hoofdstuk 4). De trend die we in deze studie hebben gevon-
den voor RHBDF2 en OPRK1 met het overstappen naar een ander type opiaat (RHBDF2) 
en overstappen van oxycodon naar een andere type opiaat (RHBDF2, OPRK1)vereist wel 
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vervolgonderzoek. Tenslotte is in een studie bij 340 mensen met kanker gekeken naar het 
e&ect van een aantal genetische variaties (ABCB1, ARRB2, COMT, GCH1, IL1RN, KCNJ6, 
METTL21A, OPRM1, RHBDF2, SCN9A, Stat6) op opiaatbehoefte, relatieve verhoging 
in dosering na consultatie bij het palliatieve pijnteam en de toediening van ketamine 
(Hoofdstuk 5). Voor dragers van het OPRM1 118G allel of het COMT Val158Val genotype, 
of beide, werd de opiaatdosering signi!cant meer verhoogd dan voor het OPRM1 118AA 
genotype in combinatie met dragerschap van het COMT 158Met allel (p = 0.0016).
Deel III
Het onderzoek beschreven in Hoofdstuk 6 betreft 136 kinderen in de leeftijd van 8–18 
jaar. We hebben onderzocht of hun pijngevoeligheid gerelateerd was aan genetische 
varianten. Voor dit doel werden ze blootgesteld aan warme en koude prikkels met de 
zogenaamde ‘"ermal Sensory Analyzer’. Van de zeven onderzochte genetische varianten 
(COMT, OPRD1, OPRM1, TRPA1, TRPV1, TAOK3, SCN9A), bleek alleen het OPRM1 
118G allel van invloed. Dragers van deze variant hadden een lagere pijngevoeligheid dan 
niet-dragers. Dragers van het G allel vonden de warme prikkel veel minder pijnlijk en 
bereikten vaker de minimale en maximale temperatuurlimiet (0–50°C). Daarnaast hadden 
dragers van het OPRM1 118G allel in combinatie met het COMT Val158Val genotype 
hogere pijndrempels.
Bij kinderen zijn processen zoals de absorptie, distributie, het metabolisme en de uit-
scheiding van geneesmiddelen gaandeweg de ontwikkeling aan verandering onderhevig. 
Het e&ect van genetische variaties zal dan niet zichtbaar zijn als de betre&ende enzymen 
en transporters onvoldoende activiteit vertonen. We hebben het verband tussen ontwik-
kelings- en genetische aspecten onderzocht voor wat betreft variaties in UGT2B7 (Hoofd-
stuk 7) en SLC22A1 (Hoofdstuk 8). Dit zijn genen welke coderen voor enzymen en 
transporters die betrokken zijn bij het metabolisme van opiaten. We konden concluderen 
dat zowel UGT2B7 als OCT1 (SLC22A1) bij de onderzochte pasgeborenen en zuigelingen 
voldoende activiteit vertoonde voor een zichtbaar e&ect tussen deze genotype-groepen. 
Vervolgonderzoek dient aan te tonen of deze genetische variaties ook invloed hebben op 
klinische uitkomstmaten zoals e&ectiviteit en bijwerkingen van opiaten.
De rol van genetische aspecten is ook onderzocht bij pasgeborenen aan de beademing 
(Hoofdstuk 9) en bij pasgeborenen en oudere kinderen met een verhoogd risico op ont-
wenningsverschijnselen (Hoofdstuk 10). Bij de pasgeborenen aan de beademing bleek 
het gecombineerde OPRM1/COMT genotype geassocieerd te zijn met de behoefte aan 
medicamenteuze pijnstilling met mor!ne. Dit was vooral het geval bij dragers van het 
OPRM1 118G allel in combinatie met het COMT Val158Val genotype. Bij het onderzoek 
naar ontwenning hebben we deze genetische varianten niet kunnen relateren aan het 
ontstaan van ontwenning. Wel vonden wijdat dragers van het OPRM1 118G allel meer 
symptomen van ontwenning vertoonden.
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Deel IV
Van alle onderzochte genen zijn de OPRM1 en COMT genen elke keer als hits naar voren 
gekomen. Ook wanneer alleen deze genen vooraf zijn geselecteerd, doordat de studie-
grootte niet toereikend was voor variaties in meer genen, blijken de betre&ende genetische 
variaties vaak gerelateerd aan de pijngevoeligheid en opiaatrespons. Alhoewel varianten in 
de OPRM1 en COMT genen gerelateerd zijn aan de mate van pijn en opiatenconsumptie, 
leidt dragerschap niet tot de noodzaak om te veranderen van type opiaat of een verhoogd 
risico op ontwenning. Hierdoor zullen deze genetische varianten zeer onwaarschijnlijk 
als losstaande toetsen worden ingezet in de klinische praktijk. Daarnaast worden veel te-
genstrijdigheden gezien tussen pijnsoorten en type opiaten. Het belang van deze variaties 
voor verschillende type opiaten zou in een experimentele setting in gezonde vrijwilligers 
onderzocht moeten worden. De variaties in andere genen die onderzocht zijn naast de 
variaties in OPRM1 en COMT, lijken minder relevant in het verklaren van de verschillen 
in pijnervaring en het opiaat respons of dienen nader onderzocht te worden (RHBDF2, 
OPRK1). Het onderzoek in dit proefschrift laat zien dat het e&ect van genetische variaties 
in UGT2B7, SLC22A1, OPRM1 en COMT ook zichtbaar is bij kinderen. Het gebruik van 
kits om speeksel of wangslijmvlies af te nemen is een kindvriendelijke methode als er geen 
intraveneuze toegang voorhanden is. In verband met de mogelijke toxiciteit van codeïne 
en tramadol lijkt het testen van genetische variaties in SLC22A1 en CYP2D6 wél klinisch 
relevant. Het verdient aanbeveling naar méér genetische variaties in SLC22A1 te kijken 
dan wij hebben gedaan, om zodoende ook patiënten van niet-Kaukasiche etniciteit mee 
te nemen.
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P
Name PhD student: Maja Matić
Department: Clinical Chemistry
  Intensive Care and Department of Pediatric Surgery
PhD period: 2012 – 2016
Promotors: Prof. dr. R.H.N. van Schaik
  Prof. dr. D. Tibboel
  Prof. dr. S.N. de Wildt
  Year
Workload
(ECTS)
General academic skills   
t Research Integrity 2014 0.3 
t Biomedical English Writing 2013 2.0 
t Presenting Skills for Junior Researchers 2013 1.0 
t Biostatistical Methods I: Basic Principles (CCO2) 2013 5.7 
Research skills   
t Basic Introduction Course on SPSS 2013 1.0 
t Basic Human Genetics Course: Genetics for dummies 2012 0.5 
t NIH Clinical Course: Clinical Pharmacology 2012–2013 1.0 
t VAZA: Pop-PK en -PD onderzoek voor beginners 2015 0.5 
Conferences, Seminars & Workshops   
t Pharmacology Days Rotterdam/Leiden: oral presentation (3x) 2013–2016 1.5 
t ESPNIC Pharmacotherapy Workshop Rotterdam 2013 0.3 
t Precision Medicine Symposium, Leiden 2014 0.3 
t MolMed Day, Rotterdam: poster presentation (1x) 2014 0.3 
t Pharmacogenetics Workshop (2x) 2014–2015 0.8 
t Sophia Research Days: poster presentation (1x) 2014–2015 0.6 
t Refereeravond ‘Biobank kinderen onder de aandacht’ Rotterdam 2015 0.1 
t NVKFB Kinderfarmacologie opleidingsochtend, Rotterdam 2015 0.1 
t Onderzoeksdag Klinische Farmacologie 2016 0.1 
International conferences   
t SIMPAR 7th congress, Rome, Italy: oral presentation 2015 1.0 
t IATDMCT 14th congress, Rotterdam, NL: oral presentation 2015 1.0 
t ASCPT 2016 congress, San Diego, USA: poster presentation 2016 1.0 
t 17th Golden Helix PGx Day, Rotterdam, NL 2016 0.5 
Teaching activities   
t Supervising internship HLO student 2014 1.5 
t Supervising internship medical student 2014 0.5 
t Writing paper in educational journal for fellows perioperative medicine 2016 1.0 
264 PhD portfolio
  Year
Workload
(ECTS)
Other   
t Clinical Chemistry Research (monthly); multiple oral presentations 2012–2016 1.5 
t Pharmacogenetics Work Floor meeting (weekly) 2012–2016 2.0 
t Pediatric Pharmacology (weekly): multiple oral presentations 2013–2016 2.0 
t Internal Oncology Research: oral presentation(2x) 2013–2014 0.6 
t IC Clinical Pharmacology: oral presentation (1x) 2013 0.3 
t Workgroup ScientiYc Integrity (bi-monthly) 2014 0.5 
t Neurology Research: oral presentation (1x) 2015 0.3 
t Horizon 2020: Organization Eu-PIC meeting (Erasmus MC) 2015 1.0 
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A
Maja Matić werd op 13 november 1986 in Zenica (Joegoslavië) 
geboren. In 2006 heeft ze haar atheneum diploma behaald aan 
het Comenius College te Capelle aan den IJssel. Daarna is zij 
gestart met de studie Farmacie aan de Universiteit van Utrecht, 
met als gevolg een bachelor diploma in 2009. Gedurende haar 
masteropleiding Farmacie heeft ze o.a. onderzoekstage gelo-
pen op de afdeling Klinische Chemie in het Erasmus Medisch 
Centrum Rotterdam onder begeleiding van Prof. dr. R.H.N. 
van Schaik. Tijdens deze stage heeft Maja bijgedragen aan het 
manuscript “Associatie van genetische variatie in CYP1A2 en 
UGT1A4 met metabole stoornissen bij gebruikers van clozapine 
en olanzapine “ in het PW Wetenschappelijk Platform. Daar-
naast heeft Maja een keuzestage gelopen bij het Rijksinstituut 
voor Volksgezondheid en Milieu (RIVM) op het onderwerp 
‘evaluatie personalised medicine producten’. Hierbij heeft zij 
bijdragen aan het RIVM rapport “Personalised medicine pro-
ducts: evaluation of the regulatory framework.”. Nadat zij haar 
master Farmacie in 2012 heeft gehaald is zij in het Erasmus 
Medisch Centrum in Rotterdam en Sophia Kinderziekenhuis 
gestart met promotieonderzoek naar de toepassing van farma-
cogenetica bij de behandeling van pijn, onder begeleiding van 
Prof. dr. R.H.N. van Schaik, Prof. dr. D. Tibboel en Prof. dr. 
S.N. de Wildt. Het huidige proefschrift is het resultaat van 
haar promotietraject.
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D
“A boat doesn’t go forward if each one is rowing their own way.” 
Swahili Proverb
Het onderzoek beschreven in dit proefschrift is tot stand gekomen door de begeleiding, 
bijdrage, deelname en/of steun van velen waarvan ik een aantal hier wil bedanken.
Allereerst mijn promotoren. Niet veel promovendi hebben de luxe positie om (uiteindelijk) 
door drie promotoren begeleid te worden. Hoewel het soms mission impossible was om 
op basis van drie drukke agenda’s een tijdstip te vinden voor overleg, ben ik dankbaar dat 
jullie mij hebben begeleid de afgelopen jaren.
Beste Prof. Van Schaik, beste Ron, ik wil je bedanken voor het vertrouwen dat jij in mij 
had door mij de mogelijkheid te geven om mijn promotieonderzoek onder andere bij jou 
op het lab te mogen doen. Bedankt voor alle begeleiding en commentaar op de stukken, 
ook wanneer ik je overspoelde met tien verschillende e-mailberichten tegelijkertijd. Ik heb 
veel van je mogen leren over farmacogenetica en onderzoek doen, mijn dank hiervoor.
Beste Prof. Tibboel, beste Dick, dank dat u vanaf het begin de rol van mijn promotor heeft 
vervuld en voor de begeleiding die u hierbij heeft geboden. Onze afspraken waren altijd 
kort maar krachtig en waren vooral gericht op het doorhakken van knopen. Ook uw ex-
pertise, helikopterblik en het snelle commentaar op de stukken heb ik enorm gewaardeerd.
Beste Prof. De Wildt, beste Saskia, jouw scherpe blik en ideeën hebben het onderzoek 
enorm ten goede gedaan! Ik heb altijd bewondering gehad voor de diepgang aan com-
mentaar die je gaf en de snelheid waarmee het weer mij kant op kwam. Dank voor al jouw 
hulp en tijd, ook in de laatste fase van mijn onderzoek desondanks je verhuizing naar 
Nijmegen.
Prof. van Gelder, Prof. Allegaert en Prof. van der Rijt, wil ik hartelijk bedanken voor het 
beoordelen van mijn proefschrift en het plaatsnemen in de grote commissie. Daarnaast 
wil ik Prof. van den Anker, Prof. Mathijssen en Dr. Van Dijk eveneens bedanken voor het 
plaatsnemen in de grote commissie.
Ik wil alle co-auteurs (Anders, Astrid, Catherijne, Elisabeth, Erwin, Gerbrich, Ilse, Jan, 
Joost J, Joost van R, Karel, Karin, Laure, Maria, Maxime, Nienke, Olof, Peter, Pieter, Ron 
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M, Richard, Sinno, Sjoerd, Vineta) bedanken. Zonder jullie expertise, inzet en/of levering 
van patiëntmateriaal was het beschreven onderzoek niet mogelijk geweest!
De ‘DNA groep’ van het AKC, bedankt voor alle hulp op het lab, de gezellige lunchpauzes 
en uitjes buiten werk! Ik heb mij altijd heel erg op mijn plek gevoeld met jullie als collega’s. 
Samira, de Rotterdammert, je bent een schat, super-mom en slimme meid! Bedankt voor 
het lachen-gieren-brullen. Pamela, bedankt voor de gezellige en grappige gesprekken. Het 
was leuk om onze zwangerschappen en het kersverse moederschap tegelijkertijd te ervaren. 
Martin, bedankt voor alle hulp op het lab. Marianne, bedankt voor de begeleiding in 
het begin en de kennismaking met de wereld van de speeksel en wangslijmvlies afnames. 
Pieter, bedankt voor het geven van de DNA cursus en je bereidheid om altijd mijn vragen 
te beantwoorden. Bertrand, dank voor de kritische en nuttige vragen tijdens mijn praatjes. 
Evert, leuk dat we nog de bruggenloop samen hebben gelopen. Corine, Marijn en Marley, 
dank voor de gezelligheid. Natascha en Jonathan, ik vond het prettig om jullie op het lab 
te hebben begeleid. Natascha, stoere motor chick in spe, super bedankt voor je inzet bij de 
pijnstudie! Lale, bedankt voor alle tips en advies tijdens de laatste periode van mijn PhD. 
Ik wens je heel veel succes met de afronding van je specialisatie!
Collega (ex-)promovendi van het AKC: Cherina, jouw sprankelende Caribische persoon-
lijkheid en gevoel voor humor is onmisbaar binnen het AKC! Ik heb onwijs veel respect 
voor je doorzettingsvermogen. Heel veel succes met de afronding van je specialisatie. 
Pooja, bringing very delicious Indian food, with the carrot ‘cake’ being my favorite ;)! 
You are a sweet, funny, smart and hard working person! I wish you all the best with your 
PhD and future career. Natanja (handjes in de lucht smiley), je bent een gezellige, slimme 
en nuchtere meid. Ik wens je heel veel liefde met je opkomend huwelijk, succes met je 
PhD en verdere carrière. Je wordt een fantastische kinderarts! Rutchanna en Helen, mijn 
kamergenoten 4.0, dank voor de gezelligheid en het luisterend oor de afgelopen maanden! 
Beide heel veel succes met jullie onderzoeken! Ethan, bedankt voor alle discussies en gezel-
ligheid. Ingrid, bedankt voor de gesprekken en veel succes met je verdere carrière.
De FARMA-groep van het Sophia bedankt voor alle gezelligheid (“Manuel en zijn kip-
petjes”), discussies en leerzame besprekingen. Annette, Bianca, Gerdien, Heleen, Joke, 
Karel, Manuel, Özge, Paola en Saskia onwijs bedankt voor de surprise ‘Farma’ babyshower 
die jullie hebben georganiseerd! Annette, Bianca, Gerdien, Manuel en Paola, veel suc-
ces met jullie onderzoeken en toekomstige carrières. Paola, bedankt voor je interesse en 
luisterend oor de afgelopen maanden.
Lieve Joke, jij was te alle tijden bereid om mij te helpen, dank hiervoor! Beste Ko Hagoort, 
hartelijk dank voor de zeer snelle (zelfs vanuit het buitenland) grammaticale edits van de 
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manuscripten. Prof. Laure Elens, Laure thank you for all your help with the statistics. 
I appreciated your expertise and speed a lot! Dr. Joost van Rosmalen, wil ik hartelijk 
bedanken voor zijn deskundigheid, het meedenken en de statistische analyses, met name 
bij het laatste hoofdstuk. Annemarie en Wendy bedankt voor alle handtekeningen!
Hoewel jullie als mijn vrienden niet direct hebben bijdragen aan de onderzoeken bes-
chreven in dit proefschrift wil ik jullie wel bedanken voor alle gezelligheid buiten werktijd. 
Jullie aanwezigheid is gunstig geweest voor mijn werk/ontspanning ratio, wat weer indirect 
heeft bijdragen aan mijn e~ciëntie op werk.
Lieve Farmacie vriendinnen: Dilek, Esma, Isma en Nawal, ik ben ontzettend blij dat wij 
na onze studententijd elkaar nog regelmatig zien. Of het nou tijdens een van onze dates is 
of elkaar via de Whatsapp spreken, wij kunnen elkaar altijd om advies vragen. Ik ben blij 
dat ik jullie heb ontmoet! Lieve Faydra en Nardos, ik vind het bijzonder dat wij sinds de 
middelbare school nog steeds bevriend zijn. Wij hebben elkaar zien opgroeien van pubers 
tot volwassen vrouwen en veel gebeurtenissen met elkaar meegemaakt. Jullie aanwezigheid 
op onze bruiloft in Kroatië hebben Miro en ik enorm gewaardeerd. Ik ben trots op jullie 
beide! Faydra, over een paar maanden mag jij ook, heel veel succes! Lieve Patrick en Darja, 
ik ben onwijs blij dat we elkaar de laatste tijd weer vaker zien (vooral zo voortzetten) en 
onze kleintjes samen kunnen opgroeien en spelen! Darja, we go waaay back (mannelijk 
top tien lijsten ;) bedankt voor al je interesse in mijn werk! Goga, Ivan, Mario E, Mario S 
en Zoran: dat de gezelligheid en geslaagde feesten (a night in Amsterdan to remember….
or not) in de toekomst (vaker!) doorgezet mogen worden!
Mijn schoonfamilie, jullie zijn fantastisch! Bedankt voor jullie interesse en steun in het 
werk wat ik doe. Ook mijn dank voor het oppassen op Ella, met name mijn schoonouders 
Drago en Ljubica, en alle hulp met het huis de afgelopen maanden en Vesna voor al mijn 
haarcreaties.
Mijn ouders, Snježana en Željko en zusjes, Žana en Ivona, zonder jullie zou ik niet de per-
soon zijn geworden die ik ben! Als ouders hebben jullie keihard geknokt om ons een goede 
toekomst te geven. Jullie steun is onvoorwaardelijk! Mama (Noni), jij bent de meeste 
sterke, lieve, zorgzame en multitaskende vrouw en moeder die ik ken. Nije ti nijedna zena 
ravna! Ik weet dat ik altijd op je kan rekenen. Mijn zusjes, ik ben ontzettend blij dat jullie 
op deze dag naast mij staan als mijn paranimfen. Žana, mijn reislustige Dora, wat ben ik 
trots op je sterke persoonlijkheid en nuchterheid in het leven. Ivona, awless make-up 
waar ik jaloers op ben, je werkt keihard voor jou en mijn schattige, knappe en lieve neee 
Zakaria. Ik hou ontzettend veel van jullie allemaal!
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Miro – Rise up this mornin’, Smiled with the risin’ sun, #ree little birds. Pitch by my doorstep 
- ik zou niemand anders dan jou naast mij wensen! Ik ben trots op jouw doorzettings-
vermogen, nuchterheid, warmte, steun, vertrouwen en unieke kijk op de wereld. Het is 
het afgelopen jaar met alle (leuke!) gebeurtenissen welke op ons pad kwamen maar weer 
gebleken dat wij dat prima aankunnen en wat voor powerkoppel wij saampjes zijn. Love 
you and our Ella to inYnity and beyond!
- Maja -
